



# 37th Annual Meeting of the European Thyroid Association

## Programme

Leiden, The Netherlands, September 7–11, 2013

---

Guest Editors

*Jan Smit*, Nijmegen, The Netherlands

*Theo Visser*, Rotterdam, The Netherlands

---

The Executive Committee of the ETA and the Dutch National Organising Committee would like to thank the following companies for their generous support of the 37th Annual Meeting



S. Karger  
Medical and Scientific Publishers  
Basel · Freiburg · Paris · London · New York ·  
New Delhi · Bangkok · Beijing · Tokyo ·  
Kuala Lumpur · Singapore · Sydney

#### Disclaimer

The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

#### Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center (see 'General Information').

© Copyright 2013 European Thyroid Association  
Published by S. Karger AG, Basel  
P.O. Box, CH-4009 Basel (Switzerland)  
ISBN 978-3-318-02521-7  
e-ISBN 978-3-318-02493-7

---

**KARGER**

E-Mail [karger@karger.com](mailto:karger@karger.com)  
[www.karger.com/etj](http://www.karger.com/etj)

## Contents

**V A Warm Welcome to the ETA Annual Meeting in the Beautiful City of Leiden**

Smit, J. (Nijmegen); Visser, T. (Rotterdam)

- 1 Registration Information**
- 3 Floor Plan of the Congress Venue – Ground Floor**
- 4 First Floor**
- 5 Poster Exhibition Areas**

Pre-Conference Events

---

- 7 Overview**
- 8 ETA-Cancer Research Network (CRN) Meeting**
- 9 Advanced Thyroid, Neck Ultrasonography & Ultrasonography-Assisted Procedures**  
**Satellite Meeting on Thyroid Ultrasonography with Live Session**
- 10 ICCIDD Global Network West-Central Europe Regional Meeting**
- 12 Basic Thyroid Course**

Scientific Programme – Oral Sessions

---

- 13 Saturday, 7th September**
- 15 Sunday, 8th September**
- 21 Monday, 9th September**
- 28 Tuesday, 10th September**
- 36 Wednesday, 11th September**

Scientific Programme – Poster Sessions

---

- 39 Sunday, 8th September**
- 48 Monday, 9th September**
- 57 Tuesday, 10th September**

General Information

---

- 66 Congress General Information**
- 71 Social Events**
- 73 Map of Leiden**
- 74 Transparency Declaration**

Abstracts

---

**75 37th Annual Meeting of the European Thyroid Association**

Leiden, The Netherlands, September 7–11, 2013

Guest Editors: Smit, J. (Nijmegen); Visser, T. (Rotterdam)

**Executive Committee of the ETA**

Theo Visser (The Netherlands) – ETA President  
Luigi Bartalena (Italy) – Secretary  
George J. Kahaly (Germany) – Treasurer

Furio Pacini (Italy) – ETA President-Elect  
Colin Dayan (UK) – ETA Secretary-Elect

Maria Alevizaki (Greece)  
Ana Aranda (Spain)  
Anita Boelen (The Netherlands)  
Rosella Elisei (Italy)  
Heike Heuer (Germany)  
Laurence Leenhardt (France)  
Simon Pearce (UK)  
Agnieszka Piekietko-Witkowska (Poland)

**Dutch National Organizing Committee**

**Chairman**

Jan Smit

**Members**

Anita Boelen  
Eric Fliers  
Thera Links  
Robin Peeters  
Warner Simonides  
Noortje van der Kleij-Corssmit  
Theo Visser

Mirella Imthorn  
Jacob Muller

**ETA Standing Office**

EndoScience Endokrinologie Service GmbH  
Contact: Sandra Crutchley  
and/or Silke Winkelhofer  
Hopfengartenweg 19  
90518 Altdorf  
Germany  
tel.: +49 (0) 9187-9742415  
fax: +49 (0) 9187-9742475  
euro-thyroid-assoc@endoscience.de  
crutchley@endoscience.de  
winkelhofer@endoscience.de

## A Warm Welcome to the ETA Annual Meeting in the Beautiful City of Leiden



Dear friends, colleagues and members,

On behalf of the National Organizing Committee, I wish you a warm welcome to the city of Leiden for the occasion of the 37th European Thyroid Association Annual Meeting.

It is a great honor and pleasure to host one of the world's most prestigious thyroid scientific conventions in an environment which is also world renowned for its rich scientific and cultural heritage. Leiden hosts the oldest university of The Netherlands, founded in 1575, and the first one to practice freedom of belief and religion, as reflected in the university's motto, Praesidium Libertatis, Bastion of Liberty. Leiden has attracted world famous scientists including Spinoza, Descartes and the physician Herman Boerhaave whose famous 'anatomical theatre' is still displayed at the Boerhaave museum.

We are convinced that you will be excited not only by the excellent scientific program, which brings top class fundamental and clinical thyroid research, but also by the beauty of the congress venue, the tastefully renovated 19th century City Music Hall, with its intimate and stylish meeting rooms.

We hope to meet you at the varying and attractive social activities, which include the opening reception at the impressive Hooglandse Kerk with its charming Northern European gothic architecture, the canal cruise in small boats followed by an informal dinner, music and dance in the former linen factory Scheltema, and the gala dinner, where you will meet your colleagues surrounded by mummies and other ancient artifacts in the National Museum of Antiquities.

As Leiden is relatively small, there are ample possibilities to discover the highlights of the city by foot or, like the Dutch, take a bike and experience the typical Dutch countryside with windmills and lakes.

We look forward to meeting you at this fruitful and exciting congress!



A stylized, handwritten signature of Johannes Smit.

*Johannes Smit*  
Chair of the National  
Organizing Committee



A stylized, handwritten signature of Theo Visser.

*Theo Visser*  
President of the ETA

## Registration Information

### Main Conference Fees

Membership status	before 30th June	1st July – 31st August	on site
Ordinary and Senior	150 €	175 €	200 €
Junior <35 yrs	60 €	80 €	100 €
Corresponding	250 €	300 €	350 €
Non-Member	500 €	550 €	600 €
Student /Res. fellow <30 yrs	125 €	160 €	200 €
Accompanying Person	30 €	40 €	50 €

### Pre-Conference Events Fees

ETA-CRN and ESES Meeting	50 €
ICCIDD	40 €
Ultrasonography Course	150 €
Basic Thyroid Course	free

#### Day Tickets (only available on site)

Saturday: 100 €

Sunday, Monday, Tuesday: 150 € per day

Wednesday: 75 €

### Main Conference Registration Entitlements

#### Delegate registration includes:

- Access to all congress sessions and commercial exhibition  
(according to Dutch Law, only physicians are permitted to visit the commercial exhibition)
- All congress materials and a name badge
- Programme/Abstract Book
- Lunch boxes
- Coffee breaks during the congress
- Welcome Reception

#### Registration does not include:

- Accommodation, tickets to the social events (unless otherwise stated) or optional excursions

#### Accompanying person registration free includes:

- Name badge
- Welcome Reception
- Access to the lecture halls and commercial exhibition is not included!

## Pre-Conference Registration Entitlements

ETA-CRN, ICCIDD and Ultrasonography Course and Basic Thyroid Course  
Admission to the Scientific Sessions, congress material, lunch and coffee breaks

## Social Programme

7th September Welcome Reception at Hooglandse Kerk	free for registered participants, registered accompanying persons and exhibitors
9th September ETA Excursion to Scheltema Complex	50 €
10th September Gala Dinner at the National Museum of Antiquities	75 €

## On-Site Registration / Secretariat Desk / Membership Information

The Congress Registration Desk will be located in the entrance area of the Congress Centre and will operate the following hours:

Saturday	7th September	07.30–19.00
Sunday	8th September	07.30–19.00
Monday	9th September	07.30–18.00
Tuesday	10th September	07.30–18.00
Wednesday	11th September	07.30–13.00

During these hours, staff at the Registration Desk can be contacted at this number: 0031 (0)71 516 24 35.


## ETA Commercial Exhibition Opening Hours


The commercial exhibition will commence on Saturday, 7th September and finish on Tuesday, 10th September.

Set-up:	Friday, 6th September	09.00–20.00
Preliminary opening times:	Saturday, 7th September	09.00–18.00
	Sunday, 8th September	09.00–18.00
	Monday, 9th September	09.00–17.00
	Tuesday, 10th September	09.00–18.00
Break-down:	Tuesday, 10th September	18.00–22.00



## Ground Floor





**Sunday, 8th September**

Poster Session	Ground Floor Poster Exhibition Area 1	First Floor Poster Exhibition Area 2	First Floor Aalmarkt Corner
PO1: Thyroid Autoimmunity Basic	Posters 01–07		
PO2: Thyroid Basic		Posters 08–17	
PO3: Thyroid Cancer Basic 1		Posters 18, 20–29	
PO4: Thyroid Cancer Diagnostics 1	Posters 30–38		
PO5: Thyroid Cancer Pathogenesis	Posters 39–47		
PO6: Thyroid Cancer Therapeutics 1	Posters 48–56		
PO7: Case Reports 1		Posters 57–65	
PO8: Clinical Thyroidology 1		Posters 66–76	
PO9: Graves' Orbitopathy		Posters 77–85	
PO10: Hyperthyroidism 1			Posters 86–94

**Monday, 9th September**

Poster Session	Ground Floor Poster Exhibition Area 1	First Floor Poster Exhibition Area 2	First Floor Aalmarkt Corner
PO11: Thyroid Autoimmunity Clinical	Posters 95–104		
PO12: Thyroid Cancer Basic 2	Posters 19, 105–115 & Oral 16		
PO13: Thyroid Cancer Diagnostics 2	Posters 116–124		
PO14: Thyroid Nodules & Goitre 1			Posters 125–132
PO15: Thyroid Cancer Therapeutics 2		Posters 133–141	
PO16: Case Reports 2		Posters 142–150	
PO17: Clinical Thyroidology 2		Posters 151–156 & 158	
PO18: Environmental Influences on Thyroid Function		Posters 159–166	
PO19: Hyperthyroidism 2		Posters 167–175	
PO20: Hypothyroidism		Posters 176–183	

## Tuesday, 10th September

Poster Session	Ground Floor Poster Exhibition Area 1	First Floor Poster Exhibition Area 2	First Floor Aalmarkt Corner
PO21: Thyroid Cancer Diagnostics 3	Posters 184–192		
PO22: Thyroid Cancer Diagnostics 4	Posters 193–201		
PO23: Thyroid Cancer Therapeutics 3	Posters 202–210		
PO24: Thyroid Cancer Therapeutics 4	Posters 211–218		
PO25: Case Reports 3			Posters 219, 221–227
PO26: Imaging		Posters 228–231, 233–237	
PO27: Thyroid Hormone Metabolism and Action		Posters 238–249	
PO28: Medullary Thyroid Cancer		Posters 250–257	
PO29: Thyroid Nodules & Goitre 2		Posters 259–266	
PO30: Thyroid in Reproduction & Development		Posters 267–275	



**Saturday, 7th September 2013**

**Grote Zaal/Main Auditorium  
08.30–15.15**

**ETA-Cancer Research Network (CRN) Meeting**

in cooperation with the European Society of Endocrine Surgeons & the European Association of Nuclear Medicine

**Kleine Foyer  
08.15–15.00**

**Advanced Thyroid, Neck Ultrasonography &  
Ultrasound-Assisted Procedures**

**Satellite Meeting on Thyroid Ultrasonography with  
Live Session**

**Aalmarkt Zaal  
08.00–15.45**

**ICCIDD Global Network West-Central Europe Regional Meeting**

**De Waag (Corner Aalmarkt/Mandenmakerssteeg)  
10.00–15.30**

**Basic Thyroid Course**

**Cornelis Schuytzaal  
12.00–13.00**

**TFI Doctors-Patients Workshop**

**A Joint Workshop from the Thyroid Federation International (TFI)  
and the Dutch Organization of Thyroid Patients (SON)**

1. Short talk by a representative from the TFI Board about how TFI came to be and about its objectives and activities (10 minutes)
2. Short talk by a representative from SON about its objectives and activities (10 minutes)
3. Discussion: 'Do's and Don'ts' of setting up a Patient Organization (10 minutes)
4. Question time (30 minutes)

## ETA-Cancer Research Network (CRN) Meeting

in cooperation with:

European Society of Endocrine Surgeons (ESES)

European Association of Nuclear Medicine (EANM)



**Grote Zaal/Main Auditorium**  
**08.30–15.15**

### Clinical Trials in Thyroid Cancer: An Update and Call for Further Studies

08.30–08.50 Registration and coffee

08.50–09.00 Presidential address

#### **Session 1 Nuclear Medicine Treatment in Europe** Chairperson: *Ulla Feldt-Rasmussen*, Denmark

09.00–09.45 The HiLo trial results: an update

*Ujjal K. Mallick*, UK

10.00–10.45 ESTIMABL trial in low risk differentiated thyroid cancer: an update

*Sophie Leboulleux*, France

11.00–11.45 How the HiLo study and ESTIMABL study have influenced the nuclear medicine practice in Europe?

*Markus Luster*, Germany

11.45–12.15 Discussion

12.15–13.00 Lunch break

#### **Session 2 Surgery of Thyroid Cancer: Prophylactic Lymphadenectomy in Papillary Thyroid Cancer – Pros and Cons** Chairpersons: *Marcin Barczynski*, Poland; *Radu Mihai*, United Kingdom

13.00–13.30 Prophylactic lymphadenectomy in papillary thyroid cancer: rationale and complications

*Juan José Sancho*, Spain

13.45–14.15 Feasibility of clinical trial for prophylactic lymphadenectomy in thyroid cancer

*Agnieszka Czarniecka*, Poland

14.15–14.45 'Insight in the quality of care for patients with thyroid cancer': update of the project in The Netherlands and discussion about the future European collaboration in this field

*Ad Hermus*, The Netherlands

14.45–15.15 General comments and discussion

15.15–16.00 ETA-CRN General Assembly. Elections of the ETA-CRN Board

#### **ETA-CRN**

President: *Ulla Feldt-Rasmussen*,  
National University Hospital,  
Copenhagen, DK  
Secretary: *Barbara Jarzqb*,  
Maria Skłodowska-Curie Memorial  
Cancer Center and Institute of  
Oncology, Gliwice Branch, Poland  
Treasurer: *Georg Brabant*,  
The University of Lübeck, Germany

#### **ESES**

President: *Bruno Niederle*,  
Medical University of Vienna, Austria  
Past President: *Jean-Francoise Henry*,  
University Hospital La Timone,  
Marseille, France  
President Elect: *Antonio Sitges-Serra*,  
Parc de Salut, Barcelona, Spain  
Secretary: *Jean-Louis Kraimps*,  
University Hospital, Poitiers, France  
Treasurer: *Frederic Triponez*, University  
Hospital of Geneva, Switzerland

#### **EANM**

President: *Fred Verzijlbergen*,  
Erasmus MC Centreal Location,  
The Netherlands  
Secretary: *Savvos Frangos*,  
Bank of Cyprus Oncology Center, Cyprus  
Treasurer: *Jure Fettich*,  
University Medical Centre Ljubljana,  
Slovenia  
President-Elect: *Arturo Chiti*,  
Istituto Clinico Humanitas, Italy



## **Advanced Thyroid, Neck Ultrasonography & Ultrasound-Assisted Procedures Satellite Meeting on Thyroid Ultrasonography with Live Session**

### **Kleine Foyer**

**08.15–15.00**

08.15–08.30 Introduction  
*Jan Smit, The Netherlands and Paolo Vitti, Italy*

### **Thyroid Ultrasound (US) Guided Fine Needle Aspiration (FNA)**

Chairperson: *Paolo Vitti*

08.30–08.45 Basics & history of US in endocrine clinics; advantages, disadvantages and pitfalls  
*Murat Erdogan, Turkey*

08.45–09.00 Doppler sonography and elastosonography in thyroid nodules. Different results and comparison of different equipment  
*Teresa Rago, Italy*

09.00–09.15 US guided FNA procedure; advantages, disadvantages and pitfalls?  
*Enrico Papini, Italy*

### **Ultrasound Management of Multinodular Goiter**

Chairperson: *Paolo Vitti*

09.15–10.45 Interactive case illustrations on video presentations.  
*Laurence Leenhardt, Teresa Rago, Enrico Papini, Gilles Russ, Alptekin Gürsoy, Herve Monpeyssen, Steen J. Bonnema*

10.45–11.15 Coffee break

### **Ultrasound Management of Thyroid Cancer**

Chairperson: *Murat Erdogan*

11.15–11.30 Undetected carcinomas: learning from one's mistakes  
*Gilles Russ, France*

11.30–11.45 Ultrasound guidelines for the follow up of thyroid cancer  
*Laurence Leenhardt, France*

11.45–12.15 Mini-invasive treatment procedures (PEI and thermal ablation) for thyroid nodules and metastatic cervical lymph nodes  
*Laszlo Hegedüs, Denmark*

12.15–13.30 Lunch break

13.30–15.00

### **Live Session, Video Presentations of Clinical Cases, US Procedures and Take Home Messages**

Chairperson: *Laurence Leenhardt*

- The Italian team (*Teresa Rago, Enrico Papini, Paolo Vitti*)
- The French team (*Gilles Russ, Herve Monpeyssen, Laurence Leenhardt*)
- The Turkish team (*Alptekin Gürsoy, Murat Erdoğan*)
- The Danish team (*Steen J. Bonnema, Laszlo Hegedüs*)

Kindly sponsored by Esaote, Benelux and Philips, The Netherlands

## ICCIDD Global Network West-Central Europe Regional Meeting

**Aalmarktzaal, First Floor, City Music Hall, Leiden**  
**08.00–15.45**

08.00–08.30 Registration

08.30–08.40 Welcome Address

*John Lazarus* (ICCIDD GN Regional Coordinator)

*Elizabeth Pearce* (ICCIDD GN Deputy Regional Coordinator The Americas)

### Scientific Symposium

#### Section 1

Chairmen: *Paolo Vitti* (Italy)

*John Lazarus* (UK)

08.40–08.55 Effects of maternal thyroid state and iodine intake on development of the offspring

*Marco Medici* (The Netherlands)

08.55–09.00 Discussion

09.00–09.15 Mild iodine deficiency and neurocognitive outcomes

*Peter Taylor* (UK)

09.15–09.20 Discussion

09.20–09.35 The Norwegian mother and child cohort study

*Helle Margrete Meltzer* (Norway)

09.35–09.40 Discussion

09.40–09.55 Coffee break

#### Section 2

Chairmen: *Peter Smyth* (Ireland)

*Elizabeth Pearce* (Deputy Regional Coordinator The Americas)

09.55–10.10 The iodine cycle and IDD protection

*Alex Stewart* (UK)

10.10–10.15 Discussion

10.15–10.30 Serum thyroglobulin as a biomarker for iodine deficiency

*Tomislav Jukic* (Croatia)

10.30–10.35 Discussion

10.35–10.50 Salt reduction/salt iodisation

*Ludmila Ivanova* (Bulgaria)

10.50–10.55 Discussion

10.55–11.25 Aldo Pinchera Memorial Lecture

*Professor Paolo Vitti* (Italy)

11.25–12.15 Lunch and Poster Viewing





### Section 3

#### **Iodine Nutrition Status in West and Central Europe: An Update on Present Status and Future Developments**

12.15–12.25 Introduction

*John Lazarus (UK)*

12.25–13.55 Presentation of Country Data: ICCIDD GN National Representatives

Chairmen: *John Lazarus* (ICCIDD West & Central Europe Regional Coordinator)

*Murat Erdogan (Turkey)*

Albania – *Agron Ylli*

Belgium – *Rodrigo Moreno-Reyes*

Bosnia Herzegovina – *Amela Lolic*

Bulgaria – *Ludmilla Ivanova*

Croatia – *Zvonko Kusic*

Cyprus – *Georgios Georgiades*

Czech Republic – *Vaclav Zamrazil*

Denmark – *Peter Laurberg*

Estonia – *Toomas Podar*

Finland – *Matti Valimaki*

France – *Phillipe Caron*

Germany – *Henry Volzke*

Greece – *Kostas Markou*

Hungary – *Endre Nagy*

Ireland – *Peter Smyth*

Israel – *Aron Troen*

Italy – *Paolo Vitti*

13.55–14.10 Coffee break

14.10–15.45 Presentation of Country Data: ICCIDD GN National Representatives

Chairmen: *Paolo Vitti* (ICCIDD West & Central Europe Deputy Regional Coordinator)

*Peter Laurberg (Denmark)*

Latvia – *Valdis Pirags*

Lithuania – *Albertas Barzda*

Luxembourg – *Yolande Wagener*

Macedonia – *Borislav Karafilski*

The Netherlands – *Robin Peeters*

Norway – *Lisbeth Dahl*

N. Cyprus – *Hasan Sav*

Poland – *Zbigniew Szybinski*

Portugal – *Edward Limbert*

Romania – *Mihaela Simescu*

Serbia – *Bozo Trbojevic*

Slovakia – *Jan Podoba*

Slovenia – *Segej Hojker*

Spain – *Lluís Vila*

Sweden – *Mehari Gebre-Medhin*

Switzerland – *Michael Zimmermann*

Turkey – *Murat Erdogan*

United Kingdom – *Mark Vanderpump*

#### ICCIDD GLOBAL NETWORK

Regional Coordinator West and Central Europe: John Lazarus

Deputy Regional Coordinator: Paolo Vitti

Secretariat ICCIDD GN West Central Europe E-Mail: ICCIDD@cf.ac.uk

## Basic Thyroid Course

**De Waag (Corner Aalmarkt/Mandenmakerssteeg)  
10.00–15.30**

### Thyroid Development, Function and Carcinogenesis

#### Session 1

Chairpersons: *Josef Köhrle, Germany; Theo J. Visser, The Netherlands*

- |             |  |
|-------------|--|
| 10.00–10.30 | Thyroid anatomy and hormone production<br><i>Patrice Rodien, France</i>                      |
| 10.30–11.00 | Regulation of the hypothalamus-pituitary-thyroid axis<br><i>Eric Fliers, The Netherlands</i> |
| 11.00–11.30 | Thyroid gland embryology<br><i>Roberto Di Lauro, Italy</i>                                   |
| 11.30–12.00 | From stem cells to thyroid gland<br><i>Sabine Costagliola, Belgium</i>                       |
| 12.00–12.30 | Discussion   |
| 12.30–13.00 | Lunch break  |

#### Session 2

Chairpersons: *Clara Alvarez, Spain; Luca Persani, Italy*

- |             |  |
|-------------|--|
| 13.00–13.30 | Congenital hypothyroidism: defects in thyroid gland development<br><i>Heiko Krude, Germany</i> |
| 13.30–14.00 | Signaling pathways in the thyroid gland<br><i>Pilar Santisteban, Spain</i>                     |
| 14.00–14.30 | Molecular causes of thyroid cancer<br><i>Massimo Santoro, Italy</i>                            |
| 14.30–15.00 | Thyroid development and carcinogenesis: reciprocal processes?<br><i>Mikael Nilsson, Sweden</i> |
| 15.00–15.30 | Discussion   |
| 15.30       | End  |

Saturday, 7th September 2013

Grote Zaal/Main Auditorium  
16.00–18.00

**Merck Serono**  
Living science, transforming lives

## Merck Serono Symposium The Impact of Hypothyroidism in Daily Life

Chairperson: *Leonidas Duntas*, Greece

Co-Chairperson: *Luigi Bartalena*, Italy

16.00 Welcome Introduction  
*Leonidas Duntas*, Greece

16.10 Hypothyroidism during pregnancy and the post-partum  
*Victor Pop*, The Netherlands

16.35 Neuroendocrine and cognitive impact of hypothyroidism  
*Peter Laurberg*, Denmark

17.00 Association of high TSH level with obesity and thyroid cancer risk  
*Furio Pacini*, Italy

17.25 Morbidity and mortality of hypothyroidism  
*George J. Kahaly*, Germany

17.50 Closing remarks  
*Luigi Bartalena*, Italy

**Grote Zaal/Main Auditorium**  
**18.00–18.15**

## **Opening Ceremony**

Welcome by *Theo Visser* and *Jan Smit*

**Grote Zaal/Main Auditorium**  
**18.15–19.00**

## **The European Thyroid Journal Lecture**

Chair: *Wilmar M. Wiersinga*, The Netherlands  
Editor-in-Chief of the European Thyroid Journal

Disorders of thyroid hormone action: insights from human genetics  
*Krishna Chatterjee*, UK

## **19.30–21.00 Welcome Reception (Hooglandse Kerk)**





Sunday, 8th September 2013

Grote Zaal/Main Auditorium

08.00–10.00

**Oral Session 1:  
Topic Highlights (OP01–OP06)**

Chairpersons: *Theo Visser*, The Netherlands  
*Jan Smit*, The Netherlands

08.00–08.20

**OP01 EFFICACY OF CABOZANTINIB IN A PHASE 3 STUDY OF MEDULLARY THYROID CANCER (MTC) PATIENTS WITH RET OR RAS MUTATIONS**

*Sherman SJ<sup>1</sup>, Cohen EEW<sup>2</sup>, Schöffski P<sup>3</sup>, Elisei R<sup>4</sup>, Schlumberger M<sup>5</sup>, Wirth L<sup>6</sup>, Mangeshkar M<sup>7</sup>, Aftab DT<sup>7</sup>, Clary DO<sup>7</sup>, Brose M<sup>8</sup>*

<sup>1</sup>University Texas MD Anderson Cancer Center, Houston, United States, <sup>2</sup>University of Chicago, Chicago, United States, <sup>3</sup>University Hospitals Leuven, KU Leuven, Leuven, Belgium, <sup>4</sup>University of Pisa, Pisa, Italy, <sup>5</sup>Institut Gustave Roussy, University Paris-Sud, Villejuif, France, <sup>6</sup>Massachusetts General Hospital, Boston, United States, <sup>7</sup>Exelixis, Inc., South San Francisco, United States, <sup>8</sup>University of Pennsylvania Health System, Philadelphia, United States

08.20–08.40

**OP02 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL (DECISION) OF SORAFENIB IN LOCALLY ADVANCED OR METASTATIC PATIENTS WITH PROGRESSIVE RADIOACTIVE IODINE-REFRACTORY DIFFERENTIATED THYROID CANCER**

*Schlumberger M<sup>1</sup>, Jarzab B<sup>2</sup>, Elisei R<sup>3</sup>, Siena S<sup>4</sup>, Bastholt L<sup>5</sup>, de la Fouchardiere C<sup>6</sup>, Pacini F<sup>7</sup>, Paschke R<sup>8</sup>, Worden F<sup>9</sup>, Bockisch A<sup>10</sup>, Nutting C<sup>11</sup>, Shong YK<sup>12</sup>, Sherman SJ<sup>13</sup>, Smit JWA<sup>14</sup>, Chung J<sup>15</sup>, Kappeler C<sup>16</sup>, Molnar I<sup>15</sup>, Brose MS<sup>17</sup>*

<sup>1</sup>Institut Gustave Roussy, Villejuif, France, <sup>2</sup>Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland, <sup>3</sup>University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, <sup>4</sup>Ospedale Niguarda Ca' Granda, Milan, Italy, <sup>5</sup>Odense University Hospital, Odense, Denmark, <sup>6</sup>Hospices Civils-Centre Anticancéreux, Consortium Cancer Thyroïdien, Lyon, France, <sup>7</sup>University of Siena, Unit of Endocrinology, Siena, Italy, <sup>8</sup>Leipzig University, Department for Endocrinology and Nephrology, Leipzig, Germany, <sup>9</sup>University of Michigan Health System, Ann Arbor, United States,

<sup>10</sup>Universitätsklinikum Essen-Radiologie, Essen, Germany,

<sup>11</sup>Royal Marsden Hospital, London, United Kingdom,

<sup>12</sup>University of Ulsan College of Medicine, Asan Medicine Center, Seoul, Republic of Korea, <sup>13</sup>The University of Texas MD Anderson Cancer Center, Houston, United States, <sup>14</sup>Radboud University Nijmegen Medical Center, Department of Internal Medicine, Nijmegen, Netherlands, <sup>15</sup>Bayer HealthCare Pharmaceuticals, Montville, United States, <sup>16</sup>Bayer Pharma AG, Berlin, Germany, <sup>17</sup>University of Pennsylvania Health, Abramson Cancer Center, Philadelphia, United States

08.40–09.00

**OP03 INAPPROPRIATE HEAT DISSIPATION IGNITES BROWN FAT THERMOGENESIS IN MICE WITH A MUTANT THYROID HORMONE RECEPTOR  $\alpha 1$**

*Warner A<sup>1</sup>, Rahman A<sup>2</sup>, Gottschling K<sup>1</sup>, Davis B<sup>2</sup>, Vennström B<sup>1</sup>, Arner A<sup>2</sup>, Mittag J<sup>1</sup>*

<sup>1</sup>Karolinska Institutet, Department of Cell and Molecular Biology, Stockholm, Sweden, <sup>2</sup>Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden

09.00–09.20

**OP04 A NOVEL MECHANISM OF TBG DEFICIENCY: MUTATION IN A LIVER SPECIFIC TRANSCRIPTION ENHANCER**

*Ferrara AM<sup>1</sup>, Dumitrescu AM<sup>1</sup>, Brown CD<sup>2</sup>, Peterson A<sup>2</sup>, Moeller LC<sup>3</sup>, Wyne K<sup>4</sup>, White KP<sup>2</sup>, Weiss RE<sup>1,5</sup>, Refetoff S<sup>1,5,6</sup>*

<sup>1</sup>University of Chicago, Medicine, Chicago, United States, <sup>2</sup>University of Chicago, Human Genetics, Chicago, United States, <sup>3</sup>University of Duisburg-Essen, Endocrinology and Metabolic Diseases, Essen, Germany, <sup>4</sup>Weill Cornell Medical College, The Methodist Hospital, Medicine, Houston, United States, <sup>5</sup>University of Chicago, Pediatrics, Chicago, United States, <sup>6</sup>University of Chicago, Committee of Genetics, Chicago, United States

09.20–09.40

**OP05 DICER1 PLAYS A CRUCIAL ROLE IN THYROID FUNCTION AND GOITER DEVELOPMENT IN MICE**

*Undeutsch H<sup>1</sup>, Löf C<sup>1</sup>, Pakarinen P<sup>1</sup>, Poutanen M<sup>1</sup>, Kero J<sup>1</sup>*

<sup>1</sup>University of Turku, Department of Physiology, Turku, Finland

A Satellite Symposium Held in Conjunction With the  
37<sup>th</sup> Annual Meeting of the European Thyroid Association

This activity is sponsored  
by prIME Oncology.



# TARGETED THERAPY FOR ADVANCED MEDULLARY THYROID CANCER: PRACTICAL ADVICE FOR CLINICIANS

Sunday, 8 September 2013 13.00–14.00

Grote Zaal/Main Auditorium  
City Music Hall (Stadsgehoorzaal)  
Breestraat 60  
2311 CS Leiden  
the Netherlands

## TARGET AUDIENCE

This educational activity is specifically designed for oncologists, endocrinologists, and other healthcare professionals interested and/or involved in the treatment of patients with medullary thyroid cancer (MTC).

## CONTINUING EDUCATION

prIME Oncology is accredited by the Accreditation Council on Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™.

## CHAIR

**Thera P. Links, MD, PhD**  
University Medical Centre Groningen  
Groningen, the Netherlands

## FACULTY

**Lars Bastholt, MD**  
Odense University Hospital  
Odense, Denmark

**Martin Schlumberger, MD**  
Institute Gustave-Roussy  
Villejuif, France

## AGENDA

- Welcome and introduction  
*Thera P. Links, MD, PhD*
- 13.00 The when, what, and how of targeted therapy for MTC in 2013  
*Martin Schlumberger, MD*
- 13.15 **Clinical scenario #1**—Symptomatic metastatic MTC in 2013: Using the right treatment for the right patient at the right time  
*Lars Bastholt, MD*
- 13.35 **Clinical scenario #2**—Progressive metastatic MTC following first-line tyrosine kinase inhibitor therapy: A look forward  
*Thera P. Links, MD, PhD*
- 13.55 Symposium “pearls” and concluding remarks  
*Thera P. Links, MD, PhD*
- 14.00 Adjourn

**Register Online:**  
[www.prIMEoncology.org/thyroid\\_leiden2013](http://www.prIMEoncology.org/thyroid_leiden2013)

**AstraZeneca**

Support for this educational activity  
is provided by AstraZeneca.

09.40–10.00

**OP06 GENOME-WIDE MICRORNA EXPRESSION ANALYSIS OF THYROID CANCER BY NEXT GENERATION SEQUENCING IDENTIFIES MICRORNAS INVOLVED IN THYROID DIFFERENTIATION**

*Riesco-Eizaguirre G<sup>1,2</sup>, Wert L<sup>2</sup>, Santisteban P<sup>2</sup>*

<sup>1</sup>Hospital Universitario La Paz (IdiPaz), Endocrinology, Madrid, Spain, <sup>2</sup>Instituto de Investigaciones Biomédicas (CSIC-UAM), Madrid, Spain

10.00–10.30

**Coffee break**

**Aalmarkt Zaal**

**10.30–12.00**

**Symposium 1 (Basic): Thyroid Hormone Regulation in Brain**

Chairpersons: *Juan Bernal*, Spain

*Anita Boelen*, The Netherlands

10.30–11.00

Role of Dio2 in the HPT axis

*Antonio Bianco*, USA

11.00–11.30

Cell-specific function of TRα

*Frédéric Flamant*, France

11.30–12.00

Role of Dio3 in brain development

*Arturo Hernandez*, USA

**Grote Zaal/Main Auditorium**

**10.30–12.00**

**Symposium 2 (Clinical): Imaging and Thyroid Incidentaloma**

Chairpersons: *Paolo Vitti*, Italy

*Romana Netea-Maier*, The Netherlands

10.30–11.00

Epidemiological aspects: the size of the problem

*Sophie Leboulleux*, France

11.00–11.30

Risk stratification by ultrasound

*Gilles Russ*, France

11.30–12.00

Management of thyroid incidentaloma

*Laszlo Hegedüs*, Denmark

**Poster Area**

**12.00–13.00**

**Lunch and Poster Discussion 1 (Posters 1–94\*)**

\*poster 19 will be presented on Monday in Poster Session 12 (see pages 39 to 47)

**Poster Session 1: Thyroid Autoimmunity Basic**

Chairperson: *Paul Banga*, UK

**Poster Session 2: Thyroid Basic**

Chairperson: *Josef Köhrle*, Germany

**Poster Session 3: Thyroid Cancer Basic 1**

Chairperson: *Rosa Marina Melillo*, Italy

**Poster Session 4: Thyroid Cancer Diagnostics 1**

Chairperson: *Sophie Leboulleux*, France

**Poster Session 5: Thyroid Cancer Pathogenesis**

Chairperson: *Cristina Romei*, Italy

**Poster Session 6: Thyroid Cancer Therapeutics 1**

Chairperson: *Christine Spitzweg*, Germany

**Poster Session 7: Case Reports 1**

Chairperson: *István Szabolcs*, Hungary

**Poster Session 8: Clinical Thyroidology 1**

Chairperson: *Murat Erdogan*, Turkey

**Poster Session 9: Graves' Orbitopathy**

Chairperson: *Anja Eckstein*, Germany

**Poster Session 10: Hyperthyroidism 1**

Chairperson: *Mario Salvi*, Italy

**Grote Zaal/Main Auditorium**

**13.00–14.00**

**AstraZeneca**

prIME Oncology Satellite Symposium supported by AstraZeneca

**Targeted Therapy for Advanced Medullary Thyroid Cancer (MTC): Practical Advice for Clinicians**

Welcome and introduction  
*Thera P. Links*, The Netherlands

13.00 The when, what, and how of targeted therapy for MTC in 2013

*Martin Schlumberger*, France

13.15 Clinical scenario #1–Symptomatic metastatic MTC in 2013: Using the right treatment for the right patient at the right time

*Lars Bastholt*, Denmark

13.35 Clinical scenario #2–Progressive metastatic MTC following first-line tyrosine kinase inhibitor therapy: A look forward

*Thera P. Links*, The Netherlands

13.55 Symposium “pearls” and concluding remarks  
*Thera P. Links*, The Netherlands

14.00 Adjourn







A BAYER HEALTHCARE-SPONSORED SATELLITE SYMPOSIUM AT THE  
37TH ANNUAL MEETING OF THE EUROPEAN THYROID ASSOCIATION



150 Years  
Science For A  
Better Life

# The Road Ahead in Differentiated Thyroid Cancer

## SATELLITE SYMPOSIUM

**Sunday 8 September 2013**

**19:00-20:30**

**City Music Hall (Stadsgehoorzaal)**

**Grote Zaal**

**Leiden, Netherlands**

Please See Full Meeting Agenda on Page 20

Dinner Will Be Provided to All Attendees



14.00–14.45

# Meet the Expert 1–4

## Kleine Foyer

14.00–14.45

### MTE 1 (Basic)

Transcriptional regulation in thyroid  
*Josef Köhrle, Germany*

## Waalse Kerk

14.00–14.45

### MTE 2 (Translational)

Thyroid hormone and lipid metabolism  
*Pieter de Lange, Italy*

## Grote Zaal/Main Auditorium

14.00–14.45

### MTE 3 (Clinical)

ETA guidelines on TSH-secreting adenomas  
*Paolo Beck-Peccoz, Italy*

## Aalmarkt Zaal

14.00–14.45

### MTE 4 (Clinical)

Assisted reproduction and thyroid dysfunction  
*Kris Poppe, Belgium*

14.45–15.15

## Coffee break

## Grote Zaal/Main Auditorium

15.15–15.45

## Harington-de Visscher Prize Lecture

Chairpersons: *Theo Visser, The Netherlands*  
*Luigi Bartalena, Italy*

Clinical consequences of variation in thyroid hormone  
pathway genes  
*Robin Peeters, The Netherlands*

## Grote Zaal/Main Auditorium

16.00–18.00

## Oral Session 2:

## Young Investigators Session (OP07–OP14)

Chairpersons: *Furio Pacini, Italy*  
*Graham Williams, UK*

16.00–16.15

## OP07 LOW BIRTH WEIGHT IN CHILDREN BORN TO MOTHERS WITH HYPERTHYROIDISM AND HIGH BIRTH WEIGHT IN HYPOTHYROIDISM, WHEREAS PRETERM BIRTH IS COMMON IN BOTH CONDITIONS: A DANISH NATIONAL HOSPITAL STUDY OF 1,638,338 CHILDREN AND THEIR MOTHERS

*Andersen SL<sup>1</sup>, Olsen J<sup>2</sup>, Wu CS<sup>2</sup>, Laurberg P<sup>1</sup>*

<sup>1</sup>Aalborg University Hospital, Department of Endocrinology, Aalborg, Denmark, <sup>2</sup>Aarhus University, Section for Epidemiology, Department of Public Health, Aarhus, Denmark

16.15–16.30

## OP08 GRAVES' ORBITOPATHY IN MICE WITH THYROTROPIN RECEPTOR PLASMID ELECTROPORATION, CHARACTERISED BY RETROBULBAR INFLAMMATION, ADIPOGENESIS, FIBROSIS AND OCULAR MANIFESTATIONS OF ACUTE CONGESTIVE OPHTHALMOPATHY

*Moshkelgosha S<sup>1</sup>, So P-W<sup>2</sup>, Deasy N<sup>3</sup>, Diaz-Cano S<sup>4</sup>, Banga JP<sup>1</sup>*

<sup>1</sup>King's College London School of Medicine, Diabetes and Endocrinology, London, United Kingdom, <sup>2</sup>King's College London School of Medicine, Institute of Psychiatry, Preclinical Imaging Unit, London, United Kingdom, <sup>3</sup>Institute of Psychiatry, Neuroradiology, London, United Kingdom, <sup>4</sup>King's College Hospital NHS Trust, Pathology, London, United Kingdom

16.30–16.45

## OP09 MATERNAL HYPOTHYROXINEMIA AND TPO ANTIBODIES, BUT NOT HIGH TSH LEVELS, ARE RISK FACTORS FOR PREMATURITY: THE GENERATION R STUDY

*Korevaar TIM<sup>1</sup>, Medici M<sup>1</sup>, de Rijke YB<sup>2</sup>, Visser W<sup>3</sup>, de Muinck Keizer-Schrama SMPF<sup>1</sup>, Jaddoe VVW<sup>4</sup>, Hofman A<sup>4</sup>, Visser WE<sup>1</sup>, Hooijkaas H<sup>5</sup>, Steegers EAP<sup>3</sup>, Tiemeier H<sup>4</sup>, Bongers-Schokking JJ<sup>1</sup>, Visser TJ<sup>1</sup>, Peeters RP<sup>1</sup>*

<sup>1</sup>Erasmus Medical Center, Endocrinology, Rotterdam, Netherlands, <sup>2</sup>Erasmus Medical Center, Clinical Chemistry, Rotterdam, Netherlands, <sup>3</sup>Erasmus Medical Center, Gynaecology, Rotterdam, Netherlands, <sup>4</sup>Erasmus Medical Center, Epidemiology, Rotterdam, Netherlands, <sup>5</sup>Erasmus Medical Center, Immunology, Rotterdam, Netherlands

16.45–17.00

## OP10 TLR3 SIGNALING PROMOTES METASTASIS OF PAPILLARY THYROID CANCER BY MODULATING CD44 EXPRESSION THROUGH PI3K/AKT PATHWAY

*Li D<sup>1,2</sup>, Gu R<sup>3</sup>, Nie X<sup>4</sup>, Zhao Q<sup>1</sup>, Du Q<sup>1</sup>, Guo H<sup>1</sup>, Shi L<sup>1</sup>, Huang T<sup>1</sup>*

<sup>1</sup>Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>2</sup>Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China, <sup>3</sup>Department of Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>4</sup>Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

17.00–17.15

**OP11 IDENTIFICATION AND FUNCTIONAL STUDIES OF DUOX2 VARIANTS IN A LARGE SERIES OF PATIENTS WITH CONGENITAL HYPOTHYROIDISM**

*Muzza M<sup>1</sup>, Rabbiosi S<sup>2</sup>, Zamproni P<sup>2</sup>, Persani L<sup>1,3</sup>, Cortinovis F<sup>2</sup>, Vigone MC<sup>2</sup>, Beccaria L<sup>4</sup>, Schoenmakers N<sup>5</sup>, Gallo F<sup>6</sup>, Weber G<sup>2</sup>, Fugazzola L<sup>1</sup>*

<sup>1</sup>University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy, <sup>2</sup>San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Department of Pediatrics, Milan, Italy, <sup>3</sup>Istituto Auxologico Italiano, Milan, Italy, <sup>4</sup>A. Manzoni Hospital, Lecco, Italy, <sup>5</sup>University of Cambridge, Institute of Metabolic Science, Cambridge, United Kingdom, <sup>6</sup>Perrino Hospital, Brindisi, Italy

17.15–17.30

**OP12 PATTERNS OF THYROID HORMONE RECEPTOR EXPRESSION DURING THE EARLY STAGES OF ZEBRAFISH DEVELOPMENT**

*Marelli F<sup>1</sup>, Chatterjee K<sup>2</sup>, Peeters RP<sup>3</sup>, Persani L<sup>1,4</sup>*

<sup>1</sup>IRCCS Istituto Auxologico Italiano, Spermental Laboratory of Endocrine and Metabolic Research, Cusano Milanino, Italy, <sup>2</sup>University of Cambridge, Metabolic Research Laboratory, Cambridge, United Kingdom, <sup>3</sup>Erasmus Medical Center, Departments of Internal Medicine, Rotterdam, Netherlands, <sup>4</sup>University of Milan, Department of Medical Science, Milan, Italy

17.30–17.45

**OP13 MICRORNA 214 IS A POTENTIAL REGULATOR OF THYROID HORMONE LEVELS IN THE POST-MI HEART BY TARGETING THE THYROID HORMONE INACTIVATING ENZYME DEIODINASE TYPE III**

*Janssen R<sup>1</sup>, Zuidwijk M<sup>1</sup>, Muller A<sup>1</sup>, Oudejans C<sup>2</sup>, Simonides W<sup>1</sup>*

<sup>1</sup>Institute for Cardiovascular Research / VU University Medical Center, Department of Physiology, Amsterdam, Netherlands, <sup>2</sup>VU University Medical Center, Department of Clinical Chemistry, Amsterdam, Netherlands

17.45–18.00

**OP14 CLINICAL AND LABORATORY FEATURES OF IGSF1 DEFICIENCY IN MALES AND FEMALES**

*Joustra S<sup>1,2</sup>, Schoenmakers N<sup>3</sup>, Oostdijk W<sup>2</sup>, Corssmit EP<sup>1</sup>, Heinen CA<sup>4</sup>, Bonomi M<sup>5</sup>, Radetti G<sup>6</sup>, Persani L<sup>5,7</sup>, Campi I<sup>7,8</sup>, Biermasz NR<sup>1</sup>, Pereira AM<sup>1</sup>, Chatterjee K<sup>3</sup>, Dattani MT<sup>9</sup>, Wit JM<sup>2</sup>, van Trotsenburg ASP<sup>4</sup>*

<sup>1</sup>Leiden University Medical Center, Endocrinology and Metabolism, Leiden, Netherlands, <sup>2</sup>Leiden University Medical Center, Paediatric Endocrinology, Leiden, Netherlands, <sup>3</sup>Addenbrooke's Hospital, Institute of Metabolic Science, Cambridge, United Kingdom, <sup>4</sup>Academic Medical Centre, Paediatric Endocrinology, Amsterdam, Netherlands, <sup>5</sup>IRCCS Istituto Auxologico Italiano, Endocrine and Metabolic Disorders, Milan, Italy, <sup>6</sup>Bolzano Hospital, Pediatric Unit, Bolzano, Italy, <sup>7</sup>Università degli Studi di Milano, Clinical Sciences & Community Health, Milan, Italy, <sup>8</sup>Fondazione IRCCS

Ca' Granda, Endocrine Unit, Milan, Italy, <sup>9</sup>UCL Institute of Child Health, Developmental Endocrinology Research Group, London, United Kingdom

**Grote Zaal/Main Auditorium**

**18.00–18.45**

**Aldo Pinchera Lecture Prize**

Chairpersons: *Theo Visser*, The Netherlands

*Furio Pacini*, Italy

Graves' orbitopathy: imperfect treatments for a rare disease  
*Luigi Bartalena*, Italy

**Grote Zaal/Main Auditorium**

**19.00–20.30**



**150 Years  
Science For A Better Life**

**Bayer HealthCare-Sponsored Satellite Symposium**

**The Road Ahead in Differentiated Thyroid Cancer**

Chair: *Martin Schlumberger*, France

19.00–19.20 Recent progress in our understanding of DTC and the RAI-refractory patient  
*Martin Schlumberger*, France

19.20–19.40 What we have learned from the biology and the signaling pathways of DTC – the rationale behind targeted therapies  
*Furio Pacini*, Italy

19.40–20.00 Recent progress in the treatment of RAI-refractory DTC  
*Marcia Brose*, USA

20.00–20.20 Learning from clinical experience and future direction with tyrosine kinase inhibitors  
*Johannes Smit*, The Netherlands

20.20–20.30 Faculty discussion and questions to the audience

Dinner will be provided to attendees

Grote Zaal

08.00–10.00

**Oral Session 3:  
Thyroid Cancer Clinical 1 (OP15–OP22)**

Chairpersons: *Rossella Elisei*, Italy  
*Iris Wakelkamp*, The Netherlands

08.00–08.17

**OP15 THYROID LUNG METASTASES TREATED WITH  
PERCUTANEOUS THERMAL ABLATION: RESULTS FROM 25  
PATIENTS AND 58 NODULES**

*Bonichon F<sup>1</sup>, de Baere T<sup>2</sup>, Godbert Y<sup>3</sup>, Leboulleux S<sup>4</sup>,  
Deschamps F<sup>2</sup>, Buy X<sup>5</sup>, Chougnet CN<sup>6</sup>, Do Cao C<sup>7</sup>, Toubreau M<sup>8</sup>,  
Giraudet A-L<sup>9</sup>, Palussiere J<sup>5</sup>, Tuthyref network*

<sup>1</sup>Institut Bergonie, Nuclear Medicine, Bordeaux Cedex, France,  
<sup>2</sup>Institut Gustave Roussy, Interventional Radiology, Villejuif,  
France, <sup>3</sup>Institut Bergonie, Nuclear Medicine, Bordeaux cedex,  
France, <sup>4</sup>Institut Gustave Roussy, Nuclear Medicine, Villejuif,  
France, <sup>5</sup>Institut Bergonie, Interventional Radiology, Bordeaux,  
France, <sup>6</sup>Institut Gustave Roussy, Nuclear Medicine and  
Endocrine Cancer, Villejuif, France, <sup>7</sup>Hôpital Claude Huriez,  
CHRU, Service d'Endocrinologie et de Maladies Métaboliques,  
Lille, France, <sup>8</sup>Centre Georges-François Leclerc,  
Nuclear Medicine, Dijon, France, <sup>9</sup>Centre Leon Berard,  
Nuclear Medicine, Lyon, France

**OP16 (to be presented as a poster: Poster session PO12 Basic  
Cancer 2)**

**OP16 CLINICAL UTILITY OF <sup>18</sup>F-FLUORODEOXYGLUCOSE  
PET/CT CONCURRENT WITH <sup>131</sup>I THERAPY IN  
INTERMEDIATE-TO-HIGH RISK PATIENTS WITH  
DIFFERENTIATED THYROID CANCER: DUAL-CENTER  
EXPERIENCE WITH 286 PATIENTS**

*Lee J-W<sup>1</sup>, Lee S-M<sup>2</sup>, Lee D-H<sup>3</sup>, Kim Y-J<sup>4</sup>*

<sup>1</sup>Yonsei University College of Medicine, Department of  
Nuclear Medicine, Seoul, Republic of Korea, <sup>2</sup>Soonchunhyang  
University Hospital, Department of Nuclear Medicine,  
Cheonan, Republic of Korea, <sup>3</sup>Wonkwang University School of  
Medicine and Hospital, Department of Internal Medicine,  
Iksan, Republic of Korea, <sup>4</sup>Soonchunhyang University Hospital,  
Department of Internal Medicine, Cheonan, Republic of Korea

08.17–08.34

**OP17 STRATIFIED GENETIC ANALYSIS ENHANCES  
THE DETECTION OF MALIGNANT LESIONS IN THYROID  
NODULES**

*Zatelli MC<sup>1,2</sup>, Filieri C<sup>1</sup>, Rossi M<sup>1</sup>, Buratto M<sup>1</sup>, Tagliati F<sup>1</sup>,  
Trasforini G<sup>1</sup>, Lanza G<sup>3</sup>, Rossi R<sup>1</sup>, degli Uberti EC<sup>1,2</sup>*

<sup>1</sup>University of Ferrara, Section of Endocrinology, Dept. of  
Medical Sciences, Ferrara, Italy, <sup>2</sup>Laboratorio in rete del  
Tecnopolo 'Tecnologie delle terapie avanzate' (LTTA) of the  
University of Ferrara, Ferrara, Italy, <sup>3</sup>University of Ferrara,  
Section of Sezione di Pathology and Bio-molecular Diagnostics,  
Dept. of Biomedical Sciences and Advanced Therapies, Ferrara,  
Italy

08.34–08.51

**OP18 AUTOIMMUNE THYROIDITIS IS NOT ASSOCIATED  
WITH INCREASED RISK OF THYROID CANCER IN A  
CYTOLOGICAL SERIES OF THYROID NODULES**

*Belardini V<sup>1</sup>, Castagna MG<sup>1</sup>, Memmo S<sup>1</sup>, Maino F<sup>1</sup>, D'Angeli F<sup>1</sup>,  
Evangelista IA<sup>1</sup>, Pacini F<sup>1</sup>*

<sup>1</sup>Section of Endocrinology, University of Siena, Siena, Italy

08.51–09.08

**OP19 RET TRANSLOCATIONS IN PAPILLARY THYROID  
CARCINOMA DETECTED BY A BREAK-APART INTERPHASE  
FLUORESCENCE IN SITU HYBRIDIZATION ASSAY**

*Pedron S<sup>1</sup>, Colato C<sup>1</sup>, Brazzarola P<sup>2</sup>, Chilosi M<sup>1</sup>, Ferdeghini M<sup>1</sup>*

<sup>1</sup>University of Verona, Pathology and Diagnostics, Verona, Italy,  
<sup>2</sup>University of Verona, Surgery and Oncology, Verona, Italy

09.08–09.25

**OP20 MODIFIED DYNAMIC RISK STRATIFICATION FOR  
PREDICTING RECURRENCE USING THE RESPONSE TO  
INITIAL THERAPY IN PATIENTS WITH DIFFERENTIATED  
THYROID CARCINOMA**

*Jeon MJ<sup>1</sup>, Kim WG<sup>1</sup>, Park WR<sup>1</sup>, Han JM<sup>1</sup>, Kim TY<sup>1</sup>, Chung K-W<sup>2</sup>,  
Song DE<sup>3</sup>, Ryu J-S<sup>4</sup>, Hong SJ<sup>2</sup>, Shong YK<sup>1</sup>, Kim WB<sup>1</sup>*

<sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine,  
Internal Medicine, Seoul, Republic of Korea, <sup>2</sup>Asan Medical  
Center, University of Ulsan College of Medicine, Surgery, Seoul,  
Republic of Korea, <sup>3</sup>Asan Medical Center, University of Ulsan  
College of Medicine, Pathology, Seoul, Republic of Korea,  
<sup>4</sup>Asan Medical Center, University of Ulsan College of Medicine,  
Nuclear Medicine, Seoul, Republic of Korea



A Satellite Symposium Held in Conjunction With the 37<sup>th</sup>  
Annual Meeting of the European Thyroid Association

# HOW I TREAT ADVANCED DIFFERENTIATED THYROID CANCER IN 2013

**Monday, 9 September 2013**  
**13.00 – 14.00**

**Grote Zaal/Main Auditorium**  
**City Music Hall (Stadsgehoorzaal)**  
**Breestraat 60**  
**2311 CS Leiden**  
**the Netherlands**

**FACULTY** **Rossella Elisei, MD (Chair)**  
*University of Pisa*  
*Pisa, Italy*

**Barbara Jarzab, MD**  
*MSC Memorial Cancer Center*  
*Gliwice, Poland*

**Furio Pacini, MD**  
*Azienda Ospedaliera Universitaria Senese*  
*Siena, Italy*

## AGENDA

### Welcome and introduction

*Rossella Elisei, MD*

### 13.00 How I treat newly-diagnosed advanced differentiated thyroid cancer (DTC)

*Furio Pacini, MD*

### 13.15 Challenge the expert

### 13.20 How I treat radioactive iodine (RAI)- refractory DTC

*Rossella Elisei, MD*

### 13.35 Challenge the expert

### 13.40 How I manage adverse events associated with targeted therapy

*Barbara Jarzab, MD*

### 13.55 Challenge the expert

### 14.00 Concluding remarks

*Rossella Elisei, MD*

## TARGET AUDIENCE

This educational activity is specifically designed for endocrinologists, oncologists, and other healthcare professionals interested and/or involved in the treatment of patients with advanced differentiated thyroid cancer.

## EDUCATIONAL OBJECTIVES

After successful completion of this educational activity, participants should be able to:

- Describe the prognosis and current management of advanced DTC
- Identify the role of multidisciplinary treatment approach in the management of DTC
- Define RAI-refractory DTC and evaluate treatment strategies, including recent advances
- Discuss importance of patient selection for treatment with tyrosine kinase inhibitors
- Evaluate importance of early recognition and management of adverse events



Support for this educational activity  
is provided by Eisai Inc.

**Register Online: [www.prIMEoncology.org/leiden2013](http://www.prIMEoncology.org/leiden2013)**

09.25–09.42

**OP21 HIGH-RISK PATIENTS WITH DIFFERENTIATED THYROID CANCER T4 PRIMARY TUMORS ACHIEVE REMNANT ABLATION EQUALLY WELL USING RECOMBINANT HUMAN TSH OR THYROID HORMONE WITHDRAWAL**

*Bartenstein P<sup>1</sup>, Caballero Calabuig E<sup>2</sup>, Maini CL<sup>3</sup>, Mazzarotto R<sup>4</sup>, Muros de Fuentes MA<sup>5</sup>, Petrich T<sup>6</sup>, Rodrigues FJC<sup>7</sup>,*

*Vallejo Casas JA<sup>8</sup>, Vianello F<sup>9</sup>, Basso M<sup>9</sup>, Gomez Balaguer M<sup>2</sup>, Haug A<sup>1</sup>, Monari F<sup>4</sup>, Sanchez-Vano R<sup>2</sup>, Sciuto R<sup>3</sup>, Magner J<sup>10</sup>*

<sup>1</sup>Klinikum der Universitaet Muenchen, Muenchen, Germany,

<sup>2</sup>Hospital Universitario Dr. Peset Valencia, Valencia, Spain,

<sup>3</sup>Istituto Nazionale Tumori Regina Elena IRCCS, Roma, Italy,

<sup>4</sup>Policlinico S. Orsola Malpighi, Bologna, Italy,

<sup>5</sup>Hospital Universitario Virgen de las Nieves, Granada, Spain,

<sup>6</sup>Medizinische Hochschule Hannover, Hannover, Germany,

<sup>7</sup>Instituto Portugues de Oncologia de Coimbra Francisco Gentil,

Coimbra, Portugal, <sup>8</sup>Hospital Universitario Reina Sofia de

Cordoba, Andalucia, Spain, <sup>9</sup>Istituto Oncologico Veneto-IRCCS,

Padova, Italy, <sup>10</sup>Genzyme, a Sanofi Company, Cambridge,

United States

09.42–10.00

**OP22 IMPACT OF CONCURRENT CHRONIC LYMPHOCYTIC THYROIDITIS (CTL) ON PAPILLARY THYROID CANCER (PTC) OUTCOME: THE POTENTIAL KEY ROLE OF FOXP3+ T LYMPHOCYTES**

*Pilli T<sup>1</sup>, Toti P<sup>2</sup>, Castagna MG<sup>1</sup>, Occhini R<sup>2</sup>, Caselli M<sup>1</sup>, Barbagli L<sup>2</sup>, Memmo S<sup>1</sup>, Maino F<sup>1</sup>, Pacini F<sup>1</sup>*

<sup>1</sup>University of Siena, Section of Endocrinology, Department of Medical, Surgical and Neurological Sciences, Siena, Italy,

<sup>2</sup>University of Siena, Section of Anatomy&Pathology,

Department of Anatomy & Pathology and Medical

Biotechnology, Siena, Italy

**Aalmarkt Zaal**

**08.00–10.00**

**Oral Session 4:**

**Thyroid Hormone Action (OP23–OP30)**

Chairpersons: *Jens Mittag*, Sweden

*Edward Visser*, The Netherlands

08.00–08.15

**OP23 EFFECT OF 3,5-DIODO-L-THYRONINE ON HIGH-FAT DIET-INDUCED VISCERAL ADIPOSITY IN THE RAT**

*Senese R<sup>1</sup>, de Lange P<sup>1</sup>, Leanza C<sup>1</sup>, Ziello A<sup>1</sup>, Lasala P<sup>1</sup>, De Matteis R<sup>2</sup>, Lattanzi D<sup>3</sup>, Lanni A<sup>1</sup>*

<sup>1</sup>Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Seconda Università degli Studi di Napoli, Caserta, Italy, <sup>2</sup>Dip. Scienze Biomolecolari-Sezione di Scienze

Motorie e della Salute, Università di Urbino 'Carlo Bo', Urbino, Italy, <sup>3</sup>Dip. Scienze della Terra, della Vita e dell'Ambiente, Università di Urbino 'Carlo Bo', Urbino, Italy

08.15–08.30

**OP24 METABOLIC EFFECTS OF 3,5-DIODO-L-THYRONINE: FOCUS ON BROWN ADIPOSE TISSUE**

*Lombardi A<sup>1</sup>, De Matteis R<sup>2</sup>, Busiello RA<sup>3</sup>, Cioffi F<sup>3</sup>, Senese R<sup>4</sup>, Goglia F<sup>5</sup>*

<sup>1</sup>Università di Napoli Federico II, Biological Science, Napoli,

Italy, <sup>2</sup>Università degli Studi di Milano di Urbino, Dipartimento

di Scienze Biomolecolari, Sezione di Scienze Motorie e della

Salute, Urbino, Italy, <sup>3</sup>Università degli Studi del Sannio,

Dipartimento di Scienze per la Biologia, la Geologia e

L'Ambiente, Benevento, Italy, <sup>4</sup>Seconda Università di

Napoli, Napoli, Italy, <sup>5</sup>Università degli Studi del Sannio,

Benevento, Italy

08.30–08.45

**OP25 BLOCKING T<sub>3</sub> SIGNALLING ENHANCES AXON REGENERATION AND OPTIC TECTUM REINNERVATION FOLLOWING OPTIC NERVE INJURY**

*Bhumika S<sup>1</sup>, Moons L<sup>2</sup>, Darras V<sup>1</sup>*

<sup>1</sup>KU Leuven, Laboratory of Comparative Endocrinology,

Leuven, Belgium, <sup>2</sup>KU Leuven, Laboratory of Neural Circuit

Development and Regeneration, Leuven, Belgium

08.45–09.00

**OP26 PRO-LEARNING AND ANTI-AMNESTIC EFFECTS OF 3-IODOTHYRONAMINE AND 3-IODOTHYROACETIC ACID IN MOUSE**

*Musilli C<sup>1</sup>, Manni ME<sup>1</sup>, De Siena G<sup>1</sup>, Logli A<sup>1</sup>, Saba A<sup>2</sup>, Landucci E<sup>1</sup>, Zucchi R<sup>2</sup>, Raimondi L<sup>1</sup>*

<sup>1</sup>University of Florence, Firenze, Italy, <sup>2</sup>University of Pisa, Pisa,

Italy

09.00–09.15

**OP27 EVIDENCE FOR A ROLE OF UNLIGANDED THYROID HORMONE RECEPTORS ON CEREBROCORICAL NEURONS IN PRIMARY CULTURE**

*Gil-Ibañez P<sup>1</sup>, Morte B<sup>1</sup>, Bernal J<sup>1</sup>*

<sup>1</sup>Instituto de Investigaciones Biomédicas (CSIC-UAM) CIBERER, Madrid, Spain

09.15–09.30

**OP28 EFFECTS OF 3,5-DIODO-L-THYRONINE ON SKELETAL MUSCLE METABOLISM: INTERRELATION BETWEEN INSULIN SENSITIVITY AND MITOCHONDRIAL PHENOTYPE**

*Cioffi F<sup>1</sup>, Glinni D<sup>1</sup>, Coppola M<sup>1</sup>, Silvestri E<sup>1</sup>, Moreno M<sup>1</sup>, Goglia F<sup>1</sup>*

<sup>1</sup>University of Sannio, Dept. of Sciences and Technologies,

Benevento, Italy



09.30–09.45

**OP29 WEIGHT LOSS WITH PRESERVED GLUCOSE HOMEOSTASIS DURING CHRONIC TREATMENT OF OBESE MICE WITH 3-IODOTHYRONAMINE (T1AM): ROLE OF THE SIRTUIN FAMILY**

*Chiellini G<sup>1,2</sup>, Assadi-Porter FM<sup>2</sup>, Reiland H<sup>2</sup>, Carnicelli V<sup>1</sup>, Butz D<sup>2</sup>, Tonelli M<sup>2</sup>, Selen ES<sup>2</sup>, Lorenzini L<sup>1</sup>, Ghelardoni S<sup>1</sup>, Scanlan TS<sup>3</sup>, Zucchi R<sup>1</sup>*

<sup>1</sup>University of Pisa, Pisa, Italy, <sup>2</sup>University of Wisconsin, Madison, United States, <sup>3</sup>Oregon Health and Science University, Portland, United States

09.45–10.00

**OP30 N-ACETYLATION OF 3-IODOTHYRONAMINE REVERSES ITS EFFECTS ON THERMOREGULATION AND CARDIOVASCULAR FUNCTION**

*Hoefig CS<sup>1</sup>, Warner A<sup>1</sup>, Vennström B<sup>1</sup>, Scanlan TS<sup>2</sup>, Mittag J<sup>1</sup>*

<sup>1</sup>Karolinska Institutet, Department of Cell & Molecular Biology, Stockholm, Sweden, <sup>2</sup>Oregon Health and Science University, Department of Physiology and Pharmacology, Portland, United States

10.00–10.30

**Coffee break**

**Aalmarkt Zaal**

**10.30–12.00**

**Symposium 3 (Basic): Thyroid Hormone and Stemness**

Chairpersons: *Clara Alvarez*, Spain  
*Robin Peeters*, The Netherlands

- |             |  |
|-------------|--|
| 10.30–11.00 | Intestinal stem cells<br><i>Micheline Plateroti</i> , France |
| 11.00–11.30 | Neuronal stem cells<br><i>Barbara Demeneix</i> , France      |
| 11.30–12.00 | Skin stem cells<br><i>Ana Aranda</i> , Spain                 |

**Grote Zaal/Main Auditorium**

**10.30–12.00**

**Symposium 4 (Clinical): Thyroid Investigations in at Risk Populations**

Chairpersons: *Simon Pearce*, UK  
*Noortje van der Kleij-Corssmit*, The Netherlands

- |             |   |
|-------------|---|
| 10.30–11.00 | Autoimmune diseases<br><i>Wilmar Wiersinga</i> , The Netherlands                      |
| 11.00–11.30 | Nodular disease and differentiated thyroid carcinoma<br><i>Ralf Paschke</i> , Germany |
| 11.30–12.00 | Cardiovascular disease<br><i>Salman Razvi</i> , UK                                    |

**Poster Area**

**12.00–13.00**

**Lunch and Poster Discussion 2 (Posters 95–183)**  
(see pages 48 to 56)

**Poster Session 11: Thyroid Autoimmunity Clinical**

Chairperson: *Stefano Mariotti*, Italy

**Poster Session 12: Thyroid Cancer Basic 2**

Chairperson: *Dagmar Führer*, Germany

**Poster Session 13: Thyroid Cancer Diagnostics 2**

Chairperson: *Ulla Feldt-Rasmussen*, Denmark

**Poster Session 14: Thyroid Nodules and Goitre 1**

Chairperson: *Laszlo Hegedüs*, Denmark

**Poster Session 15: Thyroid Cancer Therapeutics 2**

Chairperson: *Alicja Hubalewska-Dydejczyk*, Poland

**Poster Session 16: Case Reports 2**

Chairperson: *Bojan Lozanov*, Bulgaria

**Poster Session 17: Clinical Thyroidology 2**

Chairperson: *Joao de Castro*, Portugal

**Poster Session 18: Environmental Influences on Thyroid Function**

Chairperson: *Leonidas Duntas*, Greece

**Poster Session 19: Hyperthyroidism 2**

Chairperson: *Chantal Daumerie*, Belgium

**Poster Session 20: Hypothyroidism**

Chairperson: *Marek Niedziela*, Poland

**Grote Zaal/Main Auditorium**

**13.00–14.00**



prIME Oncology Satellite Symposium supported by Eisai Inc.

**How I Treat Advanced Differentiated Thyroid Cancer (DTC) in 2013**

Welcome and introduction  
*Rossella Elisei*, Italy

13.00 How I treat newly-diagnosed advanced DTC  
*Furio Pacini*, Italy

13.15 Challenge the expert

13.20 How I treat RAI-refractory DTC  
*Rossella Elisei*, Italy

13.35 Challenge the expert

13.40 How I manage adverse events associated with targeted therapy  
*Barbara Jarzab*, Poland

13.55 Challenge the expert

14.00 Concluding remarks  
*Rossella Elisei*, Italy



Grote Zaal/Main Auditorium  
14.00–14.45



### Merck Serono Prize Lecture

Chairpersons: *Theo Visser*, The Netherlands  
*Luigi Bartalena*, Italy

Building a thyroid gland from stem cells:  
a new era in endocrinology  
*Sabine Costagliola*, Belgium

14.45–15.00

Coffee break

Grote Zaal/Main Auditorium

15.00–17.00

### Oral Session 5: Clinical Thyroidology 1 (OP31–OP38)

Chairpersons: *George J. Kahaly*, Germany  
*Eric Fliers*, The Netherlands

15.00–15.15

#### OP31 ASSOCIATION OF HYPER- AND HYPOTHYROIDISM WITH ALL CAUSE MORTALITY IN A POPULATION-BASED STUDY OF 260,790 DANES

*Laulund AS*<sup>1</sup>, *Nybo M*<sup>2</sup>, *Brix TH*<sup>1</sup>, *Abrahamsen B*<sup>3,4</sup>, *Jørgensen HL*<sup>5</sup>,  
*Hegedüs L*<sup>1</sup>

<sup>1</sup>University of Southern Denmark, Department of Endocrinology, Odense, Denmark, <sup>2</sup>Odense University Hospital, Department of Clinical Biochemistry and Pharmacology, Odense, Denmark, <sup>3</sup>University of Southern Denmark, Institute of Clinical Research, Odense, Denmark, <sup>4</sup>Gentofte Hospital, Department of Medicine, Copenhagen, Denmark, <sup>5</sup>Bispebjerg Hospital, Department of Clinical Biochemistry, Copenhagen, Denmark

15.15–15.30

#### OP32 PSYCHIATRIC MORBIDITY IS INCREASED BOTH BEFORE AND AFTER THE DIAGNOSIS OF HYPERTHYROIDISM: A NATIONWIDE REGISTER-BASED STUDY

*Brandt F*<sup>1</sup>, *Thvilum M*<sup>1</sup>, *Almind D*<sup>2</sup>, *Christensen K*<sup>2</sup>, *Green A*<sup>3</sup>,  
*Hegedüs L*<sup>1</sup>, *Brix TH*<sup>1</sup>

<sup>1</sup>Odense University Hospital, Department of Endocrinology and Metabolism, Odense C, Denmark, <sup>2</sup>University of Southern Denmark, The Danish Aging Research Center and The Danish Twin Registry, Odense C, Denmark, <sup>3</sup>University of Southern Denmark, Odense Patient Data Exploratory Network, Odense C, Denmark

15.30–15.45

#### OP33 HYPERTHYROIDISM INCREASES BROWN FAT METABOLISM IN HUMANS

*Schalin-Jääntti C*<sup>1</sup>, *Lahesmaa M*<sup>2</sup>, *Orava J*<sup>2</sup>, *Soinio M*<sup>3</sup>,  
*Hannukainen JC*<sup>2</sup>, *Nojonen T*<sup>2</sup>, *Kirjavainen A*<sup>2</sup>, *Virtanen KA*<sup>2</sup>,  
*Nuutila P*<sup>2,3</sup>

<sup>1</sup>University of Helsinki and Helsinki University Hospital, Division of Endocrinology, Department of Medicine, Helsinki, Finland, <sup>2</sup>Turku PET Centre, Turku, Finland, <sup>3</sup>Department of Medicine, University of Turku, Turku, Finland

15.45–16.00

#### OP34 STUDIES ON AGRANULOCYTOSIS: ANALYSES OF PHYSICIANS' REPORTS OF THE 754 CASES OF ANTITHYROID DRUG-INDUCED AGRANULOCYTOSIS DURING 30 YEARS IN JAPAN

*Nakamura H*<sup>1</sup>, *Miyauchi A*<sup>1</sup>, *Miyawaki N*<sup>2</sup>, *Imagaw J*<sup>2</sup>

<sup>1</sup>Kuma Hospital, Kobe, Japan, <sup>2</sup>Chugai Pharmaceutical Co., Ltd, Tokyo, Japan

16.00–16.15

**OP35 THYROID FUNCTION MONITORING AND TSH LEVELS IN PREGNANT INDIVIDUALS ON LEVOTHYROXINE FOR PRIMARY HYPOTHYROIDISM IN THE UK**

*Taylor PN<sup>1</sup>, Minassian C<sup>2</sup>, Iqbal A<sup>3</sup>, Rehman A<sup>4</sup>, Thomas SL<sup>2</sup>, Okosieme O<sup>1</sup>, Lazarus J<sup>1</sup>, Dayan CM<sup>1</sup>*

<sup>1</sup>Cardiff University, Institute of Molecular and Experimental Medicine, Cardiff, United Kingdom, <sup>2</sup>London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London, United Kingdom, <sup>3</sup>University of Bristol, Henry Wellcome Laboratories for Integrative Neurosciences and Endocrinology, Bristol, United Kingdom, <sup>4</sup>Akron General Medical Center, Department of Internal Medicine, Akron, Ohio, United States

16.15–16.30

**OP36 THE TEMPORAL ASSOCIATION BETWEEN HYPOTHYROIDISM AND PSYCHIATRIC MORBIDITY. A NATIONWIDE REGISTER-BASED STUDY**

*Thvilum M<sup>1</sup>, Brandt F<sup>1</sup>, Almind D<sup>2</sup>, Christensen K<sup>2</sup>, Brix TH<sup>1</sup>, Hegedüs L<sup>1</sup>*

<sup>1</sup>Odense University Hospital, Department of Endocrinology, Odense C, Denmark, <sup>2</sup>University of Southern Denmark, Danish Twin Registry, Odense C, Denmark

16.30–16.45

**OP37 METFORMIN INHIBITS GOITROGENOUS EFFECTS OF TYPE 2 DIABETES**

*Ittermann T<sup>1</sup>, Markus MR<sup>1</sup>, Schipf S<sup>1</sup>, Derwahl M<sup>2</sup>, Meisinger C<sup>3</sup>, Völzke H<sup>1</sup>*

<sup>1</sup>University Medicine Greifswald, Greifswald, Germany, <sup>2</sup>St. Hedwig Hospital, Berlin, Germany, <sup>3</sup>German Research Center for Environmental Health, München, Germany

16.45–17.00

**OP38 RADIOFREQUENCY ABLATION USING MOVING SHOT TECHNIQUE IS A REPRODUCIBLE, EFFECTIVE TECHNIQUE FOR TREATING BENIGN THYROID NODULES. PRELIMINARY RESULTS OF AN INTERNATIONAL RANDOMIZED CONTROLLED TRIAL**

*Deandrea M<sup>1</sup>, Kee Shong Y<sup>2</sup>, Sung JY<sup>3</sup>, Kim KS<sup>3</sup>, Mormile A<sup>1</sup>, Gamarra E<sup>1</sup>, Garino F<sup>1</sup>, Ragazzoni F<sup>1</sup>, Garberoglio R<sup>4</sup>, Limone PP<sup>1</sup>, Baek JH<sup>5</sup>*

<sup>1</sup>Mauriziano Hospital 'Umberto I' of Turin, Department of Endocrinology and Metabolism, Turin, Italy, <sup>2</sup>University of Ulsan College of Medicine, Asan Medical Center, Department of Endocrinology and Metabolism, Seoul, Republic of Korea, <sup>3</sup>Daerim St. Mary's Hospital, Department of Radiology, Thyroid Center, Seoul, Republic of Korea, <sup>4</sup>Mauriziano Hospital 'Umberto I' of Turin, Mauriziano Scientific Foundation, Turin, Italy, <sup>5</sup>University of Ulsan College of Medicine, Asan Medical Center, Department of Radiology and Research Institute of Radiology, Seoul, Republic of Korea

**Aalmarkt Zaal**

15.00–17.00

**Oral Session 6:**

**Thyroid Basic/Translational (OP39–OP46)**

Chairpersons: Georg Brabant, Germany  
Sabine Costagliola, Belgium

15.00–15.15

**OP39 SMALL MOLECULE SCREENING IDENTIFIES SIGNALLING PATHWAYS REGULATING THYROID MORPHOGENESIS IN ZEBRAFISH EMBRYOS**

*Opitz R<sup>1</sup>, Vandernoot I<sup>1</sup>, Haerlingen B<sup>1</sup>, Trubiroha A<sup>1</sup>, Costagliola S<sup>1</sup>*  
<sup>1</sup>IRIBHM, Université Libre de Bruxelles, Brussels, Belgium

15.15–15.30

**OP40 IDENTIFICATION OF NIS AND DUOX2 AS DIRECT FOXE1 TARGET GENES IN THYROID CELLS**

*Fernández LP<sup>1</sup>, López-Márquez A<sup>1</sup>, Martínez AM<sup>1,2</sup>, Gómez-López G<sup>2</sup>, Santisteban P<sup>1</sup>*

<sup>1</sup>Instituto de Investigaciones Biomédicas (CSIC-UAM), Madrid, Spain, <sup>2</sup>Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

15.30–15.45

**OP41 NOVEL CARBOXY-TERMINAL MUTATIONS IN DEHAL1 AND IODOTYROSINE DEIODINASE DEFICIENCY**

*Iglesias A<sup>1</sup>, García L<sup>2</sup>, Wemeau JL<sup>3</sup>, Vincens M<sup>4</sup>, Leger A<sup>5</sup>, Brunet E<sup>6</sup>, Joubert M<sup>7</sup>, Torrabías M<sup>8</sup>, Corripio R<sup>9</sup>, Visser TJ<sup>10</sup>, Cocho J<sup>2</sup>, Moreno JC<sup>1</sup>*

<sup>1</sup>La Paz University Hospital, Institute for Medical and Molecular Genetics (INGEMM), Madrid, Spain, <sup>2</sup>University Hospital, Metabolopathies Laboratory, Santiago de Compostela, Spain, <sup>3</sup>Claude-Huriez Hospital, Endocrinology Service, Lille, France, <sup>4</sup>Cochin Hospital, Endocrinology Service, Paris, France, <sup>5</sup>La Pitié Hospital, Nuclear Medicine Service, Paris, France, <sup>6</sup>Autonomous University of Madrid, Faculty of Sciences, Madrid, Spain, <sup>7</sup>Caen Hospital, Diabetes-Endocrinology Service, Caen, France, <sup>8</sup>Vic Hospital, Endocrinology Service, Barcelona, Spain, <sup>9</sup>Parc Taulí Hospital of Sabadell, Sabadell, Spain, <sup>10</sup>Erasmus Medical Center, Rotterdam, Netherlands

15.45–16.00

**OP42 FEEDBACK REGULATION OF T3 SIGNALING PATHWAY THROUGH MICRORNAs**

*Bogusławska J<sup>1</sup>, Piekliko-Witkowska A<sup>1</sup>, Kedzierska H<sup>1</sup>, Poplawski P<sup>1</sup>, Nauman A<sup>1</sup>*

<sup>1</sup>The Centre of Postgraduate Medical Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland



16.00–16.15

**OP43 FUNCTIONAL REGENERATION OF RECURRENT LARYNGEAL NERVE INJURY AFTER THYROIDECTOMY USING AN ASYMMETRICALLY POROUS NERVE GUIDE CONDUIT**

*Lim J-Y<sup>1</sup>, Choi J-S<sup>1</sup>, Lee JH<sup>2</sup>, Kim Y-M<sup>1</sup>*

<sup>1</sup>Inha University School of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Incheon, Republic of Korea, <sup>2</sup>Hannam University, Department of Advanced Materials, Daejeon, Republic of Korea

16.15–16.30

**OP44 MODULATION OF MCT8 MRNA IN THE THYROID DURING THE WOLFF-CHAIKOFF EFFECT: NEGATIVE REGULATION BY TSH**

*Lima de Souza EC<sup>1</sup>, Cadoso Penha RC<sup>1</sup>, Fortunato RS<sup>1</sup>, Vaisman M<sup>2</sup>, Freitas Ferreira AC<sup>1</sup>, Carvalho DP<sup>1</sup>*

<sup>1</sup>Federal University of Rio de Janeiro, Institute of Biophysics Carlos Chagas Filho, Rio de Janeiro, Brazil, <sup>2</sup>University Hospital Clementino Fraga Filho, Department of Endocrinology, Rio de Janeiro, Brazil

16.30–16.45

**OP45 CORRELATION OF THE EXPRESSION AND LOCALIZATION OF THYROID HORMONE TRANSPORTERS WITH THYROGLOBULIN-PROCESSING CATHEPSINS IN MOUSE THYROID EPITHELIAL CELLS**

*Mc Innes J<sup>1</sup>, Weber J<sup>1</sup>, Rehders M<sup>1</sup>, Saftig P<sup>2</sup>, Peters C<sup>3</sup>, Reinheckel T<sup>3</sup>, Schweizer U<sup>4</sup>, Heuer H<sup>5</sup>, Wirth EK<sup>6</sup>, Brix K<sup>1</sup>*  
Jacobs University Bremen, School of Engineering and Science, Bremen, Germany, <sup>2</sup>Christian-Albrechts Universität zu Kiel, Institute of Biochemistry, Kiel, Germany, <sup>3</sup>Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung, Freiburg, Germany, <sup>4</sup>Rheinische Friedrich-Wilhelms-Universität Bonn, Institut für Biochemie und Molekularbiologie, Bonn, Germany, <sup>5</sup>Leibniz Institute for Age Research / Fritz Lipmann Institute (FLI), Jena, Germany, <sup>6</sup>Charité – Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany

16.45–17.00

**OP46 TRAIL INCREASES SIGNIFICANTLY IN HYPERTHYROID PATIENTS**

*Bernardi S<sup>1</sup>, Bossi F<sup>2</sup>, Furlanis G<sup>2</sup>, Bramante A<sup>2</sup>, Secchiero P<sup>3</sup>, Zauli G<sup>4</sup>, Carretta R<sup>2</sup>, Fabris B<sup>2</sup>*

<sup>1</sup>Ospedale di Cattinara, Medicina Clinica, Trieste, Italy, <sup>2</sup>University of Trieste, Dipartimento di Scienze Mediche Chirurgiche e della Salute, Trieste, Italy, <sup>3</sup>University of Ferrara, Dipartimento di Morfologia ed Embriologia, Trieste, Italy, <sup>4</sup>IRCCS Burlo Garofolo, Trieste, Italy

17.00–17.45

**Meet the Expert 5–8**

**Waalse Kerk**

17.00–17.45

**MTE 5 (Basic)**

Central regulation of peripheral thyroid hormone action  
*Eric Fliers, The Netherlands*

**Kleine Foyer**

17.00–17.45

**MTE 6 (Basic)**

Thyroid hormone transporters  
*Heike Heuer, Germany*

**Aalmarkt Zaal**

17.00–17.45

**MTE 7 (Clinical)**

ETA guidelines for cervical ultrasound scan and ultrasound – guided techniques in the postoperative management of patients with thyroid cancer  
*Laurence Leenhardt, France*

**Grote Zaal/Main Auditorium**

17.00–17.45

**MTE 8 (Translational)**

Selenium and thyroid function  
*Lutz Schomburg, Germany*

**18.00 Departure for Excursion  
(Boat trip and Scheltema Complex)**



Photo: Courtesy of Scheltema Leiden

Grote Zaal/Main Auditorium

08.00–10.00

Oral Session 7:

Thyroid Autoimmunity (OP47–OP54)

Chairpersons: Tomasz Bednarczuk, Poland  
Hemmo Drexhage, The Netherlands

08.00–08.15

OP47 **A GENOME WIDE META-ANALYSIS IN 27,300 SUBJECTS IDENTIFIES NOVEL LOCI ASSOCIATED WITH THYROID PEROXIDASE ANTIBODIES AND CLINICAL THYROID DISEASE**

*Medici M<sup>1</sup>, Porcu E<sup>2</sup>, Pistis G<sup>3</sup>, Teumer A<sup>4</sup>, Brown S<sup>5</sup>, Jensen R<sup>6</sup>, Rawal R<sup>7</sup>, Roef G<sup>8</sup>, Vermeulen S<sup>9</sup>, Lahti J<sup>10</sup>, Simmonds M<sup>11</sup>, Husemoen LL<sup>12</sup>, Freathy R<sup>13</sup>, Shields B<sup>14</sup>, Pietzner D<sup>15</sup>, Taes Y<sup>8</sup>, Psaty B<sup>16</sup>, Hofman A<sup>1</sup>, Wallaschofski H<sup>4</sup>, Gough S<sup>11</sup>, Meyer zu Schwabedissen H<sup>17</sup>, Frayling T<sup>18</sup>, Kaufman J-M<sup>8</sup>, Linneberg A<sup>12</sup>, Rääkkönen K<sup>10</sup>, Rivadeneira F<sup>1</sup>, Uitterlinden A<sup>1</sup>, Walsh J<sup>19</sup>, Meisinger C<sup>20</sup>, den Heijer M<sup>21</sup>, Völzke H<sup>4</sup>, Wilson S<sup>22</sup>, Visser T<sup>1</sup>, Cappola A<sup>23</sup>, Sanna S<sup>2</sup>, Toniolo D<sup>3</sup>, Naitza S<sup>2</sup>, Peeters RP<sup>1</sup>*

<sup>1</sup>Erasmus Medical Center, Rotterdam, Netherlands, <sup>2</sup>Instituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche, c/o Cittadella Universitaria di Monserrato, Monserrato, Italy, <sup>3</sup>Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milan, Italy, <sup>4</sup>University Medicine Greifswald, Greifswald, Germany, <sup>5</sup>Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia, <sup>6</sup>Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, United States, <sup>7</sup>Institute for Genetic Epidemiology, Helmholtz Zentrum Munich, Munich/Neuherberg, Germany, <sup>8</sup>Ghent University Hospital, Ghent, Belgium, <sup>9</sup>Department of Epidemiology, Biostatistics & HTA, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, <sup>10</sup>Institute of Behavioural Sciences, University of Helsinki, Helsinki, Finland, <sup>11</sup>Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford, United Kingdom, <sup>12</sup>Research Centre for Prevention and Health, Glostrup University Hospital, the Capital Region of Denmark, Glostrup, Denmark, <sup>13</sup>Genetics of Complex Traits, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom, <sup>14</sup>Peninsula NIHR Clinical Research Facility, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, United Kingdom, <sup>15</sup>Institute of Medical Epidemiology, Biostatistics, and Informatics, Martin-Luther-University, Halle-Wittenberg, Germany, <sup>16</sup>University of Washington, Seattle, United States, <sup>17</sup>Department of General

Pharmacology, University Medicine Greifswald, Greifswald, Germany, <sup>18</sup>University of Exeter, Exeter, United Kingdom, <sup>19</sup>Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia, <sup>20</sup>Institute of Epidemiology II, Helmholtz Zentrum Munich, Munich, Germany, <sup>21</sup>Department of Internal Medicine, VU Medical Center, Amsterdam, Netherlands, <sup>22</sup>Department of Twin Research and Genetic Epidemiology, King's College London, London, United Kingdom, <sup>23</sup>Perelman School of Medicine at the University of Pennsylvania, Philadelphia, United States

08.15–08.30

OP48 **CHANGES IN SERUM ADHESION MOLECULES, CHEMOKINES, CYTOKINES AND TISSUE REMODELLING FACTORS IN EUTHYROID WOMEN WITHOUT THYROID ANTIBODIES WHO ARE AT RISK FOR AUTOIMMUNE THYROID DISEASE. A HYPOTHESIS ON THE EARLY PHASES OF THE ENDOCRINE AUTOIMMUNE REACTION**

*Effraïmidis G<sup>1</sup>, Beumer W<sup>2</sup>, Drexhage RC<sup>2</sup>, Wiersinga WM<sup>1</sup>, Drexhage HA<sup>2</sup>*

<sup>1</sup>Academical Medical Centre, University of Amsterdam, Endocrinology and Metabolism, Amsterdam, Netherlands, <sup>2</sup>Erasmus Medical Center, Erasmus University, Department of Immunology, Rotterdam, Netherlands

08.30–08.45

OP49 **CELIAC DISEASE IS HIGHLY PREVALENT IN PATIENTS WITH THYROID-ASSOCIATED ORBITOPATHY**

*Kahaly GJ<sup>1</sup>, Schuppan D<sup>1</sup>, Ponto K<sup>2</sup>, Diana T<sup>1</sup>, Matheis N<sup>1</sup>*

<sup>1</sup>Gutenberg University Medical Center, Department of Medicine I, Mainz, Germany, <sup>2</sup>Gutenberg University Medical Center, Department of Ophthalmology, Mainz, Germany

08.45–09.00

OP50 **SELENIUM SUPPLEMENTATION IN PREGNANT WOMEN WITH CHRONIC AUTOIMMUNE THYROIDITIS: EFFECTS ON SELENIUM, SERUM CONCENTRATION AND AUTOIMMUNE PARAMETERS**

*Duntas LH<sup>1</sup>, Boutsiadis A<sup>1</sup>, Mantzou E<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Evgenidion Hospital, University of Athens, Athens, Greece



09.00–09.15

**OP51 THYROID STIMULATING ANTIBODIES IN GRAVES' DISEASE ARISING FROM PATHOGEN-SPECIFIC PRECURSORS: THE CONNECTION WITH *YERSINIA ENTEROCOLITICA***

*Hargreaves CE<sup>1</sup>, Grasso M<sup>2</sup>, Hampe CS<sup>3</sup>, Stenkova A<sup>4</sup>, Atkinson S<sup>2</sup>, Joshua GW<sup>5</sup>, Wren B<sup>5</sup>, Buckle AM<sup>6</sup>, Dunn-Walters D<sup>7</sup>, Banga JP<sup>1</sup>*

<sup>1</sup>King's College London School of Medicine, Diabetes and Endocrinology, London, United Kingdom, <sup>2</sup>University of Nottingham, School of Molecular Medical Sciences, Nottingham, United Kingdom, <sup>3</sup>University of Nottingham, Medicine, Seattle, United States, <sup>4</sup>Pacific Institute of Bioorganic Chemistry, FEB RAS, Vladivostok, Russian Federation, <sup>5</sup>London School of Hygiene and Tropical Medicine, Pathogen Molecular Biology, London, United Kingdom, <sup>6</sup>Monash University, Biochemistry and Molecular Biology, Clayton, Australia, <sup>7</sup>King's College London School of Medicine, Immunobiology, London, United Kingdom

09.15–09.30

**OP52 DOWNREGULATION OF PPAR $\gamma$  EXPRESSION BY TH1 CYTOKINES AND RELATIONSHIP WITH CAVEOLIN-1: A CLUE TO THE PATHOGENESIS OF HASHIMOTO'S THYROIDITIS**

*Wérion A<sup>1</sup>, Van Regermorter V<sup>1</sup>, Marique L<sup>1</sup>, Craps J<sup>1</sup>, Joris V<sup>1</sup>, Senou M<sup>1</sup>, Brichard S<sup>2</sup>, Daumerie C<sup>3</sup>, Mourad M<sup>4</sup>, Lengelé B<sup>1</sup>, Gérard A-C<sup>1</sup>, Many M-C<sup>1</sup>*

<sup>1</sup>UCL, MORF, Brussels, Belgium, <sup>2</sup>UCL, ENDO, Brussels, Belgium, <sup>3</sup>UCL, Endocrinology, Brussels, Belgium, <sup>4</sup>UCL, Surgery, Brussels, Belgium

09.30–09.45

**OP53 THYROID-STIMULATING AUTOANTIBODIES ARE PREVALENT IN PATIENTS WITH HASHIMOTO'S THYROIDITIS AND ASSOCIATED ORBITOPATHY – A PROSPECTIVE, CONTROLLED TRIAL**

*Diana T<sup>1</sup>, Kanitz M<sup>1</sup>, Cronau M<sup>1</sup>, Matheis N<sup>1</sup>, Kahaly GJ<sup>1</sup>*

<sup>1</sup>Gutenberg University Medical Center, Molecular Thyroid Research Laboratory, Mainz, Germany

09.45–10.00

**OP54 HLA CLASS II HAPLOTYPES AND GENOTYPES DIFFERENTIATE BETWEEN THYROID AND POLYGLANDULAR AUTOIMMUNITY**

*Flesch BK<sup>1</sup>, Matheis N<sup>2</sup>, Alt T<sup>3</sup>, Bux J<sup>1</sup>, Kahaly GJ<sup>2</sup>*

<sup>1</sup>German Red Cross Blood Service West Hagen and Bad Kreuznach, Laboratory of Immunogenetics/HLA, Bad Kreuznach, Germany, <sup>2</sup>Gutenberg University Medical Center, Molecular Thyroid Research Laboratory, Mainz, Germany, <sup>3</sup>German Red Cross Blood Service West, Hagen and Bad Kreuznach, Bioinformatics Unit, Bad Kreuznach, Germany

**Aalmarkt Zaal**

**08.00–10.00**

**Oral Session 8:**

**Thyroid Cancer Clinical 2 (OP55–OP62)**

Chairpersons: *Gabriella Pellegriti*, Italy

*Pim Burger*, The Netherlands

08.00–08.15

**OP55 PROPHYLACTIC CENTRAL COMPARTMENT LYMPH NODE DISSECTION (CCND) DOES NOT IMPROVE THE OUTCOME OF PAPILLARY THYROID CANCER (PTC) PATIENTS: RESULTS FROM THE FIRST PROSPECTIVE COHORT STUDY**

*Valerio L<sup>1</sup>, Viola D<sup>1</sup>, Materazzi G<sup>2</sup>, Miccoli P<sup>2</sup>, Basolo F<sup>3</sup>, Sensi E<sup>3</sup>, Faviana P<sup>3</sup>, Molinaro E<sup>1</sup>, Agate L<sup>1</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, <sup>2</sup>Department of Surgery, University of Pisa, Pisa, Italy, <sup>3</sup>Department of Surgical, Medical and Molecular Pathology of the Clinical Area, University of Pisa, Pisa, Italy

08.15–08.30

**OP56 ARE PAPILLARY THYROID MICROCARCINOMA WITH MINIMAL EXTRA-THYROIDAL INVASION AT HIGH RISK OF RECURRENCE?**

*Buffet C<sup>1,2</sup>, Chéraud N<sup>2,3</sup>, Trésallet C<sup>2,3</sup>, Lupinacci R<sup>2,3</sup>, Godiris-Petit G<sup>2,3</sup>, Tissier F<sup>4,5</sup>, Leenhardt L<sup>1,2</sup>, Ménégaux F<sup>2,3</sup>*

<sup>1</sup>APHP- Pitié-Salpêtrière Hospital, Nuclear Medicine, Thyroid Department, Paris, France, <sup>2</sup>Pierre et Marie Curie University (Paris VI), Paris, France, <sup>3</sup>APHP- Pitié-Salpêtrière Hospital, Endocrine Surgery, Paris, France, <sup>4</sup>APHP- Pitié-Salpêtrière Hospital, Pathology Department, Paris, France, <sup>5</sup>Descartes University (Paris V), Paris, France

08.30–08.45

**OP57 IMMUNOHISTOCHEMICAL ASSAY OF THE BRAF<sup>V600E</sup>-MUTATED PROTEIN IN PAPILLARY THYROID CARCINOMA AND COMPARISON WITH SEQUENCING ANALYSIS**

*Colato C<sup>1</sup>, Marchetti I<sup>2</sup>, Piccoli P<sup>1</sup>, Montagna L<sup>1</sup>, Di Coscio G<sup>2</sup>, Brazzarola P<sup>3</sup>, Chilosi M<sup>1</sup>, Ferdeghini M<sup>1</sup>*

<sup>1</sup>University of Verona, Pathology and Diagnostics, Verona, Italy, <sup>2</sup>University of Pisa, Surgical, Molecular, and Ultrastructural Pathology, Pisa, Italy, <sup>3</sup>University of Verona, Surgery and Oncology, Verona, Italy

08.45–09.00

**OP58 THE B-RAF<sup>V600E</sup> MUTATION IS NOT ASSOCIATED WITH POORER CLINICAL PROGNOSIS IN PAPILLARY THYROID CANCER**

*Scheffel RS<sup>1</sup>, Romitti M<sup>1</sup>, Ceolin L<sup>1</sup>, Antunes D<sup>1</sup>, Pinto Ribeiro RV<sup>1</sup>, Dora JM<sup>1</sup>, Maia AL<sup>1</sup>*

<sup>1</sup>Thyroid Section, Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil



# Personalized Approach in the Management of Well-Differentiated Thyroid Cancer

**TUESDAY, 10<sup>th</sup> September**

Leiden, The Netherlands

**13.00-14.00 Genzyme Symposium**  
**City Music Hall, Grote Zaal/Main Auditorium**

## program & speakers

**Chair: Prof. Jan Smit**

Radboud University Nijmegen Medical Center, The Netherlands

**How to manage FNA indeterminate results**

Speaker: Prof. Erik Alexander,  
Brigham & Women's Hospital/Harvard Medical School, Boston, USA

**Ablation with low dose radioiodine**

Speaker: Dr. Steve Hyer,  
Epsom & St Helier University Hospitals NHS Trust, London, UK

**Risk re-stratification – role of stimulated Tg test**

Speaker: Prof. Rossella Elisei,  
Dept. Endocrinology and Metabolism, University of Pisa, Italy

**1<sup>st</sup> Thyroid  
Cancer  
Awareness  
Run**



**MONDAY, 9<sup>th</sup> September**

**Time:** 7.00 hrs

**Place:** Leiden, City Center

**Starting point:** Stadsgehoorzaal/City Music Hall,  
back entrance

**Route:** To Be Confirmed

**Distance:** 3 Km

**Registration:**

online: ETA congress site

on site: Genzyme Booth No.7, Breezaal Hall

**genzyme**  
A SANOFI COMPANY

09.00–09.15

OP59 **HER-2 EXPRESSION IN DIFFERENTIATED THYROID CARCINOMA (DTC): AN IMMUNOHISTOCHEMICAL CHARACTERIZATION IN VIEW OF TARGETED THERAPIES**  
*Giovinazzo S<sup>1</sup>, Campenni A<sup>2</sup>, Simone A<sup>3</sup>, Benvenaga S<sup>1</sup>, Tuccari G<sup>3</sup>, Trimarchi F<sup>1</sup>, Ruggeri RM<sup>1</sup>*

<sup>1</sup>University of Messina, Dep of Clinical and Experimental Medicine, Messina, Italy, <sup>2</sup>University of Messina, Unit of Nuclear Medicine, Messina, Italy, <sup>3</sup>University of Messina, Department of Pathology, Messina, Italy

09.15–09.30

OP60 **INCIDENTAL THYROID CANCER: EPIDEMIOLOGICAL, CLINICAL AND MOLECULAR ANALYSES IN A LARGE SERIES OF PATIENTS TREATED FOR BENIGN DISEASES**

*De Leo S<sup>1</sup>, Perrino M<sup>1</sup>, Badiali S<sup>2</sup>, Rossi S<sup>3</sup>, Cirello V<sup>1</sup>, Colombo C<sup>1</sup>, Beck-Peccoz P<sup>1</sup>, Vicentini L<sup>2</sup>, Fugazzola L<sup>1</sup>*

<sup>1</sup>University of Milan, Milan, Italy, <sup>2</sup>Fondazione IRCCS Ca' Granda, Endocrine Surgery Unit, Milan, Italy, <sup>3</sup>Unit of Pathological Anatomy, San Paolo Hospital Medical School, Milan, Italy

09.30–09.45

OP61 **IMMUNOHISTOCHEMICAL AND BIOCHEMICAL EVIDENCE THAT MEDULLARY THYROID CARCINOMA (MTC) CAN SECRETE CARBOHYDRATE ANTIGEN 19.9 (CA 19.9)**

*Lorusso L<sup>1</sup>, Romei C<sup>1</sup>, Pani F<sup>2</sup>, Guerini A<sup>3</sup>, Menghi A<sup>3</sup>, Poletti A<sup>3</sup>, Torregrossa L<sup>4</sup>, Agate L<sup>1</sup>, Bottici V<sup>1</sup>, Molinaro E<sup>1</sup>, Vitti P<sup>1</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, <sup>2</sup>University Hospital of Cagliari, Cagliari, Italy, <sup>3</sup>Department of Laboratory Medicine, Anatomy and Histopathology, Bassano Del Grappa, Italy, <sup>4</sup>Department of Surgical, Medical and Molecular Pathology of the Clinical Area, University of Pisa, Pisa, Italy

09.45–10.00

OP62 **ATYPIA OF UNDETERMINED SIGNIFICANCE AT CYTOLOGY: PREDICTION OF MALIGNANCY BY US AND COMPARISON OF FURTHER MANAGEMENT**

*Lee KH<sup>1</sup>, Shin JH<sup>2</sup>, Han B-K<sup>2</sup>, Ko EY<sup>2</sup>*

<sup>1</sup>Inje University Haeundae Paik Hospital, Radiology, Busan, Korea, Republic of, <sup>2</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Radiology, Seoul, Republic of Korea

10.00–10.30

**Coffee break**

## Grote Zaal/Main Auditorium

10.30–12.00

### Symposium 5 (Translational): Obesity and the Thyroid

Chairpersons: Colin Dayan, UK  
Marco Medici, The Netherlands

- |             |   |
|-------------|---|
| 10.30–11.00 | Adipocytes and the thyroid<br><i>Marian Ludgate, UK</i>                   |
| 11.00–11.30 | Thyroid function and body composition<br><i>Peter Laurberg, Denmark</i>   |
| 11.30–12.00 | Effects of obesity and metformin treatment<br><i>Luca Chiovato, Italy</i> |

## Aalmarkt Zaal

10.30–12.00

### Symposium 6 (Translational): Molecular Aspects of Thyroid Cancer

Chairpersons: Agnieszka Piekliko-Witkowska, Poland  
Jan Smit, The Netherlands

- |             |   |
|-------------|---|
| 10.30–11.00 | miRNA in thyroid cancer<br><i>Alfredo Fusco, Italy</i>                      |
| 11.00–11.30 | BRAF mutations in thyroid cancer<br><i>Carmelo Nucera, USA</i>              |
| 11.30–12.00 | Gene expression profiles of thyroid cancer<br><i>Barbara Jarzab, Poland</i> |

## Poster Area

12.00–13.00

### Lunch and Poster Discussion 3 (Posters 184–275) (see pages 57 to 65)

#### Poster Session 21: Thyroid Cancer Diagnostics 3

Chairperson: Kalliopi Pazaitou-Panayiotou, Greece

#### Poster Session 22: Thyroid Cancer Diagnostics 4

Chairperson: Valeriano Leite, Portugal

#### Poster Session 23: Thyroid Cancer Therapeutics 3

Chairperson: Françoise Borson-Chazot, France

#### Poster Session 24: Thyroid Cancer Therapeutics 4

Chairperson: Lionel Groussin, France

#### Poster Session 25: Case Reports 3

Chairperson: Valentin Fadeyev, Russia

#### Poster Session 26: Imaging

Chairperson: Markus Luster, Germany

#### Poster Session 27: Thyroid Hormone Metabolism and Action

Chairperson: Maria Jesus Obregon, Spain

#### Poster Session 28: Medullary Thyroid Cancer

Chairperson: Laura Fugazzola, Italy

#### Poster Session 29: Thyroid Nodules and Goitre 2

Chairperson: Ralf Paschke, Germany

#### Poster Session 30: Thyroid in Reproduction and Development

Chairperson: Peter Bisschop, The Netherlands



**Grote Zaal/Main Auditorium**  
**13.00–14.00**



**Genzyme Symposium**

**Personalized Approach in the Management of Well-Differentiated Thyroid Cancer**

13.00–13.05	Welcome and Introduction <i>Jan Smit, The Netherlands</i>
13.05–13.20	How to manage FNA indeterminate results <i>Erik Alexander, USA</i>
13.20–13.35	Ablation with low dose radioiodine <i>Steve Hyer, UK</i>
13.35–13.50	Risk re-stratification – the role of stimulated Tg test <i>Rossella Elisei, Italy</i>
13.50–14.00	Final discussion and symposium close <i>Jan Smit, The Netherlands</i>

**14.00–14.45**

**Meet the Expert 9–12**

<b>Waalse Kerk</b> 14.00–14.45	<b>MTE 9 (Basic)</b> Thyroid hormone action in muscle differentiation <i>Domenico Salvatore, Italy</i>
<b>Kleine Foyer</b> 14.00–14.45	<b>MTE 10 (Clinical)</b> Lessons from the pathology report in differentiated thyroid carcinoma <i>Sofia Tseleni-Balafouta, Greece</i>
<b>Aalmarkt Zaal</b> 14.00–14.45	<b>MTE 11 (Clinical)</b> ETA guidelines on genetic screening of medullary thyroid carcinoma <i>Rossella Elisei, Italy</i>
<b>Grote Zaal/Main Auditorium</b> 14.00–14.45	<b>MTE 12 (Clinical)</b> Can we prevent Graves' orbitopathy? <i>Petros Perros, UK</i>

14.45–15.00 **Coffee break**

**Grote Zaal/Main Auditorium**

**15.00–17.00**

**Oral Session 9:**  
**Clinical Thyroidology 2 (OP63–OP70)**

Chairpersons: *Laurence Leenhardt, France*  
*Georg Hennemann, The Netherlands*

15.00–15.15

**OP63 THE RELATIONSHIP BETWEEN TSH AND FREE T4 IN A LARGE POPULATION IS COMPLEX, NON-LINEAR AND DIFFERS BY AGE AND GENDER**

*Hadlow NC<sup>1,2</sup>, Rothacker KM<sup>3</sup>, Wardrop R<sup>2</sup>, Brown SJ<sup>3</sup>, Lim EM<sup>2,3</sup>, Walsh JP<sup>3,4</sup>*

<sup>1</sup>Western Diagnostic Pathology, Myaree, Australia, <sup>2</sup>PathWest Laboratory Medicine, Nedlands, Australia, <sup>3</sup>Sir Charles Gairdner Hospital, Department of Endocrinology and Diabetes, Nedlands, Australia, <sup>4</sup>University of Western Australia, School of Medicine and Pharmacology, Crawley, Australia

15.15–15.30

**OP64 HOMOZYGOUS RESISTANCE TO THYROID HORMONE: CAN THE COMBINATION OF TRIAC AND CARBIMAZOLE PREVENT CARDIAC COMPLICATIONS?**

*Moran C<sup>1</sup>, Habeb A<sup>2</sup>, Kydd A<sup>3</sup>, Kahaly G<sup>4</sup>, Mohr-Kahaly S<sup>5</sup>, Kampmann C<sup>5</sup>, Lyons G<sup>1</sup>, Rajanayagam O<sup>1</sup>, Schoenmakers E<sup>1</sup>, Halsall D<sup>6</sup>, Mollon J<sup>7</sup>, Baguley D<sup>8</sup>, Morsy M<sup>2</sup>, Chatterjee VK<sup>1</sup>*

<sup>1</sup>Institute of Metabolic Science, Cambridge, United Kingdom, <sup>2</sup>Maternity & Childrens Hospital & Taibah University, Paediatric Department, Al-Madinah, Saudi Arabia, <sup>3</sup>Addenbrookes Hospital, Cardiology Dept, Cambridge, United Kingdom, <sup>4</sup>Johannes Gutenberg University Medical Center, Department of Medicine, Mainz, Germany, <sup>5</sup>Johannes Gutenberg University Medical Center, Department of Cardiology, Mainz, Germany, <sup>6</sup>Addenbrookes Hospital, Department of Biochemistry, Cambridge, United Kingdom, <sup>7</sup>University of Cambridge, Department of Experimental Psychology, Cambridge, United Kingdom, <sup>8</sup>Addenbrookes Hospital, Department of Audiology, Cambridge, United Kingdom

15.30–15.45

**OP65 COGNITIVE FUNCTIONS IN PRIMARY HYPOTHYROIDISM AFTER LONG-TERM SUBSTITUTION**

*Djurovic MM<sup>1</sup>, Pereira AM<sup>2</sup>, Pavlovic D<sup>3</sup>, Salak B<sup>4</sup>, Jemuovic ZH<sup>1</sup>, Jankovic D<sup>1</sup>, Petakov M<sup>1</sup>, Djukic V<sup>5</sup>, Damjanovic S<sup>1</sup>*

<sup>1</sup>Institute of Endocrinology, Diabetes and Diseases of Metabolism, Clinical Centre of Serbia, Belgrade, Serbia, <sup>2</sup>Department of Endocrinology and Metabolic Diseases Leiden University Medical Center, Leiden, Netherlands, <sup>3</sup>Faculty of Philosophy, University of Belgrade, Belgrade, Serbia, <sup>4</sup>Institute of Neurology, Clinical Centre of Serbia, Belgrade, Serbia, <sup>5</sup>Emergency Center, Clinical Centre of Serbia, Belgrade, Serbia

15.45–16.00

**OP66 EVALUATING THE PREVALENCE OF THYROTROPIN RECEPTOR (TSHR) INACTIVATING MUTATIONS IN ADULTS WITH SUBCLINICAL HYPOTHYROIDISM (SH); IMPACT ON BONE DENSITY**

*de Lloyd AC<sup>1</sup>, Bakhsh A<sup>1</sup>, Zhang L<sup>1</sup>, Evans C<sup>2</sup>, Dodd A<sup>2</sup>, Durrant H<sup>2</sup>, Neale S<sup>2</sup>, Mitchem K<sup>2</sup>, Whatley S<sup>2</sup>, Rees DA<sup>1</sup>, Ludgate M<sup>1</sup>*

<sup>1</sup>IMEM, Cardiff University School of Medicine, University Hospital of Wales, Cardiff, United Kingdom, <sup>2</sup>Department of Medical Biochemistry, Cardiff & Vale University Health Board, Cardiff, United Kingdom

16.00–16.15

**OP67 TPO ANTIBODIES ARE ASSOCIATED WITH A LOWER LIVE BIRTH RATE IN WOMEN WITH RECURRENT MISCARRIAGE**

*Vissenberg R<sup>1</sup>, Fliers E<sup>2</sup>, van der Post JAM<sup>3</sup>, van Wely M<sup>1</sup>, Bisschop PH<sup>2</sup>, Goddijn M<sup>1</sup>*

<sup>1</sup>Academic Medical Centre, Centre for Reproductive Medicine, Amsterdam, Netherlands, <sup>2</sup>Academic Medical Centre, Endocrinology and Metabolism, Amsterdam, Netherlands, <sup>3</sup>Academic Medical Centre, Obstetrics and Gynaecology, Amsterdam, Netherlands

16.15–16.30

**OP68 90% OF PREGNANT WOMEN WILL BE MISCLASSIFIED BY THE USE OF PREDETERMINED FREE T4 REFERENCE RANGES FROM DIFFERENT LABORATORIES**

*Bliddal S<sup>1</sup>, Feldt-Rasmussen U<sup>1</sup>, Boas M<sup>2</sup>, Faber J<sup>3</sup>, Juul A<sup>4</sup>, Precht DH<sup>5</sup>*

<sup>1</sup>Copenhagen University Hospital (Rigshospitalet), Department of Endocrinology, Copenhagen, Denmark, <sup>2</sup>Copenhagen University Hospital (Hillerød), Department of Pediatrics, Hillerød, Denmark, <sup>3</sup>Copenhagen University Hospital (Herlev), Herlev, Denmark, <sup>4</sup>Copenhagen University Hospital (Rigshospitalet), Department of Growth and Reproduction, Copenhagen, Denmark, <sup>5</sup>Copenhagen University Hospital (Hvidovre), Family Outpatient Clinic, Copenhagen, Denmark

16.30–16.45

**OP69 HIGH PREVALENCE OF THYROID DISORDERS IN PREGNANT WOMEN IN A MILDLY IODINE-DEFICIENT COUNTRY: A POPULATION-BASED STUDY**

*Moreno-Reyes R<sup>1</sup>, Glinioer D<sup>2</sup>, Van Oyen H<sup>3</sup>, Vandevijvere S<sup>3</sup>*

<sup>1</sup>Université Libre de Bruxelles, Department of Nuclear Medicine, Hôpital Erasme, Brussels, Belgium, <sup>2</sup>Université Libre de Bruxelles, Division of Endocrinology, Hôpital Saint-Pierre, Brussels, Belgium, <sup>3</sup>Scientific Institute of Public Health, Department of Public Health and Surveillance, Brussels, Belgium

16.45–17.00

**OP70 IS THYROID HYPOFUNCTION A TRUE FEATURE OF BREAST CANCER?**

*Smyth PP<sup>1,2</sup>, Mc Dermott EWM<sup>1</sup>, O'Higgins NJ<sup>1</sup>*

<sup>1</sup>University College Dublin, School of Medicine, Dublin, Ireland,

<sup>2</sup>National University of Ireland, Galway, School of Physics, Galway, Ireland

**Aalmarkt Zaal**

**15.00–17.00**

**Oral Session 10:**

**Thyroid Cancer Basic (OP71–OP78)**

Chairpersons: *Corinne Dupuy*, Belgium

*Pilar Santisteban*, Spain

15.00–15.15

**OP71 THYROID CANCER SUSCEPTIBILITY GENE FOXE1 PROMOTES CELL MOTILITY AND IS REQUIRED FOR SURVIVAL OF ADULT THYROID CELLS**

*De Menna M<sup>1</sup>, Marotta P<sup>2</sup>, Esposito R<sup>1</sup>, Orlacchio A<sup>2</sup>, De Vita G<sup>1</sup>, Garbi C<sup>1</sup>, De Felice M<sup>2</sup>, Di Lauro R<sup>1</sup>*

<sup>1</sup>Università degli Studi di Napoli 'Federicoll', Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Napoli, Italy,

<sup>2</sup>Biogem s.c.a.r.l., Ariano Irpino, Italy

15.15–15.30

**OP72 INHIBITION OF MTOR SIGNALING INDUCES APOPTOSIS AND TTF-1 DEPENDENT REDIFFERENTIATION OF THYROID CARCINOMA CELL LINES**

*Plantinga TS<sup>1</sup>, Heinhuis B<sup>1</sup>, Joosten LAB<sup>2</sup>, Netea MG<sup>2</sup>, Hermus ARMM<sup>1</sup>, Schweppe RE<sup>3</sup>, Haugen BR<sup>3</sup>, Smit JWA<sup>2</sup>, Netea-Maier RT<sup>1</sup>*

<sup>1</sup>Radboud University Nijmegen Medical Center, Department of Medicine, Division of Endocrinology, Nijmegen, Netherlands,

<sup>2</sup>Radboud University Nijmegen Medical Center, Department of Medicine, Nijmegen, Netherlands, <sup>3</sup>University of Colorado Denver, Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes, Aurora, United States

15.30–15.45

**OP73 ISOLATION OF NOVEL TARGETS GENES OF TWIST1 IN ANAPLASTIC THYROID CARCINOMA**

*Orlandella FM<sup>1</sup>, Di Maro G<sup>1</sup>, Salerno P<sup>1</sup>, Santoro M<sup>1</sup>, Salvatore G<sup>2</sup>*

<sup>1</sup>Università di Napoli Federico II, Napoli, Italy, <sup>2</sup>Università di Napoli Parthenope, Napoli, Italy

15.45–16.00

**OP74 CROSSTALK BETWEEN WNT/BETA-CATENIN AND PI3K/AKT SIGNALING PATHWAY IN THYROID CANCER**

*Sastre-Perona AM<sup>1</sup>, Riesco-Eizaguirre G<sup>1</sup>, Santisteban Sanz P<sup>1</sup>*

<sup>1</sup>Instituto de Investigaciones Biomédicas (CSIC-UAM), Molecular Fisiopathology, Madrid, Spain

16.00–16.15

**OP75 RESISTANCE OF ANAPLASTIC THYROID CANCER TO BRAF(V600E) INHIBITION THROUGH FEEDBACK ACTIVATION OF EGFR**

*Koh YW<sup>1</sup>, Yang YJ<sup>1</sup>, Na HJ<sup>1</sup>, Kim W-S<sup>1</sup>, Bong JP<sup>1</sup>, Baek SJ<sup>1</sup>, Kim JW<sup>2</sup>, Park JH<sup>3</sup>, Shin DY<sup>4</sup>, Hong HJ<sup>1</sup>, Kwon JH<sup>1</sup>, Lee EJ<sup>4</sup>, Choi EC<sup>1</sup>*

<sup>1</sup>Yonsei University College of Medicine, Otorhinolaryngology, Seoul, Republic of Korea, <sup>2</sup>Soonchunhyang University Hospital, Otolaryngology-Head and Neck Surgery, Seoul, Republic of Korea, <sup>3</sup>Soonchunhyang University Hospital, Otolaryngology-Head and Neck Surgery, Cheonan, Republic of Korea, <sup>4</sup>Yonsei University College of Medicine, Endocrinology, Seoul, Republic of Korea

16.15–16.30

**OP76 AN INTRONIC DELETION IN PHOSPHOLIPASE-C  $\beta$ 1 (PLC $\beta$ 1) IS ASSOCIATED WITH EUTHYROID MULTINODULAR GOITRE (MNG) PROGRESSING TO PAPILLARY THYROID CANCER (PTC)**

*Grennan-Jones FA<sup>1</sup>, Bakhsh A<sup>1</sup>, Hampshire M<sup>2</sup>, Gregory J<sup>3</sup>, Kirov G<sup>2</sup>, Williams D<sup>4</sup>, Bullock M<sup>5</sup>, Clifton-Bligh R<sup>5</sup>, Ludgate M<sup>1</sup>*

<sup>1</sup>Cardiff University, Thyroid Research Group, Institute of Molecular and Experimental Medicine, Cardiff, United Kingdom, <sup>2</sup>Cardiff University, Institute of Psychological Medicine & Clinical Neurosciences, Cardiff, United Kingdom, <sup>3</sup>Cardiff University, Dept of Child Health, Institute of Molecular and Experimental Medicine, Cardiff, United Kingdom, <sup>4</sup>Cambridge University, Strangeways Research Laboratory, Cambridge, United Kingdom, <sup>5</sup>University of Sydney, Kolling Institute of Medical Research, Sydney, Australia

16.30–16.45

**OP77 MOLECULAR CONSEQUENCES OF BRAFV600E MUTATION EVALUATED IN A MOUSE MODEL**

*Rusinek D<sup>1</sup>, Swierniak M<sup>1</sup>, Chmielik E<sup>2</sup>, Kowalska M<sup>1</sup>, Kowal M<sup>1</sup>, Widlak W<sup>3</sup>, Jarzab B<sup>1</sup>*

<sup>1</sup>MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland, <sup>2</sup>MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Tumor Pathology, Gliwice, Poland, <sup>3</sup>MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Center for Translational Research and Molecular Biology of Cancer, Gliwice, Poland

16.45–17.00

**OP78 POSSIBLE MODIFIER ROLE FOR THE RET FUNCTIONAL POLYMORPHISM G691S**

*Colombo C<sup>1</sup>, Rizzetti MG<sup>2</sup>, Mondellini P<sup>2</sup>, Romeo P<sup>2</sup>, Minna E<sup>2</sup>, Greco A<sup>2</sup>, Fugazzola L<sup>1</sup>, Borrello MG<sup>2</sup>*

<sup>1</sup>University of Milan, Department of Clinical Sciences and Community Health, Endocrinology and Diabetology Unit, Fondazione IRCCS Ca' Granda, Milan, Italy, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Experimental Oncology and Molecular Medicine, Molecular Mechanism Unit, Milan, Italy



**Grote Zaal/Main Auditorium**  
**17.00–17.45**

## **Special Lecture in Honour of Georg Hennemann**

Chairpersons: *Theo Visser*, The Netherlands  
*Luigi Bartalena*, Italy

Non-thyroidal illness: a syndrome with different faces  
*Greet Van den Berghe*, The Netherlands

**Grote Zaal/Main Auditorium**  
**18.00–19.15**

## **ETA General Assembly**

(For Members only)

### **20.00 Gala Dinner at the National Museum of Antiquities**



Photos: Courtesy of the Rijksmuseum van Oudheden

Aalmarkt Zaal

07.45–08.45

## Short-Call Abstracts

Aalmarkt Zaal

08.45–10.45

### Oral Session 11: Graves' Orbitopathy (OP79–OP86)

Chairpersons: *Luigi Bartalena*, Italy  
*Maarten Soeters*, The Netherlands

08.45–09.00

#### OP79 **PROTEOMIC PROFILE OF ORBITAL TISSUE IN GRAVES' ORBITOPATHY**

*Matheis N<sup>1</sup>, Grus F<sup>2</sup>, Diana T<sup>1</sup>, Ponto K<sup>3</sup>, Pitz S<sup>3</sup>, Kahaly GJ<sup>1</sup>*

<sup>1</sup>Gutenberg University Medical Center, Molecular Thyroid Research Laboratory, Mainz, Germany, <sup>2</sup>Gutenberg University Medical Center, Laboratory of Experimental Ophthalmology, Mainz, Germany, <sup>3</sup>Gutenberg University Medical Center, Department of Ophthalmology, Mainz, Germany

09.00–09.15

#### OP80 **POSSIBLE TARGETS FOR NON-IMMUNOSUPPRESSIVE THERAPY OF GRAVES' ORBITOPATHY (GO)**

*Zhang L<sup>1</sup>, Grennan-Jones F<sup>1</sup>, Draman MS<sup>1</sup>, Lane C<sup>2</sup>, Dayan CM<sup>1</sup>, Ludgate M<sup>1</sup>*

<sup>1</sup>Cardiff University, Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff, United Kingdom, <sup>2</sup>Cardiff & Vale University Health Board, Heath Park, Department of Ophthalmology, Cardiff, United Kingdom

09.15–09.30

#### OP81 **IMMEDIATE EARLY GENES ARE OVEREXPRESSED IN SMOKERS WITH GRAVES' OPTHALMOPATHY COMPARED TO NON-SMOKERS**

*Planck T<sup>1,2</sup>, Shahida B<sup>1</sup>, Parikh H<sup>1,3</sup>, Åsman P<sup>4,5</sup>, Hallengren B<sup>1,2</sup>, Lantz M<sup>1,2</sup>*

<sup>1</sup>Lund University, Dpt. of Clinical Sciences, Diabetes and Endocrinology, Malmö, Sweden, <sup>2</sup>Skåne University Hospital, Dpt. of Endocrinology, Malmö, Sweden, <sup>3</sup>Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States, <sup>4</sup>Lund University, Dpt. of Clinical Sciences, Ophthalmology, Malmö, Sweden, <sup>5</sup>Skåne University Hospital, Dpt. of Ophthalmology, Malmö, Sweden

09.30–09.45

#### OP82 **THYROID STIMULATING AUTOANTIBODIES INDICATE THE ONSET OF DYSTHYROID OPTIC NEUROPATHY**

*Ponto K<sup>1</sup>, Diana T<sup>2</sup>, Kanitz M<sup>2</sup>, Matheis N<sup>2</sup>, Kahaly GJ<sup>2</sup>*

<sup>1</sup>Gutenberg University Medical Center, Department of Ophthalmology, Mainz, Germany, <sup>2</sup>Gutenberg University Medical Center, Department of Medicine I, Mainz, Germany

09.45–10.00

#### OP83 **COMPARISON OF EARLY TOTAL THYROIDECTOMY WITH ANTITHYROID TREATMENT IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE GRAVES' ORBITOPATHY, A RANDOMIZED PROSPECTIVE TRIAL**

*Erdoğan MF<sup>1</sup>, Demir Ö<sup>1</sup>, Ersoy RÜ<sup>2</sup>, Gül K<sup>2</sup>, Ünlütürk U<sup>1</sup>, Aydoğan Bİ<sup>1</sup>, Üç ZA<sup>3</sup>, Mete T<sup>4</sup>, Ertek S<sup>5</sup>, Çakır B<sup>2</sup>, Güler S<sup>4</sup>, Çorapçıoğlu D<sup>1</sup>, Dağdelen S<sup>6</sup>, Erdoğan G<sup>5</sup>*

<sup>1</sup>Ankara University School of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, <sup>2</sup>Yıldırım Beyazıt University, School of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, <sup>3</sup>Ankara Educational and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, <sup>4</sup>Ankara Numune Educational and Research Hospital, Endocrinology and Metabolic Diseases, Ankara, Turkey, <sup>5</sup>Ufuk University School of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, <sup>6</sup>Hacettepe University, School of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey

10.00–10.15

#### OP84 **LACK OF OCCURRENCE OF GRAVES' ORBITOPATHY (GO) AFTER RADIOIODINE (RAI) THERAPY WITH AND WITHOUT STEROID PROPHYLAXIS: A PROSPECTIVE STUDY**

*Vannucchi GM<sup>1</sup>, Covelli D<sup>1</sup>, Campi I<sup>1</sup>, Currò N<sup>2</sup>, Dazzi D<sup>3</sup>, Rodari M<sup>4</sup>, Pepe G<sup>4</sup>, Chiti A<sup>4</sup>, Beck-Peccoz P<sup>1</sup>, Salvi M<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Fondazione IRCCS Cà Granda, Milan, Italy, <sup>2</sup>Ophthalmology, Fondazione IRCCS Cà Granda, Milan, Italy, <sup>3</sup>Internal Medicine, Ospedale di Fidenza, Fidenza, Italy, <sup>4</sup>Nuclear Medicine, Istituto Clinico Humanitas, Rozzano, Italy

10.15–10.30

#### OP85 **IMPACT OF PREVIOUS ORBITAL IRRADIATION ON THE OUTCOME OF DECOMPRESSION SURGERY IN DYSTHYROID ORBITOPATHY**

*Grunenwald S<sup>1</sup>, Jalbert F<sup>2</sup>, Leray B<sup>3</sup>, Imbert P<sup>4</sup>, Bachaud J-M<sup>5</sup>, Boutault F<sup>2</sup>, Caron P<sup>1</sup>*

<sup>1</sup>CHU Larrey, Endocrinology and Metabolic Diseases, Toulouse, France, <sup>2</sup>CHU Purpan, Maxillo-facial Unit, Toulouse, France, <sup>3</sup>CHU Toulouse, Department of Ophthalmology, Toulouse, France, <sup>4</sup>Clinique du Parc, Ophthalmology, Toulouse, France, <sup>5</sup>Institut Claudius Regaud, Radiotherapy, Toulouse, France

10.30–10.45

**OP86 DIFFERENTIAL MODULATION OF CXCL8 CHEMOKINE, IN COMPARISON WITH CXCL10, BY CYTOKINES IN HUMAN THYROCYTES IN GRAVES' DISEASE AND IN PRIMARY FIBROBLASTS OR PREADIPOCYTES FROM GRAVES' OPHTHALMOPATHY**

*Ferrari SM<sup>1</sup>, Fallahi P<sup>1</sup>, Ruffilli I<sup>1</sup>, Corrado A<sup>1</sup>, Nardi M<sup>1</sup>, Sellari-Franceschini S<sup>1</sup>, Antonelli A<sup>1</sup>*

<sup>1</sup>University of Pisa, Pisa, Italy

**Kleine Foyer**

**08.45–10.45**

**Oral Session 12:  
Thyroid Hormone Transporters and  
Deiodinases (OP87–OP94)**

Chairpersons: *Ulrich Schweizer*, Germany  
*Heike Heuer*, Germany

08.45–09.00

**OP87 KNOCKDOWN OF TYPE 3 IODOTHYRONINE DEIODINASE DISTURBS EMBRYONIC AND LARVAL DEVELOPMENT IN ZEBRAFISH**

*Heijlen M<sup>1</sup>, Bagci E<sup>2</sup>, Houbrechts A<sup>1</sup>, Knapen D<sup>2,3</sup>, Darras VM<sup>1</sup>*

<sup>1</sup>KU Leuven, Laboratory of Comparative Endocrinology, Department of Biology, Leuven, Belgium, <sup>2</sup>University of Antwerp, Systemic Physiological & Ecotoxicological Research, Department of Biology, Antwerpen, Belgium, <sup>3</sup>University of Antwerp, Veterinary Physiology and Biochemistry, Department of Veterinary Sciences, Antwerpen, Belgium

09.00–09.15

**OP88 THYROID HORMONE INACTIVATION IS ESSENTIAL FOR THE PROLIFERATION OF MUSCLE STEM CELLS AND THE REGENERATION PROCESS**

*Dentice M<sup>1</sup>, Ambrosio R<sup>1</sup>, Luongo C<sup>1</sup>, Alfano F<sup>1</sup>, Langella M<sup>1</sup>, Salvatore D<sup>1</sup>*

<sup>1</sup>University of Naples Federico II, Clinical Medicine and Surgery, Naples, Italy

09.15–09.30

**OP89 EFFECTIVE TRANSPORT BY THE BILE ACID TRANSPORTER SLC10A1 EXPLAINS THE LIVER SELECTIVE ACTION OF THE LIPID-LOWERING THYROID HORMONE ANALOGUE EPROTIROME**

*Kersseboom S<sup>1</sup>, Carlsson B<sup>2</sup>, Visser TJ<sup>1</sup>*

<sup>1</sup>Erasmus University Medical Center, Department of Internal Medicine, Rotterdam, Netherlands, <sup>2</sup>Karo Bio, Huddinge, Sweden

09.30–09.45

**OP90 EXPRESSION PROFILE AND MANIPULATION OF THYROID HORMONE TRANSPORTERS AND DEIODINASES IN THE DEVELOPING CHICK CEREBELLUM**

*Delbaere J<sup>1</sup>, Bourgeois NMA<sup>1</sup>, Van Herck SLJ<sup>1</sup>, Darras VM<sup>1</sup>*

<sup>1</sup>KU Leuven, Laboratory of Comparative Endocrinology, Leuven, Belgium

09.45–10.00

**OP91 LIVER THYROID HORMONE METABOLISM DURING FASTING**

*de Vries E<sup>1</sup>, Eggels L<sup>1</sup>, van Wijk N<sup>1</sup>, Kalsbeek A<sup>1</sup>, Fliers E<sup>1</sup>, Boelen A<sup>1</sup>*

<sup>1</sup>AMC Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, Netherlands

10.00–10.15

**OP92 3,3'-T<sub>2</sub> IS TRANSPORTED BY THE L-TYPE AMINO ACID TRANSPORTER LAT2**

*Wittner M<sup>1</sup>, Köhrle J<sup>2</sup>, Schüle R<sup>1</sup>, Krause G<sup>1</sup>, Kinne A<sup>1</sup>*

<sup>1</sup>Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, <sup>2</sup>Institut für Experimentelle Endokrinologie, Charité-Universitätsmedizin, Berlin, Germany

10.15–10.30

**OP93 DECREASED SELENOCYSTEINE (SEC) READ-THROUGH BY A PATIENT MUTATION IN THE SEC INSERTION SEQUENCE OF THE TYPE 2 DEIODINASE**

*Zevenbergen C<sup>1</sup>, Visser WE<sup>1</sup>, Peeters RP<sup>1</sup>, Larsen PR<sup>2</sup>, Chavatte L<sup>3</sup>, Visser TJ<sup>1</sup>*

<sup>1</sup>Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands, <sup>2</sup>Brigham and Women's Hospital, Department of Internal Medicine, Boston, United States, <sup>3</sup>Centre de Génétique Moléculaire, Département Expression des Gènes, Gif-sur-Yvette Cedex, France

10.30–10.45

**OP94 DEVELOPMENTAL EXPRESSION PATTERN OF THYROID HORMONE TRANSPORTERS AND DEIODINASES IN THE CHOROID PLEXUS AND BLOOD VESSELS IN THE CHICKEN BRAIN**

*Van Herck SL<sup>1</sup>, Delbaere J<sup>1</sup>, Bourgeois NM<sup>1</sup>, Geysens S<sup>1</sup>, McAllan BM<sup>2</sup>, Richardson SJ<sup>3</sup>, Darras VM<sup>1</sup>*

<sup>1</sup>KU Leuven, Laboratory of Comparative Endocrinology, Department of Biology, Leuven, Belgium, <sup>2</sup>The University of Sydney, Physiology, School of Medical Sciences, and Bosch Institute, Sydney, Australia, <sup>3</sup>RMIT University, School of Medical Sciences, Melbourne, Australia

10.45–11.00

**Coffee break**



#### Kleine Foyer

11.00–12.30

### Symposium 7 (Basic): Deiodinases in Local Thyroid Hormone Control

Chairpersons: *Monica Dentice*, Italy  
*Warner Simonides*, The Netherlands

- |             |  |
|-------------|--|
| 11.00–11.30 | Deiodinases in inflammatory cells<br><i>Joan Kwakkel</i> , The Netherlands |
| 11.30–12.00 | Deiodinases in aging<br><i>W. Edward Visser</i> , The Netherlands          |
| 12.00–12.30 | Deiodinases in bone<br><i>Duncan Bassett</i> , UK                          |

#### Aalmarkt Zaal

12.30–13.00

### Young Investigator Awards, Poster Prizes, Jack Robbins Prize and Closing Ceremony

*Furio Pacini*, Italy (President)  
*Colin Dayan*, UK (Secretary)

#### Aalmarkt Zaal

11.00–12.30

### Symposium 8 (Clinical): Pros and Cons of Novel Diagnostic Tools for Differentiated Thyroid Carcinoma

Chairpersons: *Maria Alevizaki*, Greece  
*Thera Links*, The Netherlands

- |             |   |
|-------------|---|
| 11.00–11.20 | Molecular genetics of fine needle aspirates<br>– Markers for benign neoplasia<br><i>Richard Kloos</i> , USA |
| 11.20–11.40 | – Markers for malignancy<br><i>Furio Pacini</i> , Italy   |
| 11.40–12.05 | Thyroglobulin antibody interferences with thyroglobulin measurements<br><i>Carole Spencer</i> , USA         |
| 12.05–12.30 | Supersensitive Tg assays: clinical application<br><i>Maria Grazia Castagna</i> , Italy                      |



Sunday, 8th September 2013

Poster Exhibition Area

12.00–13.00

Poster Session 1

PO1 Thyroid Autoimmunity Basic

Chair: Paul Banga, UK

P1 **A REDUNDANT ROLE FOR PROPEPTIDE IN HUMAN THYROID PEROXIDASE PROTEIN FOR ITS CELLULAR, ENZYMATIC AND IMMUNOLOGICAL ACTIVITY**

Godlewska M<sup>1</sup>, Gora M<sup>2</sup>, Buckle AM<sup>3</sup>, Porebski BT<sup>3</sup>, Kemp EH<sup>4</sup>, Sutton BJ<sup>5</sup>, Czarnocka B<sup>1</sup>, Banga JP<sup>6</sup>

<sup>1</sup>Medical Centre of Postgraduate Education, Biochemistry, Warsaw, Poland, <sup>2</sup>Institute Biochemistry and Biophysics, Genetics, Warsaw, Poland, <sup>3</sup>Monash University, Biochemistry and Molecular Biology, Clayton, Australia, <sup>4</sup>University of Sheffield, Human Metabolism, Sheffield, United Kingdom, <sup>5</sup>King's College London School of Medicine, Cell and Molecular Biophysics, London, United Kingdom, <sup>6</sup>King's College London School of Medicine, Diabetes and Endocrinology, London, United Kingdom

P2 **ALTERATIONS IN THE HYPOXIC RESPONSE OF ORBITAL FIBROBLASTS FROM GRAVES' ORBITOPATHY PATIENTS**

Berchner-Pfannschmidt U<sup>1</sup>, Müller M<sup>1</sup>, Delos Reyes B<sup>2</sup>, Steuhl K-P<sup>1</sup>, Fandrey J<sup>2</sup>, Eckstein A<sup>1</sup>

<sup>1</sup>University of Duisburg-Essen, Department of Ophthalmology, Essen, Germany, <sup>2</sup>University of Duisburg-Essen, Institute for Physiology, Essen, Germany

P3 **ROLE OF IL-12B AND IL-10 GENE POLYMORPHISMS IN DEVELOPMENT OF HASHIMOTO'S THYROIDITIS**

Geranova J<sup>1</sup>, Avramova A<sup>2</sup>, Stanilova S<sup>2</sup>

<sup>1</sup>Trakia University, Endocrinology, Stara Zagora, Bulgaria, <sup>2</sup>Trakia University, Molecular Biology, Immunology and Medical Genetics, Stara Zagora, Bulgaria

P4 **TNFα (G/A -308) AND TLR-4 (ASP299GLY) POLYMORPHISMS IN TUNISIAN PATIENTS WITH AUTOIMMUNE THYROIDITIS (GRAVES' DISEASE AND HASHIMOTO'S THYROIDITIS)**

Haouat E<sup>1</sup>, Boubakri M<sup>1</sup>, Dhaouadi T<sup>1</sup>, Sfar I<sup>1</sup>, Ben Abdallah T<sup>1</sup>, Gorgi Y<sup>1</sup>

<sup>1</sup>Charles Nicolle hospital, Laboratory of Research in Immunology of Renal Transplantation and Immunopathology (LR03SP01), Tunis, Tunisia

P5 **HLA-DRB1\*0301 AND HLA-DRB1\*1101 ARE ASSOCIATED TO GRAVES' DISEASE IN ROMANIAN POPULATION, WHEREAS HLA-DRB1\*0101 AND HLA-DRB1\*1501 SEEM TO BE PROTECTIVE**

Martin CS<sup>1,2</sup>, Dutescu MI<sup>3</sup>, Fica SV<sup>1,2</sup>

<sup>1</sup>Carol Davila University of Medicine and Pharmacy, Endocrinology, Bucharest, Romania, <sup>2</sup>Elias University Hospital, Endocrinology, Bucharest, Romania, <sup>3</sup>National Institute of Hematology Transfusion Prof. C Nicolau, National HLA Laboratory, Bucharest, Romania

P6 **INTERACTION OF THE IMMUNE REGULATORY GENES WITH THE THYROID SPECIFIC GENES IN THE PREDISPOSITION TO HASHIMOTO'S DISEASE**

Hubalewska-Dydejczyk A<sup>1</sup>, Jabrocka-Hybel A<sup>1</sup>, Skalniak A<sup>1</sup>, Piątkowski J<sup>1</sup>, Pach D<sup>1</sup>

<sup>1</sup>Jagiellonian University Medical College, Department of Endocrinology, Krakow, Poland

P7 **THE VALUE OF SOME CLINICAL AND IMMUNOLOGICAL PARAMETERS IN DETERMINING THE OUTCOMES OF SURGICAL TREATMENT OF AUTOIMMUNE THYROIDITIS (AIT) COMBINED WITH NODE**

Ryabchenko E<sup>1</sup>

<sup>1</sup>State Institution of Health 'Regional Clinical Hospital № 2', Department of Endocrinological Surgery, Krasnodar, Russian Federation

## PO2 Thyroid Basic

Chair: Josef Köhrle, Germany

### P8 HISTONE DEACETYLASE INHIBITOR VALPROIC ACID IMPAIRS FOLLICLE FORMATION AND ANGIOGENESIS IN THE DIFFERENTIATING THYROID

*Gawade S<sup>1</sup>, Hafen K<sup>2</sup>, Szinnai G<sup>1</sup>*

<sup>1</sup>Paediatric Endocrinology, and <sup>2</sup>Paediatric Immunology, Department of Biomedicine, University of Basel and University Children's Hospital Basel, Basel, Switzerland

### P9 ALTERED MITOCHONDRIAL FUNCTION IN PREGNANT WOMEN WITH SUBCLINICAL HYPOTHYROIDISM AND GESTATIONAL HYPERTENSION

*Feldthusen A-D<sup>1,2,3</sup>, Larsen J<sup>2</sup>, Pedersen PL<sup>2</sup>, Kristensen TT<sup>2,3</sup>, Anthonsen S<sup>2</sup>, Kvetny J<sup>2,4</sup>*

<sup>1</sup>Naestved Hospital, Department of Obstetrics & Gynecology, Naestved, Denmark, <sup>2</sup>Naestved Hospital, The Mitochondrial Research Unit, Naestved, Denmark, <sup>3</sup>University of Copenhagen, Copenhagen, Denmark, <sup>4</sup>Department of Internal Medicine, University of Southern Denmark, Naestved, Denmark

### P10 THYROID FUNCTION AND IODINE DEFICIENCY DISORDERS: AN INTENSIVE STUDY OF 8 HIMALAYAN VILLAGES

*Kathait A<sup>1,2</sup>, Farswan A<sup>3</sup>, Bamola V<sup>4</sup>, Yadav N<sup>1</sup>, Chandola-Saklani A<sup>1</sup>*

<sup>1</sup>Apeejay Stya University, Centre for Biosciences & Clinical Research, Gurgaon, India, <sup>2</sup>HNBG Central University, Dept of Biotechnology, Srinagar, India, <sup>3</sup>Govt PG College, Dept of Zoology, Augutmuni, India, <sup>4</sup>All India Institute of Medical Sciences, Dept of Microbiology, Delhi, India

### P11 AN ULTRA-SHORT FEEDBACK LOOP FOR T3 ON THE SODIUM IODIDE SYMPORTER

*Abdulrahman RM<sup>1</sup>, Sips HCM<sup>1</sup>, Smit JWA<sup>1,2</sup>, Hovens GCJ<sup>1</sup>*

<sup>1</sup>Leiden University Medical Center, Endocrinology, Leiden, Netherlands, <sup>2</sup>Nijmegen University Medical Center, Internal Medicine, Nijmegen, Netherlands

### P12 IMPACT OF SOYBEAN ISOFLAVONES GENISTEIN AND DAIDZEIN ON SERUM LEVELS OF TSH AND T4 – EFFECTS OF AGING AND ORCHIDECTOMY

*Sosic-Jurjevic B<sup>1</sup>, Filipovic B<sup>1</sup>, Ajdzanovic V<sup>1</sup>, Trifunovic S<sup>1</sup>, Nestorovic N<sup>1</sup>, Manojlovic Stojanoski M<sup>1</sup>, Jankovic S<sup>2</sup>, Milosevic V<sup>1</sup>*

<sup>1</sup>Institute for Biological Research, University of Belgrade, Belgrade, Serbia, <sup>2</sup>Institute for Science Application in Agriculture, University of Belgrade, Belgrade, Serbia

### P13 MODELING THE ABSORBED DOSE TO THE COMMON CAROTID ARTERIES FOLLOWING RADIOIODINE TREATMENT OF BENIGN THYROID DISEASE

*la Cour JL<sup>1</sup>, Hedemann-Jensen P<sup>2</sup>, Søgaard-Hansen J<sup>2</sup>, Nygaard B<sup>3</sup>, Jensen LT<sup>1,4</sup>*

<sup>1</sup>Glostrup University Hospital, Department of Diagnostics, Section of Clinical Physiology, Glostrup, Denmark, <sup>2</sup>Danish Decommissioning, Department of Radiation and Nuclear Safety, Roskilde, Denmark, <sup>3</sup>University Hospital of Herlev, Department of Medicine, Section of Endocrinology, Herlev, Denmark, <sup>4</sup>University Hospital of Herlev, Department of Clinical Physiology and Nuclear Medicine, Herlev, Denmark

### P14 GENETIC ANALYSIS OF THE PAX8 GENE IN CHILDREN WITH CONGENITAL HYPOTHYROIDISM AND DYSGENETIC THYROID GLANDS – THE PILOT STUDY

*Kumorowicz-Czoch M<sup>1</sup>, Madetko-Talowska A<sup>2</sup>, Tylek-Lemanska D<sup>3</sup>, Pietrzyk JJ<sup>2</sup>, Starzyk J<sup>1</sup>*

<sup>1</sup>Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Department of Pediatric and Adolescent Endocrinology, Chair of Pediatrics, Cracow, Poland, <sup>2</sup>Polish-American Institute of Pediatrics, Jagiellonian University Medical College, Division of Medical Genetics, Chair of Pediatrics, Cracow, Poland, <sup>3</sup>University Children's Hospital of Cracow, Division of Mass Screening and Metabolic Diseases, Cracow, Poland

### P15 FUNCTIONAL LONG-TERM MAINTENANCE OF HUMAN THYROID PRIMARY CULTURES IN HUMANIZED MEDIUM (H7H)

*Garcia-Rendueles AR<sup>1</sup>, Rodrigues JS<sup>1</sup>, Perez-Romero S<sup>1</sup>, Suarez-Fariña M<sup>1</sup>, Garcia-Lavandeira M<sup>1</sup>, Rodriguez-Garcia J<sup>2</sup>, Cameselle-Teijeiro J<sup>3</sup>, Bravo SB<sup>4</sup>, Garcia-Rendueles MER<sup>1</sup>, Alvarez CV<sup>1</sup>*

<sup>1</sup>University of Santiago de Compostela (USC), Centre for Medical Investigations (CIMUS), Santiago de Compostela, Spain, <sup>2</sup>Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Clinical Biochemistry, Santiago de Compostela, Spain, <sup>3</sup>Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Pathology, Santiago de Compostela, Spain, <sup>4</sup>Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), Instituto de Investigaciones Sanitarias (IDIS), Santiago de Compostela, Spain

### P16 EFFICACY OF A NEW BLOCKER AGAINST ANTI-RUTHENIUM ANTIBODY INTERFERENCE IN THE NEW ELECSYS FT3 III AND FT4 II ASSAY

*Roeddiger R<sup>1</sup>, O'Mullane J<sup>2</sup>, Stapleton M<sup>2</sup>, Hafner G<sup>3</sup>, O'Shea P<sup>4</sup>, Lotz J<sup>5</sup>*

<sup>1</sup>Roche Diagnostics GmbH, Clinical Operations, Mannheim, Germany, <sup>2</sup>Cork University Hospital, Cork, Ireland, <sup>3</sup>ZLM GmbH, Essen, Germany, <sup>4</sup>Galway University Hospital, Galway, Ireland, <sup>5</sup>Johannes Gutenberg-University, Medical Center, Mainz, Germany

**P17 A NEW CLASS OF ANTITHYROID AGENT INHIBITING IODIDE TRANSPORT AND PEROXIDASE-H<sub>2</sub>O<sub>2</sub> REACTION IN VITRO**

*Sugawara M<sup>1</sup>*

<sup>1</sup>Greater Los Angeles VA Hospital and CLA, Endocrinology and Diabetes (111M), Los Angeles, United States

**PO3 Thyroid Cancer Basic 1**

Chair: *Rosa Marina Mellilo, Italy*

**P18 A NOVEL ROLE FOR INTRACELLULAR INTERLEUKIN-32 IN PROMOTING CELL DEATH BY MODULATION OF THE IL-8/FOCAL ADHESION KINASE 1 SIGNALING PATHWAY IN THYROID CANCER**

*Heinhuis B<sup>1,2,3</sup>, Plantinga TS<sup>1,2,3</sup>, Dinarello CA<sup>1,2</sup>, Hermus ARMM<sup>1,3</sup>, Netea MG<sup>1,2</sup>, Smit JWA<sup>1,3</sup>, Joosten LAB<sup>1,2</sup>, Netea-Maier RT<sup>1,3</sup>*

<sup>1</sup>Radboud University Nijmegen Medical Centre, Department of Medicine, Nijmegen, Netherlands, <sup>2</sup>Nijmegen Institute of Infection, Immunity and Inflammation (N4i), Nijmegen, Netherlands, <sup>3</sup>Radboud University Nijmegen Medical Centre, Division of Endocrinology, Nijmegen, Netherlands

P19 (*will be presented in PO12 Basic Cancer 2 on Monday*)

**TUMOR-EDUCATED MAST CELLS INDUCE EPITHELIAL-TO-MESENCHYMAL TRANSITION AND EXPANSION OF STEM CELL POPULATION VIA IL-8/CXCR1/CXCR2 AXIS IN THYROID CANCER.**

*Visciano C<sup>1</sup>, Liotti F<sup>1</sup>, Prevete N<sup>2</sup>, Cali G<sup>3</sup>, de Paulis A<sup>2</sup>, Marone G<sup>2</sup>, Santoro M<sup>1,3</sup>, Melillo RM<sup>1,3</sup>*

<sup>1</sup>Università di Napoli Federico II, Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Naples, Italy, <sup>2</sup>Università di Napoli Federico II, Dipartimento di Scienze Mediche Traslazionali e Centro Interdipartimentale di Ricerca in Scienze Immunologiche di Base e Cliniche, Naples, Italy, <sup>3</sup>Università di Napoli Federico II, Istituto per L'Endocrinologia e l'Oncologia Molecolare del CNR, Naples, Italy

**P20 MIGRATION AND REDUCED APOPTOSIS IN FOLLICULAR THYROID CARCINOMAS AS AN EFFECT OF DIFFERENTIAL MIRNA EXPRESSION**

*Wojtas B<sup>1</sup>, Ferraz C<sup>2</sup>, Stokowy T<sup>1,3</sup>, Jarzab B<sup>1</sup>, Paschke R<sup>2</sup>, Eszlinger M<sup>2</sup>*

<sup>1</sup>MSC Memorial Cancer Center and Institute of Oncology Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland, <sup>2</sup>University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, <sup>3</sup>Silesian University of Technology, Institute of Automatic Control, Gliwice, Poland

**P21 CELL CYCLE TARGETING IN CELLS CARRYING P53 POINT MUTATIONS: A NOVEL PERSPECTIVE FOR UNDIFFERENTIATED THYROID CANCER THERAPY**

*Grassi ES<sup>1</sup>, Vezzoli V<sup>1</sup>, Negri P<sup>2</sup>, Persani L<sup>1,3</sup>*

<sup>1</sup>University of Milan, Clinical Sciences & Community Health, Milan, Italy, <sup>2</sup>University of Milan, Milan, Italy, <sup>3</sup>IRCCS Istituto Auxologico Italiano, Division of Endocrine and Metabolic Diseases & Lab. of Endocrine and Metabolic Research, Milan, Italy

**P22 NUCLEAR CYSTEINE CATHEPSIN VARIANTS IN THYROID CANCER**

*Tedelind S<sup>1</sup>, Perera R<sup>1</sup>, Yurtdas Y<sup>1</sup>, Pinzaru A<sup>1</sup>, Szumska J<sup>1</sup>, Burden R<sup>2</sup>, Rehders M<sup>1</sup>, Scott C<sup>2</sup>, Führer D<sup>3</sup>, Brix K<sup>1</sup>*

<sup>1</sup>Jacobs University Bremen, School of Engineering and Science, Bremen, Germany, <sup>2</sup>Queen's University of Belfast, School of Pharmacy, Belfast, United Kingdom, <sup>3</sup>Universitätsklinikum Essen, Klinik für Endokrinologie und Stoffwechselerkrankungen, Essen, Germany

**P23 IMPACT OF CLAUDIN-1 ON EPITHELIAL-MESENCHYMAL TRANSITION IN PAPILLARY THYROID CARCINOMA**

*Zwanziger D<sup>1</sup>, Amborska R<sup>1</sup>, Jaeger A<sup>1</sup>, Führer D<sup>1</sup>*

<sup>1</sup>University Hospital Essen, Essen, Germany

**P24 MIRNAS WITH THE POTENTIAL TO DISTINGUISH FOLLICULAR THYROID CARCINOMAS FROM BENIGN FOLLICULAR THYROID TUMORS – RESULTS OF A META ANALYSIS**

*Stokowy T<sup>1,2</sup>, Wojtas B<sup>1</sup>, Fajarewicz K<sup>2</sup>, Jarzab B<sup>1</sup>, Eszlinger M<sup>3</sup>, Paschke R<sup>3</sup>*

<sup>1</sup>Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland, <sup>2</sup>Silesian University of Technology, Gliwice, Poland, <sup>3</sup>University of Leipzig, Division of Endocrinology and Nephrology, Germany

**P25 CYTOLOGY OF LYMPHOMAS IN THE THYROID GLAND**

*Vasilj A<sup>1</sup>, Kojic Katovic S<sup>1</sup>, Curic-Juric S<sup>1</sup>, Maricevic I<sup>1</sup>, Sokcevic M<sup>1</sup>, Zokvic E<sup>1</sup>*

<sup>1</sup>University Hospital Center 'Sestre milosrdnice', Department of Cytology, Zagreb, Croatia

**P26 THE CLINICAL SIGNIFICANCE OF TUMOR SUPPRESSOR GENE METHYLATION – EXPRESSION IN NODULAR THYROID DISEASE**

*Wei E<sup>1</sup>, Wang Z<sup>1</sup>, Wu Y<sup>1,2</sup>, Li Y<sup>1</sup>, Yu Y<sup>1</sup>*

<sup>1</sup>The First Affiliated Hospital, Bao Tou Medical College, Inner Mongol ia Science & Technology University, Department of Endocrinology, Bao Tou, China, <sup>2</sup>The First Hospital, Bao Tou Medical College, Inner Mongolia University of Science and Technology, Endocrinology Department, Baotou, China



**P27 MULTICENTER EVALUATION OF A HIGHLY SENSITIVE THYROGLOBULIN IMMUNOASSAY ON ELECSYS SYSTEMS**

*Roeddiger R<sup>1</sup>, Hafner G<sup>2</sup>, Keller F<sup>3</sup>, d'Herbomez M<sup>4</sup>, Kratzsch J<sup>5</sup>*

<sup>1</sup>Roche Diagnostics GmbH, Clinical Operations, Mannheim, Germany, <sup>2</sup>ZLM GmbH, Essen, Germany, <sup>3</sup>EOLAB, Lugano, Switzerland, <sup>4</sup>CHRU, Lille, France, <sup>5</sup>University Leipzig, Leipzig, Germany

**P28 DESCRIPTION OF A NEW HIGHLY SENSITIVE THYREOGLOBULIN IMMUNOASSAY: THERMO SCIENTIFIC B-R-A-H-M-S HTG SENSITIVE KRYPTOR**

*Theimer C<sup>1</sup>, Thomas E<sup>2</sup>, Algeciras-Schimnich A<sup>3</sup>, Preissner CM<sup>3</sup>*

<sup>1</sup>Thermo Fisher Scientific, Hennigsdorf, Germany, <sup>2</sup>Thermo Fisher Scientific, Nîmes, France, <sup>3</sup>MAYO Clinic, Rochester, United States

**P29 PARANEOPLASTIC LEUKOCYTOSIS – POSSIBLE SYMPTOM OF THYROID CANCER PROGRESSION?**

*Krajewska J<sup>1</sup>, Olczyk T<sup>1</sup>, Paliczka-Cieslik E<sup>1</sup>, Kalemba M<sup>1</sup>, Jarzab B<sup>1</sup>*

<sup>1</sup>Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland

**PO4 Thyroid Cancer Diagnostics 1**

Chair: *Sophie Leboulleux, France*

**P30 MALIGNANCY RATE OF THYROID NODULES DETECTED BY HEALTH EXAMINATION WAS ASSOCIATED WITH PATIENTS' AGE AND NODULE SIZE IN PATIENTS AGED 60 YEARS OR OLDER**

*Choi H<sup>1</sup>, Roh E<sup>1</sup>, Hwang Bo Y<sup>1</sup>, Kang SM<sup>2</sup>, Choi SI<sup>2</sup>, Moon JH<sup>2</sup>, Kim KW<sup>1</sup>, Choi SH<sup>2</sup>, Jang HC<sup>2</sup>, Yi KH<sup>1</sup>, Park DJ<sup>1</sup>, Park YJ<sup>1</sup>*

<sup>1</sup>Seoul National University Hospital, Internal Medicine, Seoul, Korea, Republic of, <sup>2</sup>Seoul National University Bundang Hospital, Internal Medicine, Seongnam-Si, Republic of Korea

**P31 TGAB POSITIVE (+) PAPILLARY THYROID CANCER (PTC) PATIENTS WITH LYMPHOCYTIC THYROIDITIS (LT) DETECTED AT THYROIDECTOMY (TX) SUGGESTS AN INCREASED RISK OF RECURRENCE (R) DURING FOLLOW-UP (F/U)**

*Fatemi S<sup>1</sup>, LoPresti J<sup>2</sup>, Singer P<sup>2</sup>, Spencer C<sup>2</sup>*

<sup>1</sup>Southern California Permanente Medical Group, Endocrinology, Panorama City, United States, <sup>2</sup>University of Southern California/Keck School of Medicine, Medicine, Los Angeles, United States

**P32 EVALUATION OF A NEW ULTRASENSITIVE THYROGLOBULIN ASSAY IN THE FOLLOW-UP OF PATIENTS WITH DIFFERENTIATED THYROID CANCER**

*Accornero S<sup>1</sup>, Pignatti P<sup>2</sup>, Coperchini F<sup>1</sup>, Testoni C<sup>2</sup>, Theimer C<sup>3</sup>, Chiovato L<sup>1</sup>*

<sup>1</sup>Fondazione Salvatore Maugeri – IRCCS, Internal Medicine and Endocrinology Unit, Pavia, Italy, <sup>2</sup>Fondazione Salvatore Maugeri – IRCCS, Allergy and Immunology Unit, Pavia, Italy, <sup>3</sup>Thermo Scientific Biomarkers, Hennigsdorf, Germany

**P33 RECOMBINANT HUMAN THYROTROPIN STIMULATION THYROGLOBULIN (RHTSH-TG) TEST CAN IDENTIFY FALSE SERUM TG DUE TO HETEROPHILIC ANTIBODIES IN DIFFERENTIATED THYROID CANCER (DTC) PATIENTS**

*Matrone A<sup>1</sup>, Gambale C<sup>1</sup>, Taddei D<sup>1</sup>, Nencetti C<sup>1</sup>, Molinaro E<sup>1</sup>, Agate L<sup>1</sup>, Bottici V<sup>1</sup>, Viola D<sup>1</sup>, Vitti P<sup>1</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>University of Pisa, Endocrine Unit – Department of Clinical and Experimental Medicine, Pisa, Italy

**P34 SURGEON-PERFORMED ULTRASOUND-GUIDED FINE-NEEDLE ASPIRATION CYTOLOGY SHORTENS TIME FOR DIAGNOSIS OF THYROID NODULES**

*Gu W<sup>1</sup>, Tan CS<sup>2</sup>, Ho TWT<sup>3</sup>*

<sup>1</sup>National University of Singapore, Yong Loo Lin School of Medicine, Singapore, Singapore, <sup>2</sup>National University of Singapore, Saw Swee Hock School of Public Health, Singapore, Singapore, <sup>3</sup>Tan Tock Seng Hospital, Section of Head and Neck Surgery, Department of General Surgery, Singapore, Singapore

**P35 CYSTIC CHANGE AFTER FINE NEEDLE ASPIRATION BIOPSY OF CIRCUMSCRIBED SOLID THYROID NODULES WITHOUT MALIGNANT US FEATURES: IS IT MEANINGFUL?**

*Rhee SJ<sup>1,2</sup>, Shin JH<sup>1</sup>, Han B-K<sup>1</sup>, Ko EY<sup>1</sup>, Ko ES<sup>1</sup>, Hahn SY<sup>1</sup>*

<sup>1</sup>Samsung Medical Center, Radiology, Seoul, Republic of Korea, <sup>2</sup>Kyung Hee University Hospital at Gangdong, Radiology, Seoul, Republic of Korea

**P36 FINE-NEEDLE ASPIRATION (FNA) OF THYROID NODULES GUIDED BY ULTRASONOGRAPHY. VALUE TIRADS**

*Jiménez M<sup>1,2</sup>, Gayoso R<sup>2</sup>, Sapunar J<sup>1,2</sup>, Granzotto C<sup>1</sup>, Roa JC<sup>1,2</sup>, Huenchullan C<sup>1</sup>, Ortiz E<sup>1,2</sup>*

<sup>1</sup>Clinica Alemana Temuco, Unidad Endocrinología y Diabetes, Temuco, Chile, <sup>2</sup>Temuco German Clinic, Faculty of Medicine University of La Frontera to Temuco, Temuco, Chile

**P37 ROLE OF ELASTOGRAPHY IN DIAGNOSIS OF SUSPICIOUS THYROID NODULES**

*Abo Elwafa WAH<sup>1</sup>*

<sup>1</sup>Faculty of Medicine, Alexandria University, Department of Surgery, Alexandria, Egypt

**P38 THYROID NODULES IN MADEIRA ISLAND, PORTUGAL – A RETROSPECTIVE STUDY**

*Resende E<sup>1</sup>, Ferreira M<sup>1</sup>, Sá M<sup>1</sup>, Abreu S<sup>1</sup>*

<sup>1</sup>Hospital Central do Funchal, Endocrinology, Funchal, Portugal

## PO5 Thyroid Cancer Pathogenesis

Chair: *Cristina Romei, Italy*

### P39 CLINICAL IMPLICATION OF BRAF<sup>V600E</sup> MUTATION IN PAPILLARY THYROID CARCINOMA

*Kim YS<sup>1</sup>, Park WC<sup>2</sup>, Kim JS<sup>1</sup>*

<sup>1</sup>College of Medicine, The Catholic University of Korea, Department of Surgery, Uijeongbu-si, Republic of Korea, <sup>2</sup>College of Medicine, The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

### P40 HURTHLE CELL THYROID CARCINOMA: A MULTICENTRIC RETROSPECTIVE STUDY WITH MIRNA PROFILING

*Bonichon F<sup>1</sup>, Do Cao C<sup>2</sup>, Guyetant S<sup>3</sup>, Schvartz C<sup>4</sup>, Soubeyran P<sup>5</sup>, Rohmer V<sup>6</sup>, Toubreau M<sup>7</sup>, Savagner F<sup>8,9</sup>*

<sup>1</sup>Institut Bergonie, Bordeaux, France, <sup>2</sup>Endocrinologie, Lille, France, <sup>3</sup>Laboratoire d'anatomopathologie, Tours, France, <sup>4</sup>Laboratoire d'anatomopathologie, Dijon, France, <sup>5</sup>Laboratoire d'anatomopathologie, Bordeaux, France, <sup>6</sup>Endocrinologie, Angers, France, <sup>7</sup>Medecine Nucleaire, Dijon, France, <sup>8</sup>Laboratoire de Genetique moleculaire, Angers, France, <sup>9</sup>EA3143, Angers, France

### P41 ASSOCIATION BETWEEN CYP2E1 PROMOTER POLYMORPHISMS AND PAPILLARY THYROID CANCER WITH EXTRATHYROIDAL EXTENSION IN KOREAN POPULATION

*Kim D-Y<sup>1</sup>, Hong IK<sup>1</sup>, Kim SK<sup>2</sup>, Chung J-H<sup>2</sup>*

<sup>1</sup>Kyung Hee University Hospital, Nuclear Medicine, Seoul, Republic of Korea, <sup>2</sup>Kohwang Medical Research Institute, Kyung Hee University, Seoul, Republic of Korea

### P42 BRAF<sup>V600E</sup> MUTATIONAL STATUS AND ITS CLINICAL SIGNIFICANCE IN MULTIFOCAL PAPILLARY THYROID CARCINOMA OF THE KOREAN POPULATION

*Ahn HY<sup>1</sup>, Chung YJ<sup>1</sup>, Kang KH<sup>2</sup>, Park SJ<sup>2</sup>, Cho BY<sup>1</sup>*

<sup>1</sup>Chung-Ang University Hospital, Internal Medicine, Seoul, Korea, Republic of, <sup>2</sup>Chung-Ang University Hospital, Surgery, Seoul, Republic of Korea

### P43 DETAILS OF HISTOPATHOLOGY IN PATIENTS WITH ONE OR MORE FIRST DEGREE RELATIVE WHO HAVE WELL DIFFERENTIATED THYROID CANCER (WDTC)

*Frangos S<sup>1</sup>, Vanezi A<sup>1</sup>, Savva A<sup>1</sup>, Rousounidou A<sup>1</sup>, Patsali L<sup>1</sup>*

<sup>1</sup>Bank of Cyprus Oncology Center, Nuclear Medicine, Strovolos, Nicosia, Cyprus

### P44 CLINICOPATHOLOGICAL SIGNIFICANCE OF CARCINOMA ASSOCIATED FIBROBLASTS (CAF) IN PAPILLARY THYROID CARCINOMA: THE PREDICTIVE MAKER OF CERVICAL LYMPH NODE METASTASES

*Cho J-G<sup>1</sup>, Park M-W<sup>1</sup>, Baek S-K<sup>1</sup>, Kwon S-Y<sup>1</sup>, Jung K-Y<sup>1</sup>, Woo J-S<sup>1</sup>*

<sup>1</sup>Korea University Medical College, Otorhinolaryngology-Head and Neck Surgery, Seoul, Republic of Korea

### P45 ISTHMIC LOCATION OF MALIGNANT THYROID NODULES REPRESENTS AN ADDITIONAL RISK FACTOR FOR METASTATIC DISEASE IN PATIENTS AFFECTED BY LOW RISK DIFFERENTIATED THYROID CANCER (DTC).

*Ruggeri RM<sup>1</sup>, Cucinotta M<sup>2</sup>, Giovinazzo S<sup>1</sup>, Quartuccio N<sup>2</sup>, Stipo ME<sup>2</sup>, Baldari S<sup>2</sup>, Trimarchi F<sup>1</sup>, Campennì A<sup>2</sup>*

<sup>1</sup>University of Messina, Dep of Clinical and Experimental Medicine, Messina, Italy, <sup>2</sup>University of Messina, Unit of Nuclear Medicine, Messina, Italy

### P46 THYROID CANCER AFTER IN VITRO FERTILIZATION: A RETROSPECTIVE, NON-CONSECUTIVE CASE-SERIES ANALYSIS

*Pazaitou-Panayiotou K<sup>1</sup>, Toulis KA<sup>1,2</sup>, Mandanas S<sup>1</sup>, Tarlatzis BC<sup>2</sup>*

<sup>1</sup>Theagenio Cancer Hospital, Dept. of Endocrinology-Endocrine Oncology, Thessaloniki, Greece, <sup>2</sup>Unit for Human Reproduction, First Department of Obstetrics and Gynaecology, Aristotle University of Thessaloniki, Thessaloniki, Greece

### P47 SYNCHRONOUS MICROPAPILLARY THYROID CARCINOMA AND NON HYPERCALCEMIC PARATHYROID CARCINOMA: A CASE REPORT

*Ramos CO<sup>1</sup>, Aquino E<sup>1</sup>*

<sup>1</sup>St. Luke's Medical Center, Endocrinology and Metabolism, Quezon City, Philippines

## PO6 Thyroid Cancer Therapeutics 1

Chair: *Christine Spitzweg, Munich*

### P48 RETROAURICULAR ROBOTIC THYROIDECTOMY WITH OR WITHOUT MODIFIED RADICAL NECK DISSECTION

*Koh YW<sup>1</sup>, Baek SJ<sup>1</sup>, Bong JP<sup>1</sup>, Hong HJ<sup>1</sup>, Kim JW<sup>2</sup>, Kim W-S<sup>1</sup>, Kwon JH<sup>1</sup>, Park JH<sup>3</sup>, Lee HJ<sup>1</sup>, Ahn SH<sup>1</sup>, Choi EC<sup>1</sup>*

<sup>1</sup>Yonsei University College of Medicine, Otorhinolaryngology, Seoul, Korea, Republic of, <sup>2</sup>Soonchunhyang University Hospital, Otolaryngology-Head and Neck Surgery, Seoul, Republic of Korea, <sup>3</sup>Soonchunhyang University Hospital, Otolaryngology-Head and Neck Surgery, Cheonan, Republic of Korea

### P49 COMPARISON BETWEEN SPORADIC AND FAMILIAL PAPILLARY THYROID MICROCARCINOMA

*Busonero G<sup>1</sup>, Capezzone M<sup>1</sup>, Forleo R<sup>1</sup>, Durante C<sup>2</sup>, Filetti S<sup>2</sup>, Pazaitou-Panayiotou K<sup>3</sup>, Pacini F<sup>1</sup>*

<sup>1</sup>University of Siena, Section of Endocrinology, Department of Medical, Surgical and Neurological Sciences, Siena, Italy, <sup>2</sup>University of Rome La Sapienza, Department of Clinical Sciences, Rome, Italy, <sup>3</sup>University of Thessaloniki, Department of Endocrinology-Endocrine Oncology, Thessaloniki, Greece

**P50 A COMPARISON OF CLINICAL EFFECTIVENESS OF LOW VERSUS HIGH DOSE RADIOABLATION IN DIFFERENTIATED THYROID CANCER PATIENTS**

*Urhan M<sup>1</sup>, San H<sup>1</sup>, Yucel E<sup>2</sup>, Cagiltay E<sup>3</sup>, Ozsari L<sup>3</sup>, Yonem A<sup>3</sup>*

<sup>1</sup>GATA Haydarpasa Training Hospital, Nuclear Medicine, Istanbul, Turkey, <sup>2</sup>GATA Haydarpasa Training Hospital, Surgery, Istanbul, Turkey, <sup>3</sup>GATA Haydarpasa Training Hospital, Endocrinology and Metabolism, Istanbul, Turkey

**P51 LOW-RISK PAPILLARY THYROID CARCINOMA: TO ABLATE OR NOT TO ABLATE**

*Azevedo TC<sup>1</sup>, Rodrigues FJ<sup>1</sup>, Martins TM<sup>1</sup>, Neto J<sup>2</sup>, Rovira E<sup>2</sup>, Lemos MC<sup>1,3</sup>, Martinho M<sup>1,4</sup>, Oliveira S<sup>2</sup>*

<sup>1</sup>Instituto Português de Oncologia de Coimbra, Serviço de Endocrinologia, Coimbra, Portugal, <sup>2</sup>Instituto Português de Oncologia de Coimbra, Serviço de Medicina Nuclear, Coimbra, Portugal, <sup>3</sup>Universidade da Beira Interior, Centro de Investigação em Ciências da Saúde (CICS), Covilhã, Portugal, <sup>4</sup>Centro Hospitalar do Tâmega e Sousa, Penafiel, Portugal

**P52 IS THE DISSECTION OF RIGHT SIDE SUPERIOR MEDIASTINAL LYMPH NODES IS NECESSARY DURING OPERATION FOR PAPILLARY THYROID CANCER?**

*Oh EM<sup>1</sup>, Cheung YS<sup>1</sup>, Song WJ<sup>1</sup>, Lee YD<sup>1</sup>*

<sup>1</sup>Gachon Gil University Hospital, Thyroid Clinic, General Surgery, Incheon, Republic of Korea

**P53 LIGASURE VS. HARMONIC SCALPEL IN TOTAL THYROIDECTOMY: COMPARING OUTCOMES AND COMPLICATIONS**

*Byon W<sup>1</sup>, Hyun K<sup>1</sup>, Yun J-S<sup>1</sup>, Park YL<sup>1</sup>, Park CH<sup>1</sup>*

<sup>1</sup>Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Department of Surgery & Breast-Thyroid Cancer Center, Seoul, Republic of Korea

**P54 SURVIVAL RATES AND PROGNOSTIC FEATURES OF 1167 PAPILLARY THYROID CARCINOMA PATIENTS WITH LONG-TERM FOLLOW-UP**

*Jukić T<sup>1</sup>, Franceschi M<sup>1</sup>, Lukinac L<sup>1</sup>, Granić R<sup>1</sup>, Staničić J<sup>1</sup>, Šiško Markoš I<sup>1</sup>, Punda M<sup>1</sup>, Dabelić N<sup>1</sup>, Mateša N<sup>1</sup>, Sonicki Z<sup>2</sup>, Kusić Z<sup>1</sup>*

<sup>1</sup>University Hospital Center 'Sestre milosrdnice', Department of Oncology and Nuclear Medicine, Zagreb, Croatia, <sup>2</sup>School of Public Health 'Andrija Štampar', Zagreb, Croatia

**P55 OUTCOMES FOR DIFFERENTIATED THYROID CANCER (DTC) ARISING IN PATIENTS WITH A PRIOR PAEDIATRIC MALIGNANCY**

*Mulholland LE<sup>1,2</sup>, Newbold K<sup>1</sup>*

<sup>1</sup>Royal Marsden Hospital, Thyroid Unit, Sutton, United Kingdom, <sup>2</sup>Northern Ireland Cancer Centre, Clinical Oncology, Belfast, United Kingdom

**P56 TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF REFRACTORY THYROID CANCER: BALANCING EFFICACY AND QUALITY OF LIFE**

*Chrisoulidou A<sup>1</sup>, Mathiopoulou L<sup>1</sup>, Mandanas S<sup>1</sup>, Boudina M<sup>1</sup>, Pazaitou-Panayiotou K<sup>1</sup>*

<sup>1</sup>Theagenio Cancer Hospital, Dept. of Endocrinology-Endocrine Oncology, Thessaloniki, Greece

**PO7 Case Reports 1**

Chair: István Szabolcs, Hungary

**P57 INDICATIONS FOR THE GASLESS TRANSAXILLARY ROBOTIC APPROACH TO THYROID SURGERY – EXPERIENCE OF 100 PROCEDURES AT THE AMERICAN HOSPITAL OF PARIS**

*Aidan P<sup>1</sup>, Boccara G<sup>2</sup>, Monpeyssen H<sup>3</sup>, Beressi N<sup>4</sup>*

<sup>1</sup>American Hospital of Paris, ENT department, Neuilly sur Seine, France, <sup>2</sup>American Hospital of Paris, Anesthetist, Neuilly sur Seine, France, <sup>3</sup>American Hospital of Paris, Radiology, Neuilly sur Seine, France, <sup>4</sup>American Hospital of Paris, Endocrinology, Neuilly sur Seine, France

**P58 CLINICAL CHARACTERISTICS OF ESOPHAGEAL DIVERTICULA MISDIAGNOSED AS THYROID NODULE**

*Lee DC<sup>1</sup>, Kim TH<sup>1</sup>, Kim HW<sup>1</sup>, Jo SK<sup>1</sup>, Jung SW<sup>1</sup>, Lee SJ<sup>1</sup>, Kim SH<sup>1</sup>, Lim JK<sup>1</sup>*

<sup>1</sup>Kwangju Christian Hospital, Endocrinology, Gwangju, Republic of Korea

**P59 HYALINISING TRABECULAR TUMOUR IN ADENOMATOID GOITER – A CASE OF 59-YEAR-OLD MAN WITH HIV DISEASE**

*Petranović Ovčariček P<sup>1</sup>, Jukić T<sup>1</sup>, Franceschi M<sup>1</sup>, Čupić H<sup>2</sup>, Kusić Z<sup>1</sup>*

<sup>1</sup>University Hospital Center 'Sestre milosrdnice', Department of Oncology and Nuclear Medicine, Zagreb, Croatia, <sup>2</sup>University Hospital Center 'Sestre milosrdnice', Department of Pathology 'Ljudevit Jurak', Zagreb, Croatia

**P60 THE SCLEROTHERAPY WITH ETHANOL – AN UNCOMMON, BUT SUCCESSFUL METHOD OF TREATMENT OF A HUGE BRANCHIAL CLEFT CYST**

*Raykov NI<sup>1</sup>, Vicheva S<sup>2</sup>, Raykova AN<sup>3</sup>*

<sup>1</sup>Varna 'Hospital, Department of Internal Diseases, Varna, Bulgaria, <sup>2</sup>Oncological Dispensary 'Marko Markov', Department of Clinical Pathology, Varna, Bulgaria, <sup>3</sup>MU-Pleven, Pleven, Bulgaria

**P61 PAPILLARY THYROID CARCINOMA WITH LYMPHOCYTIC THYROIDITIS IN AN AUTONOMOUS HYPERFUNCTIONING THYROID NODULE**

*Calimon MAP<sup>1</sup>, Lim Uy SW<sup>1</sup>*

<sup>1</sup>St. Luke's Medical Center, Section of Endocrinology, Diabetes and Metabolism, Quezon City, Philippines



**P62 10.000KM ON BICYCLE UNDER TYROSINE KINASE INHIBITOR THERAPY WITH VANDETANIB**

*Weidner S<sup>1</sup>, Klaeser B<sup>1</sup>, Wartenberg J<sup>1</sup>, Krause T<sup>1</sup>*

<sup>1</sup>Inselspital, University Hospital of Berne, Berne, Switzerland

**P63 CONTEMPORANEOUS OCCURRENCE OF THYROID GLAND CYST AND LINGUAL THYROID IN THE ABSENCE OF AN ORTHOTOPIC THYROID GLAND – CASE REPORT**

*Kim SW<sup>1</sup>, Park IS<sup>2</sup>*

<sup>1</sup>VHS Medical Center, Department of Otolaryngology-Head and Neck Surgery, Seoul, Korea, Republic of, <sup>2</sup>Dongtan Sacred Heart Hospital Hallym University, Department of Otolaryngology-Head and Neck Surgery, Dongtan, Republic of Korea

**P64 TUBERCULOUS ABSCESS OF THE THYROID GLAND**

*Gapuz KT<sup>1</sup>, Esposito EA<sup>1</sup>*

<sup>1</sup>St. Luke's Medical Center-Quezon City, Department of Medicine, Quezon City, Philippines

**P65 MULTIPLE TREATMENT OF PATIENTS WITH BONE METASTASES FROM DIFFERENTIATED THYROID CARCINOMA**

*Gerqari I<sup>1</sup>, Rizvanolli N<sup>2</sup>, Miftari R<sup>1</sup>, Bajrami I<sup>1</sup>, Bajqinca A<sup>1</sup>, Spahiu F<sup>1</sup>*

<sup>1</sup>University Clinical Center of Kosovo, Nuclear Medicine Service, Pristina, Albania, <sup>2</sup>Diagnostika plus, Pristina, Albania

**PO8 Clinical Thyroidology 1**

Chair: Murat Erdogan, Turkey

**P66 LOW NORMAL FREE T4 CONFERS DECREASED HIGH DENSITY LIPOPROTEIN ANTI-OXIDATIVE FUNCTIONALITY IN THE CONTEXT OF HYPERGLYCEMIA**

*Dullaart RP<sup>1</sup>, Triolo M<sup>1</sup>, Kwakernaak A<sup>2</sup>, Annema W<sup>2</sup>, Tietge UJ<sup>3</sup>*

<sup>1</sup>University of Groningen, Endocrinology, Groningen, Netherlands, <sup>2</sup>University of Groningen, Groningen, Netherlands, <sup>3</sup>University of Groningen, Center for Liver, Digestive and Metabolic Diseases, Groningen, Netherlands

**P67 THE VALUE OF RED BLOOD CELL DISTRIBUTION WIDTH IN THE SUBCLINICAL HYPOTHYROIDISM**

*Yu HM<sup>1</sup>, Park KS<sup>1</sup>, Lee JM<sup>1</sup>, Ryu AJ<sup>1</sup>*

<sup>1</sup>Research Institute of Clinical Medicine, Eulji University Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon, Republic of Korea

**P68 MYOCARDIAL DIASTOLIC FUNCTION IN PATIENTS WITH AUTOIMMUNE THYROIDITIS AND TSH VALUES WITHIN THE REFERENCE OR SUBCLINICAL RANGE: RELATIONSHIP TO THYROID AND METABOLIC INDICES**

*Strongin LG<sup>1</sup>, Nekrasova TA<sup>1</sup>, Ledentsova OV<sup>2</sup>, Kasakova LV<sup>3</sup>, Lukushkina AY<sup>1</sup>*

<sup>1</sup>Nizhny Novgorod State Medical Academy, Endocrinology, Nizhny Novgorod, Russian Federation, <sup>2</sup>Nizhny Novgorod Regional Diagnostic Center, Endocrinology, Nizhny Novgorod, Russian Federation, <sup>3</sup>Volga Region Medical Center of MBA, Internal Medicine, Nizhny Novgorod, Russian Federation

**P69 ATHEROGENIC LIPOPROTEINS IN SUBCLINICAL HYPOTHYROIDISM AND THEIR RELATIONSHIP WITH HEPATIC LIPASE ACTIVITY. RESPONSE TO REPLACEMENT TREATMENT WITH LEVOTHYROXINE**

*Brenta G<sup>1</sup>, Berg G<sup>2</sup>, Mikszowicz V<sup>2</sup>, Lopez G<sup>2</sup>, Lucero D<sup>2</sup>, Faingold C<sup>1</sup>, Nakajima K<sup>2,3</sup>, Schreier L<sup>2</sup>*

<sup>1</sup>Cesar Milstein Hospital, Endocrinology, Buenos Aires, Argentina, <sup>2</sup>Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Lipids and Lipoprotein Laboratory, Buenos Aires, Argentina, <sup>3</sup>Graduate School of Health Sciences, Gunma University, Gunma, Japan

**P70 AUTOIMMUNE THYROIDITIS: ADIPOKINES AND CARDIOVASCULAR RISK FACTORS IN SUBCLINICAL HYPOTHYROIDISM**

*Neves C<sup>1</sup>, Esteves C<sup>1</sup>, Pereira M<sup>1</sup>, Dias C<sup>2</sup>, Palmares C<sup>3</sup>, Sokhatska O<sup>3</sup>, Carvalho D<sup>1</sup>, Delgado L<sup>3</sup>, Medina J<sup>1</sup>*

<sup>1</sup>São João Hospital, Faculty of Medicine, University of Porto, Department of Endocrinology, Diabetes and Metabolism, Porto, Portugal, <sup>2</sup>São João Hospital, Faculty of Medicine, University of Porto, Department of Biostatistics and Medical Informatics, Porto, Portugal, <sup>3</sup>São João Hospital, Faculty of Medicine, University of Porto, Department of Immunology, Porto, Portugal

**P71 LOW T3 CONCENTRATIONS AT THE BEGINNING OF HEMODIALYSIS TREATMENT ARE ASSOCIATED WITH A HIGH MORTALITY RATE IN PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)**

*Reinhardt W<sup>1</sup>, Dolff S<sup>1</sup>, Broecker-Preuss M<sup>2</sup>, Führer D<sup>2</sup>, Witzke O<sup>1</sup>*

<sup>1</sup>University of Duisburg-Essen, Clinic of Nephrology, Essen, Germany, <sup>2</sup>University of Duisburg-Essen, Clinic of Endocrinology and Metabolism, Essen, Germany

**P72 SUBCLINICAL HYPOTHYROIDISM, SPONTANEOUS EVOLUTION IN AN URBAN POPULATION OF THE MEDITERRANEAN COAST**

*Tortosa F<sup>1</sup>, Ossó J<sup>2</sup>, Gomez Ramirez M<sup>2</sup>, Sanchez A<sup>3</sup>, Aldea M<sup>4</sup>, Mesa J<sup>1</sup>, Lecube A<sup>1</sup>*

<sup>1</sup>Hospital de la Vall d'Hebron, Endocrinology and Nutrition, Barcelona, Spain, <sup>2</sup>EAP St Andreu, Family Medicine, Barcelona, Spain, <sup>3</sup>Ambit Barcelona. ICS, Barcelona, Spain, <sup>4</sup>Hospital Clinic i Provincial, Preventive Medicine, Barcelona, Spain

**P73 THE EFFECT OF IODINE RESTRICTION ON THYROID FUNCTION IN SUBCLINICAL HYPOTHYROIDISM PATIENTS**

*Sohn SY<sup>1</sup>, Joung JY<sup>1</sup>, Cho YY<sup>1</sup>, Kim NK<sup>1</sup>, Kim SW<sup>1</sup>, Chung JH<sup>1</sup>*

<sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Division of Endocrinology & Metabolism, Department of Medicine, Seoul, Republic of Korea

**P74 FUNCTIONAL GASTROINTESTINAL DISORDERS IN CHILDREN WITH GOITER**

*Bugayenko OA<sup>1</sup>, Mamenko MY<sup>1</sup>, Belykh NA<sup>1</sup>, Yerokhina Ol<sup>1</sup>, Budnik TV<sup>1</sup>*

<sup>1</sup>Luhansk State Medical University, Department of Postgraduate Education in Pediatrics, Luhansk, Ukraine

**P75 PANCYTOPENIA RELATED TO AMIODARONE INDUCED HYPOTHYROIDISM: CASE REPORT**

*Resende E<sup>1</sup>, Ferreira M<sup>2</sup>, Sá M<sup>2</sup>, Abreu S<sup>2</sup>*

<sup>1</sup>Hospital Central do Funchal, Funchal, Portugal, <sup>2</sup>Hospital Central do Funchal, Endocrinology, Funchal, Portugal

**P76 GRAVES DISEASE AND MEMBRANOUS GLOMERULONEPHRITIS**

*Stojkovic M<sup>1</sup>, Beleslin B<sup>1</sup>, Ciric J<sup>1</sup>, Savic S<sup>1</sup>, Simic S<sup>2</sup>, Nisic T<sup>1</sup>, Lalic T<sup>1</sup>, Stojanovic M<sup>1</sup>, Trbojevic B<sup>1</sup>, Zarkovic M<sup>1</sup>*

<sup>1</sup>Clinic of Endocrinology, Diabetes and Metabolism, Clinical Center of Serbia, Belgrade, Serbia, <sup>2</sup>Clinic of Nephrology, Clinical Center of Serbia, Belgrade, Serbia

**PO9 Graves' Orbitopathy**

Chair: Anja Eckstein, Germany

**P77 INTRANASAL MEDIAL ENDOSCOPIC DECOMPRESSION (IMED) AS AN EFFICIENT TREATMENT FOR PATIENTS WITH DYSTHYROID OPTIC NEUROPATHY (DON)**

*Miśkiewicz P<sup>1</sup>, Trautsolt K<sup>1</sup>, Pirko-Kotela K<sup>1</sup>, Jabłońska A<sup>2</sup>, Samsel A<sup>2</sup>, Wołczańska N<sup>1</sup>, Milczarek-Banach J<sup>1</sup>, Kęcik D<sup>2</sup>, Krzeski A<sup>3</sup>, Bednarczuk T<sup>1</sup>*

<sup>1</sup>Medical University of Warsaw, Department of Endocrinology and Internal Medicine, Warsaw, Poland, <sup>2</sup>Medical University of Warsaw, Department of Ophthalmology, Warsaw, Poland, <sup>3</sup>Medical University of Warsaw, Department of Otolaryngology, Division of Dentistry, First Faculty of Medicine, Warsaw, Poland

**P78 SOME ASPECTS OF TREATMENT OF THE DRY EYE SYNDROME CAUSED BY OF ENDOCRINE OPHTHALMOPATHY**

*Papava M<sup>1</sup>, Javashvili L<sup>2</sup>, Dundua T<sup>2</sup>, Gaprindashvili N<sup>3</sup>*

<sup>1</sup>Research Institute of Clinical Medicine, Tbilisi, Georgia, <sup>2</sup>Clinic Cortex, Tbilisi, Georgia, <sup>3</sup>Medical Center Neoclinic, Tbilisi, Georgia

**P79 THE ROLE OF THYROTROPIN RECEPTOR ANTIBODIES IN GRAVE'S OPHTHALMOPATHY ACTIVITY AND RESPONSE TO TREATMENT**

*Petunina NA<sup>1</sup>, Martirosian N<sup>1</sup>, Trukhina LV<sup>1</sup>, Saakyan SV<sup>2</sup>, Panteleeva OG<sup>2</sup>, Sirmays OS<sup>2</sup>*

<sup>1</sup>I.M.Sechenov First Moscow State Medical University, Department of Endocrinology, Faculty of Postgraduate Education, Moscow, Russian Federation, <sup>2</sup>The Helmholtz Moscow Research Institute of Eye Diseases, Moscow, Russian Federation

**P80 CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME IN PATIENTS WITH MODERATE GRAVE'S ORBITOPATHY**

*Hristozov K<sup>1</sup>, Petrova M<sup>1</sup>, Siderova M<sup>1</sup>, Zlatanova E<sup>1</sup>*

<sup>1</sup>Medical University – Varna, Clinic of Endocrinology, Varna, Bulgaria

**P81 COMPARISON EFFICACY OF DIFFERENT SCHEMES OF GRAVES' ORBITOPATHY TREATMENT**

*Shestakova T<sup>1</sup>, Dreval A<sup>1</sup>, Perepelova O<sup>1</sup>, Nechaeva O<sup>1</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute n.M.F Vladimirskii, Endocrinology, Moscow, Russian Federation

**P82 THE CA/OA RATIO AS A TOOL FOR PLANNING SURGERY IN PATIENTS SUBMITTED TO ORBITAL DECOMPRESSION FOR GRAVES' ORBITOPATHY (GO)**

*Campi I<sup>1</sup>, Vannucchi G<sup>1</sup>, Covelli D<sup>1</sup>, Brevi A<sup>2</sup>, Iofrida E<sup>2</sup>, Currò N<sup>3</sup>, Guastella C<sup>2</sup>, Pignataro L<sup>2</sup>, Avignone S<sup>4</sup>, Beck-Peccoz P<sup>1,5</sup>, Salvi M<sup>1</sup>*

<sup>1</sup>Fondazione IRCCS Ca' Granda, Department of Clinical Science and Community Health, Milan, Italy, <sup>2</sup>Fondazione IRCCS Ca' Granda, Otolaryngology, Milan, Italy, <sup>3</sup>Fondazione IRCCS Ca' Granda, Ophthalmology, Milan, Italy, <sup>4</sup>Fondazione IRCCS Ca' Granda, Neuroradiology, Milan, Italy, <sup>5</sup>Università degli Studi di Milano, Milan, Italy

**P83 DIFFERENT FEATURES OF GRAVES' OPHTHALMOPATHY IN TYPE 1 AND TYPE 2 DIABETES**

*Le Moli R<sup>1</sup>, Muscia V<sup>1</sup>, Castoro C<sup>1</sup>, Furneri MT<sup>1</sup>, Regalbuto C<sup>1</sup>, Squatrito S<sup>1</sup>, Vigneri R<sup>1</sup>*

<sup>1</sup>Catania University, Biomedicine Clinical and Molecular, Catania, Italy

**P84 THYROID AUTOANTIBODIES IN GRAVES' ORBITOPATHY: DIFFERENCES BETWEEN HYPERTHYROID AND EUTHYROID PATIENTS**

*Beleslin B<sup>1</sup>, Ciric J<sup>1</sup>, Zarkovic M<sup>1</sup>, Stojkovic M<sup>1</sup>, Ciric S<sup>1</sup>, Lalic T<sup>1</sup>, Trbojevic B<sup>1</sup>*

<sup>1</sup>Clinic of Endocrinology, Diabetes and Metabolic Disorders, Clinical Center of Serbia, Belgrade, Serbia

**P85 LATE RELAPSE OF GRAVES OPTHALMOPATHY IN A CASE WITH TREATED GRAVES' DISEASE**

*Simescu MM<sup>1</sup>, Podia Igna CC<sup>2</sup>, Parlog Cristian AL<sup>3</sup>*

<sup>1</sup>SC SIMEDIS CONSULT SRL, Endocrinology, Bucharest, Romania, <sup>2</sup>Astra Clinic, Endocrinology, Sibiu, Romania, <sup>3</sup>MEDLIFE, Endocrinology, Bucharest, Romania

**PO10 Hyperthyroidism 1**

Chair: Mario Salvi, Italy

**P86 ANTI-THYROID DRUGS AS TREATMENT FOR NEUTROPENIA IN GRAVES' THYROTOXICOSIS**

*Aggarwal N<sup>1</sup>, Saqib W<sup>1</sup>, Fretwell T<sup>1</sup>, Razvi SS<sup>1,2</sup>*

<sup>1</sup>Queen Elizabeth Hospital, Endocrinology, Gateshead, United Kingdom, <sup>2</sup>Newcastle University, Endocrinology, Gateshead, United Kingdom

**P87 PROSPECTIVE STUDY ON THE TRIGGERING ROLE OF STRESS IN GRAVES' DISEASE (GD)**

*Vita R<sup>1</sup>, Lapa D<sup>1</sup>, Trimarchi F<sup>1</sup>, Benvenga S<sup>1</sup>*

<sup>1</sup>University of Messina, Department of Clinical & Experimental Medicine, Messina, Italy

**P88 PLASMA BRAIN NATRIURETIC PEPTIDE (BNP) IN GRAVES' HYPERTHYROIDISM WITH OR WITHOUT ATRIAL FIBRILLATION**

*Okamura K<sup>1</sup>, Bandai S<sup>1</sup>, Fujikawa M<sup>1</sup>, Sato K<sup>1</sup>, Chishaki A<sup>2</sup>, Kitazono T<sup>1</sup>*

<sup>1</sup>Kyushu University, 2nd Dept Intern Med, Fukuoka, Japan, <sup>2</sup>Kyushu University, Dept Health Sciences, Fukuoka, Japan

**P89 THYROID FUNCTION STATUS IN PATIENTS RECEIVING HEMODIALYSIS AND PERITONEAL DIALYSIS FOR CHRONIC KIDNEY DISEASE**

*Darvishnia S<sup>1</sup>, Emmami A<sup>1</sup>*

<sup>1</sup>Isfahan University of Medical Sciences, Esfahan, Islamic Republic of Iran

**P90 LEVELS OF TSH, FREE T4 AND ANTI-TPO LEVELS IN AN EUTHYROID BULGARIAN POPULATION WITHOUT HISTORY, LABORATORY OR ULTRASOUND DATA OF THYROID DISEASE**

*Shinkov A<sup>1</sup>, Borissova A-M<sup>1</sup>, Vlahov J<sup>1</sup>, Dakovska L<sup>1</sup>*

<sup>1</sup>Medical University of Sofia, Clinical Center of Endocrinology, Sofia, Bulgaria

**P91 AN INTRIGUING CASE OF HYPOTHYROID WOMAN BECOMING HYPERTHYROID**

*Kudugunti N<sup>1</sup>, Sahay RK<sup>1</sup>, Kumaresan K<sup>2</sup>*

<sup>1</sup>Osmania Medical College, NTR University of Health Sciences, Endocrinology, Hyderabad, India, <sup>2</sup>K.K Nuclear Scan, Nuclear Medicine, Hyderabad, India

**P92 TRANSIENT THYROTOXICOSIS DIFFERENT FROM SUBACUTE THYROIDITIS**

*Milicevic Z<sup>1</sup>*

<sup>1</sup>Vinca Institute of Nuclear Sciences, Laboratory of Molecular Biology and Endocrinology, Belgrade, Serbia

**P93 LATE RECURRENCES OF GRAVES HYPERTHYROIDISM AFTER SURGICAL THERAPY**

*Ursu HJ<sup>1,2</sup>, Galoiu S<sup>1,2</sup>, Podia C<sup>3</sup>, Purice M<sup>4</sup>, Stanescu B<sup>2,5</sup>, Goldstein A<sup>4</sup>, Alexandrescu D<sup>6</sup>*

<sup>1</sup>C.I. Parhon' Institute of Endocrinology, Thyroid Unit 1, Bucharest, Romania, <sup>2</sup>Carol Davila' University of Medicine and Pharmacy, Endocrinology, Bucharest, Romania, <sup>3</sup>Astra' Polyclinic, Sibiu, Romania, <sup>4</sup>C.I. Parhon' Institute of Endocrinology, Nuclear Medicine, Bucharest, Romania, <sup>5</sup>C.I. Parhon' Institute of Endocrinology, Endocrine Surgery, Bucharest, Romania, <sup>6</sup>C.I. Parhon' Institute of Endocrinology, Ophthalmology, Bucharest, Romania

**P94 LITHIUM-ASSOCIATED HYPERPARATHYROIDISM: A CASE REPORT**

*Marcelino M<sup>1</sup>, Silva J<sup>1</sup>, Lopes F<sup>1</sup>, Lopes L<sup>1</sup>, Salgado L<sup>2</sup>, Lopes C<sup>3</sup>, de Castro JJ<sup>1</sup>*

<sup>1</sup>Armed Forces University Hospital, Endocrinology, Lisbon, Portugal, <sup>2</sup>Armed Forces University Hospital, Nuclear Medicine, Lisbon, Portugal, <sup>3</sup>Armed Forces University Hospital, Surgery, Lisbon, Portugal



Poster Exhibition Area

12.00–13.00

Poster Session 2

**PO11 Thyroid Autoimmunity Clinical**

Chair: *Stefano Mariotti*, Italy

**P95 THE CONTRIBUTION OF POLYMORPHISMS WITHIN GENES ENCODING CO-STIMULATORY MOLECULES TO THE SUSCEPTIBILITY TO GRAVES' DISEASE AND ORBITOPATHY**

*Pawlak-Adamska E<sup>1</sup>, Daroszewski J<sup>2</sup>, Frydecka I<sup>1</sup>, Karabon L<sup>1</sup>, Jonkisz A<sup>1</sup>, Tomkiewicz A<sup>1</sup>, Partyka A<sup>1</sup>, Lebioda A<sup>3</sup>, Bolanowski M<sup>2</sup>*

<sup>1</sup>Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland, <sup>2</sup>Wrocław Medical University, Dept. of Endocrinology, Diabetes and Isotope Therapy, Wrocław, Poland, <sup>3</sup>Wrocław Medical University, Dept. of Forensic Medicine, Wrocław, Poland

**P96 SELENOMETHIONINE SUPPLEMENTATION IN EUTHYROID PATIENTS WITH AUTOIMMUNE THYROIDITIS: EFFECTS OF TWO DOSES (80 OR 160 µG) VERSUS PLACEBO**

*Cenci V<sup>1</sup>, Pilli T<sup>1</sup>, Cardinale S<sup>1</sup>, Cantara S<sup>1</sup>, Fioravanti C<sup>1</sup>, Sestini F<sup>1</sup>, Pasqui L<sup>1</sup>, Pacini F<sup>1</sup>*

<sup>1</sup>University of Siena, Section of Endocrinology, Department of Medical, Surgical and Neurological Sciences, Siena, Italy

**P97 CHRONIC LYMPHOCITIC THYROIDITIS (CLT) IS INCREASED IN INDUSTRIALIZED AREAS WITH PETROCHEMICAL PLANTS IN SOUTH-EASTERN SICILY. A CYTOLOGICAL-BASED STUDY**

*Arena S<sup>1</sup>, Gullo D<sup>2</sup>, Latina A<sup>2</sup>, Benvenega S<sup>3</sup>*

<sup>1</sup>A.S.P. 8 – Umberto I Hospital, Internal Medicine, Section of Endocrinology and Metabolic Disease, Siracusa, Italy,

<sup>2</sup>Garibaldi-Nesima Hospital, Endocrinology, Catania, Italy,

<sup>3</sup>University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy

**P98 EFFECTS OF STEROID PROPHYLAXIS FOR GRAVES' ORBITOPATHY ON THE RADIOIODINE (RAI) THERAPEUTIC OUTCOME AND THYROID FUNCTION**

*Covelli D<sup>1</sup>, Vannucchi G<sup>1</sup>, Campi I<sup>1</sup>, Currò N<sup>2</sup>, Dazzi D<sup>3</sup>, Rodari M<sup>4</sup>, Pepe G<sup>4</sup>, Chiti A<sup>4</sup>, Beck-Peccoz P<sup>1</sup>, Salvi M<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Department of Clinical Science and Community Health, Fondazione Cà Granda Policlinico IRCCS, Milan, Italy, <sup>2</sup>Ophthalmology, Fondazione IRCCS Cà Granda, Milan, Italy, <sup>3</sup>Internal Medicine, Ospedale di Fidenza, Fidenza, Italy, <sup>4</sup>Nuclear Medicine, Istituto Clinico Humanitas, Rozzano, Italy

**P99 PENDRIN AUTOANTIBODIES, USING A RADIOLIGAND BINDING ASSAY, ARE DETECTED WITH LOW FREQUENCY IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE AND ARE UNDETECTABLE IN NORMAL CONTROLS**

*Brix TH<sup>1</sup>, Hegedüs L<sup>1</sup>, Weetman T<sup>2</sup>, Kemp H<sup>2</sup>*

<sup>1</sup>Odense University Hospital, Endocrinology and Metabolism, Odense, Denmark, <sup>2</sup>Medical School, University of Sheffield, Department of Human Metabolism, Sheffield, United Kingdom

**P100 OXIDATIVE STRESS IS ASSOCIATED WITH THYROID HORMONES AND THYROID AUTOIMMUNITY IN EUTHYROID WOMEN**

*Giannakou M<sup>1</sup>, Saltiki K<sup>1</sup>, Loukari E<sup>1</sup>, Mantzou A<sup>1</sup>, Philippou G<sup>1</sup>, Terzidis K<sup>1</sup>, Stavrianos C<sup>1</sup>, Alevizaki M<sup>1</sup>*

<sup>1</sup>Athens University School of Medicine, Dept of Endocrinology and Metabolism 'Evgenidion' Hospital, Athens, Greece

**P101 PRIMARY THYROID DISORDERS IN PATIENTS WITH ENDOGENOUS HYPERCORTISOLISM AND THE ROLE OF IMMUNE DYSREGULATION: AN OBSERVATIONAL STUDY**

*Demir Onal E<sup>1</sup>, Sağlam F<sup>1</sup>, Saçıkara M<sup>1</sup>, Ersoy R<sup>1</sup>, Çakır B<sup>1</sup>*

<sup>1</sup>Yıldırım Beyazıt University Ankara Atatürk Education and Research Hospital, Endocrinology and Metabolism, Ankara, Turkey

**P102 FACTORS INFLUENCING GRAVES' DISEASE RECURRENCE AFTER SUCCESSFUL TREATMENT WITH ANTITHYROID DRUGS**

*Zaletel K<sup>1</sup>, Arko R<sup>2</sup>, Gaberšček S<sup>1</sup>, Pirnat E<sup>1</sup>, Hojker S<sup>1</sup>*

<sup>1</sup>University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, Slovenia, <sup>2</sup>Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

**P103 THYROID AUTOIMMUNITY IN PATIENTS WITH HYPERPROLACTINEMIA: AN OBSERVATIONAL STUDY**

*Demir Onal E<sup>1</sup>, Sağlam F<sup>1</sup>, Saçıkara M<sup>1</sup>, Ersoy R<sup>1</sup>, Çakır B<sup>1</sup>*

<sup>1</sup>Yıldırım Beyazıt University Medical School Ankara Atatürk Education and Research Hospital, Endocrinology and Metabolism, Ankara, Turkey

**P104 AUTOIMMUNE THYROIDITIS AND PAPILLARY THYROID CANCER**

*Podoba J<sup>1</sup>, Grigerová M<sup>2</sup>, Podobová M<sup>2</sup>*

<sup>1</sup>Slovak Medical University, Dept. Endocrinology, Bratislava, Slovakia, <sup>2</sup>St. Elizabeth Cancer Institute, Dept. Endocrinology, Bratislava, Slovakia

## PO12 Thyroid Cancer Basic 2

Chair: Dagmar Führer, Germany

### P105 DISTINCT GENETIC ALTERATIONS IN MAPK PATHWAY MODULATE TYPE 3 DEIODINASE IN HUMAN PTC CELL LINES

*Romitti M<sup>1</sup>, Wajner SM<sup>1</sup>, Pinto Ribeiro RV<sup>1</sup>, Ceolin L<sup>1</sup>, Ferreira CV<sup>1</sup>, Rohenkohl HC<sup>1</sup>, Fuziwara CS<sup>2</sup>, Edna KT<sup>2</sup>, Maia AL<sup>1</sup>*

<sup>1</sup>Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, <sup>2</sup>Universidade de São Paulo, Institute of Biomedical Science, São Paulo, Brazil

### P106 IMPORTANCE OF THE TRANSIENT RECEPTOR POTENTIAL CANONICAL 1 (TRPC1) CHANNEL IN THE MIGRATION AND PROLIFERATION OF FOLLICULAR ML-1 THYROID CANCER CELLS

*Asgar MY<sup>1</sup>, Magnusson M<sup>1</sup>, Kemppainen K<sup>1</sup>, Bergelin N<sup>2</sup>, Törnquist K<sup>1,2</sup>*

<sup>1</sup>Åbo Akademi University, Biosciences, Turku, Finland, <sup>2</sup>The Minerva Foundation Institute for Medical Research, Helsinki, Finland

### P107 THE USE OF PGLA NANOPARTICLES AS A DELIVERY SYSTEM OF DIFFERENT ANTITUMOURAL DRUGS AS A CONTROL OF THE PROLIFERATION CELLS IN THE EPITHELIAL THYROID NEOPLASIAS

*Mato E<sup>1,2,3</sup>, Bordas A<sup>1</sup>, Puras G<sup>4</sup>, Zararte J<sup>4</sup>, Hernández RM<sup>4</sup>, Igartua M<sup>4</sup>, González C<sup>1,2</sup>, Bell O<sup>1,2</sup>, Moral A<sup>5</sup>, Pérez JI<sup>5</sup>, Pedraz JL<sup>4</sup>, de Leiva A<sup>1,2</sup>*

<sup>1</sup>Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Endocrinology, Barcelona, Spain, <sup>2</sup>EUADB-HSP Hospital Santa Creu i Sant Pau, Autonomous University, Barcelona, Spain, <sup>3</sup>Departamento de Biología Celular, Inmunología y Neurociencias Facultad de Medicina UB, Barcelona, Spain, <sup>4</sup>NanoBioCel Group, at the Department of Pharmacy and Food Sciences, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain, <sup>5</sup>General Surgery, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

### P108 MOLECULAR EPIDEMIOLOGY STUDY OF CHERNOBYL THYROID CANCER FROM BELARUS AND UKRAINE

*Saenko V<sup>1</sup>, Takahashi M<sup>2</sup>, Rogounovitch TI<sup>3</sup>, Akulevich NM<sup>4</sup>, Drozd VM<sup>4</sup>, Danilova LI<sup>4</sup>, Lushchik ML<sup>4</sup>, Demidchik YE<sup>4</sup>, Bogdanova TI<sup>5</sup>, Tronko MD<sup>5</sup>, Mitsutake N<sup>3</sup>, Takamura N<sup>6</sup>, Matsuda F<sup>2</sup>, Yamashita S<sup>1,3</sup>*

<sup>1</sup>Nagasaki University, Department of Health Risk Control, Nagasaki, Japan, <sup>2</sup>Kyoto University Graduate School of Medicine, Center for Genomic Medicine, Kyoto, Japan, <sup>3</sup>Nagasaki University, Department of Radiation Medical Sciences, Nagasaki, Japan, <sup>4</sup>Belarusian Medical Academy for Postgraduate Education, Minsk, Belarus, <sup>5</sup>Institute of Endocrinology and Metabolism, Kiev, Ukraine, <sup>6</sup>Nagasaki University, Department of Global Health, Medicine and Welfare, Nagasaki, Japan

### P109 THYROCYTE IS PARTICULARLY WELL PROTECTED AGAINST OXIDATIVE STRESS INDUCED BY H<sub>2</sub>O<sub>2</sub>

*Ghaddhab C<sup>1</sup>, Hancisse O<sup>1</sup>, Verstehe S<sup>1</sup>, Driessens N<sup>1</sup>, Dumont JE<sup>1</sup>, Miot F<sup>1</sup>, Corvilain B<sup>1</sup>*

<sup>1</sup>ULB, Brussels, Belgium

### P110 α-LIPOIC ACID INHIBITS EPITHELIAL TO MESENCHYMAL TRANSITION IN THYROID CANCER CELLS

*Kim WG<sup>1</sup>, Choi H-J<sup>2</sup>, Han JM<sup>1</sup>, Kim TY<sup>1</sup>, Shong YK<sup>1</sup>, Kim WB<sup>1</sup>*

<sup>1</sup>Asan Medical Center, University of Ulsan College of Medicine, Internal Medicine, Seoul, Korea, Republic of, <sup>2</sup>Asan Institute of Life Science, Seoul, Republic of Korea

### P111 CELLULAR ABSORPTION OF SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES IN HUMAN THYROID CANCER (FB3) AND FIBROBLASTIC CELL LINES (NHDF): IN VITRO STUDY

*Pasqualetti G<sup>1</sup>, Di Bari L<sup>2</sup>, Ursino S<sup>3</sup>, Lenzi P<sup>4</sup>, Tognini S<sup>3</sup>, Polini A<sup>3</sup>, Vitulli G<sup>2</sup>, Vantaggiato C<sup>3</sup>, Barbaro D<sup>5</sup>, Fornai F<sup>4</sup>, Salvatori P<sup>2</sup>, Monzani F<sup>3</sup>*

<sup>1</sup>University of Pisa, Department of Clinical and Experimental Medicine, Geriatrics Unit, Pisa, Italy, <sup>2</sup>Advanced Catalysts S.r.l., Pisa, Italy, <sup>3</sup>University of Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy, <sup>4</sup>University of Pisa, Department of Translational Research and New Technology in Medicine, Pisa, Italy, <sup>5</sup>Livorno Hospital, Department of Internal Medicine, Livorno, Italy

### P112 AFTER 20 YEARS, RET GENETIC SCREENING STILL IDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS

*Tacito A<sup>1</sup>, Romei C<sup>1</sup>, Vivaldi A<sup>1</sup>, Ciampi R<sup>1</sup>, Matrone A<sup>1</sup>, Bottici V<sup>1</sup>, Cappagli V<sup>1</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>University of Pisa, Section of Endocrinology, Department of Clinical and Experimental Medicine, Pisa, Italy

### P113 MISSENSE POLYMORPHISMS IN XIAP-ASSOCIATED FACTOR 1 (XAF1) AND RISK OF PAPILLARY THYROID CANCER IN KOREAN POPULATION : CORRELATION WITH CLINICOPATHOLOGIC FEATURES

*Kim SW<sup>1</sup>, Kwon KH<sup>2</sup>*

<sup>1</sup>VHS Medical Center, Department of Otolaryngology-Head and Neck Surgery, Seoul, Korea, Republic of, <sup>2</sup>Ilson Memorial Institute of Head and Neck Cancer, Hallym University College of Medicine, Department of Otolaryngology-Head and Neck Surgery, Seoul, Republic of Korea

### P114 LESS INTRATUMORAL MICROVESSELS AND MORE NUMEROUS PERITUMORAL LYMPHATIC VASCULATURE IN RECURRENT THYROID CANCERS

*Hakala T<sup>1</sup>, Kholová P<sup>2</sup>, Kellokumpu-Lehtinen P-L<sup>1</sup>, Sand J<sup>1</sup>*

<sup>1</sup>Tampere University Hospital, Tampere, Finland, <sup>2</sup>Fimlab Laboratories, Pathology, Tampere, Finland

**P115 PARVOVIRUS B 19 AS AN ETIOLOGICAL AGENT OF PAPILLARY THYROID CANCER IN A KOREAN POPULATION**

*Lee IS<sup>1</sup>, Jang YS<sup>1</sup>, Kim HS<sup>1</sup>, Lee KJ<sup>1</sup>, Lee DH<sup>1</sup>, Lee JM<sup>1</sup>*

<sup>1</sup>The Catholic University College of Medicine, Daejeon, Republic of Korea

**PO13 Thyroid Cancer Diagnostics 2**

Chair: *Ulla Feldt-Rasmussen*, Germany

**P116 CORRELATION OF THE PRESURGICAL DIAGNOSIS OF FOLLICULAR VARIANT OF PAPILLARY THYROID CANCER WITH THE DISEASE STATUS AFTER 10 YEARS OF FOLLOW UP**

*Giani C<sup>1</sup>, Torregrossa L<sup>2</sup>, Angeli M<sup>1</sup>, Molinaro E<sup>1</sup>, Cacciato Insilla A<sup>2</sup>, Materazzi G<sup>2</sup>, Marchetti I<sup>3</sup>, Basolo F<sup>2</sup>, Miccoli P<sup>2</sup>, Di Coscio G<sup>3</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, <sup>2</sup>Department of Surgical, Medical and Molecular Pathology of the Clinical Area, University of Pisa, Pisa, Italy, <sup>3</sup>Department of Translational Research and New Technologies in Medicine and Surgeons, University of Pisa, Pisa, Italy

**P117 IDENTIFICATION OF SOMATIC MUTATIONS BY MATRIX-ASSISTED LASER DESORPTION IONIZATION TIME-OF-FLIGHT MASS SPECTROMETRY IN FINE NEEDLE ASPIRATION OF PAPILLARY THYROID CANCER**

*Cho YY<sup>1</sup>, Joung JY<sup>1</sup>, Kim NK<sup>1</sup>, Sohn SY<sup>1</sup>, Kim SW<sup>1</sup>, Chung JH<sup>1</sup>*

<sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

**P118 CLINICAL PREDICTORS OF PERSISTENT DISEASE IN PATIENTS WITH BRAFV600E MUTATED PAPILLARY THYROID CANCER (PTC)**

*Repaci A<sup>1</sup>, Vicennati V<sup>1</sup>, Paccapelo A<sup>1</sup>, Cavicchi O<sup>2</sup>, Monari F<sup>3</sup>, Mazzarotto R<sup>3</sup>, Tallini G<sup>4</sup>, Altimari A<sup>5</sup>, Gruppioni E<sup>5</sup>, Fiorentino M<sup>5</sup>, Pasquali R<sup>1</sup>*

<sup>1</sup>Sant'Orsola-Malpighi Hospital/University of Bologna, Endocrinology Unit, Bologna, Italy, <sup>2</sup>Sant'Orsola-Malpighi Hospital/University of Bologna, Department of Otolaryngology, Bologna, Italy, <sup>3</sup>Sant'Orsola-Malpighi Hospital/University of Bologna, Department of Radiotherapy, Bologna, Italy, <sup>4</sup>Department of Haematology and Oncological Sciences L. and A. Seragnoli, Section of Anatomic Pathology at Bellaria Hospital, University of Bologna Malpighi Università di Bologna, Bologna, Italy, <sup>5</sup>Molecular and Transplantation Pathology Laboratory, 'F. Addarii' / Sant'Orsola-Malpighi Hospital/University of Bologna, Bologna, Italy

**P119 THE EVALUATION OF SALIVARY GLAND DYSFUNCTION AFTER I-131 THERAPY IN PATIENTS FOLLOWING TOTAL THYROIDECTOMY**

*Kim D-Y<sup>1</sup>, Hong IK<sup>1</sup>, An JY<sup>2</sup>, Lee KM<sup>2</sup>, Kim EJ<sup>2</sup>*

<sup>1</sup>Kyung Hee University Hospital, Nuclear Medicine, Seoul, Republic of Korea, <sup>2</sup>Kyung Hee University Hospital, Radiology, Seoul, Republic of Korea

**P120 THE DISCORDANCE BETWEEN PRE-OPERATIVE AND POST-OPERATIVE BRAF MUTATION ANALYSIS OF PAPILLARY THYROID CANCER BY US-GUIDED FNA: ULTRASOUND FEATURES**

*Kim S<sup>1</sup>, Park SH<sup>1</sup>, Lee SJ<sup>1</sup>, Hur J<sup>1</sup>*

<sup>1</sup>Chung-Ang University, Seoul, Republic of Korea

**P121 DO CHARACTERISTICS OF PAPILLARY THYROID CARCINOMAS CORRELATE WITH PREOPERATIVE SERUM TSH CONCENTRATIONS?**

*Park J-W<sup>1</sup>, Kim D-J<sup>1</sup>*

<sup>1</sup>Chungbuk National University, Department of Surgery, Cheongju, Republic of Korea

**P122 BASAL THYROGLOBULIN LEVELS MAY PREDICT RECURRENT AND PERSISTENT DISEASE IN DIFFERENTIATED THYROID CANCER (DTC)**

*Aydoğan BI<sup>1</sup>, Erdogan MF<sup>1</sup>, Öztürk B<sup>1</sup>, Özkan E<sup>2</sup>, Şahin M<sup>1</sup>, Emral R<sup>1</sup>, Küçük Ö<sup>2</sup>, Çorapçıoğlu D<sup>1</sup>, Başkal N<sup>1</sup>, Uysal AR<sup>1</sup>, Güllü S<sup>1</sup>*

<sup>1</sup>Ankara University School of Medicine, Endocrinology and Metabolism Diseases, Ankara, Turkey, <sup>2</sup>Ankara University School of Medicine, Nuclear Medicine, Ankara, Turkey

**P123 SILENT BONE METASTASES FROM DIFFERENTIATED THYROID CANCER – A STUDY ON INCIDENCE AND OUTCOME OF TREATMENT**

*Kumaresan K<sup>1</sup>, Dillikar G<sup>1</sup>*

<sup>1</sup>KK Nuclear Scans, Hyderabad, India

**P124 VERY RARE METASTASES IN DIFFERENTIATED THYROID CANCER: DIAGNOSIS WITH 18F FDG PET/CT OR 131I SPECT/CT IMAGING; ON BEHALF OF THE FRENCH TUTHYREF (TUMEURS DE LA THYROÏDE REFRACTAIRES) NETWORK**

*Faugeron I<sup>1</sup>, Bonichon F<sup>2</sup>, Schwartz C<sup>3</sup>, Dejoux C<sup>4</sup>, Bournaud C<sup>5</sup>, Benisvy D<sup>6</sup>, Lebouilleux S<sup>7</sup>, Méas T<sup>1</sup>, Schneegans O<sup>8</sup>, Toubert M-E<sup>1</sup>*

<sup>1</sup>Saint-Louis Hospital, APHP, Nuclear Medicine, Paris, France, <sup>2</sup>Institut Bergonie, Nuclear Medicine, Bordeaux, France, <sup>3</sup>Centre Jean Godinot, Nuclear Medicine, Reims, France, <sup>4</sup>Centre Jean Perrin, Nuclear Medicine, Clermont-Ferrand, France, <sup>5</sup>Hospices Civils de Lyon, GH Est, Nuclear Medicine, Bron, France, <sup>6</sup>Centre Antoine Lacassagne, Nuclear Medicine, Nice, France, <sup>7</sup>Institut Gustave Roussy, Nuclear Medicine, Villejuif, France, <sup>8</sup>Centre Paul Strauss, Nuclear Medicine, Strasbourg, France



## P014 Thyroid Nodules and Goitre 1

Chair: Laszlo Hegedüs, Denmark

### P125 MCL-1 UPREGULATION AND P27 DOWNREGULATION DIFFERENTIATE THE PATHOGENESIS OF PAPILLARY THYROID CARCINOMA AND BENIGN THYROID NODULES: CLINICAL, SCINTIGRAPHY AND SONOGRAPHIC CORRELATIONS

*Maia FFR<sup>1</sup>, Vassallo J<sup>2</sup>, Pinto GA<sup>3</sup>, Pavin EJ<sup>1</sup>, Matos PS<sup>4</sup>, Zantut-Wittmann DE<sup>1</sup>*

<sup>1</sup>University of Campinas – UNICAMP, Internal Medicine, Endocrinology Division, Campinas, Brazil, <sup>2</sup>Laboratory of Investigative and Molecular Pathology, CIPED, University of Campinas, Department of Pathology, Campinas, Brazil, <sup>3</sup>Laboratory of Specialized Pathology, CAISM, Medical Science School, University of Campinas, Department of Pathology, Campinas, Brazil, <sup>4</sup>Medical Science School, University of Campinas, Department of Pathology, Campinas, Brazil

### P126 THE EFFECT OF HEMITHYROIDECTOMY FOR BENIGN EUTHYROID GOITER ON THE MITOCHONDRIAL MEMBRANE POTENTIAL OF PERIPHERAL MONONUCLEAR BLOOD CELLS

*Toft Kristensen T<sup>1</sup>, Larsen J<sup>2</sup>, Pedersen PL<sup>3</sup>, Feldthusen A-D<sup>4</sup>, Anthonsen S<sup>3</sup>, Jelstrup S<sup>1</sup>, Kvetny J<sup>5</sup>*

<sup>1</sup>Department of Otorhinolaryngology – Head and Neck Surgery, Slagelse Hospital, Region Zealand, Slagelse, Denmark, <sup>2</sup>Department of Clinical Pathology, Næstved Hospital, Region Zealand, Næstved, Denmark, <sup>3</sup>Department of Clinical Biochemistry, Næstved Hospital, Region Zealand, Næstved, Denmark, <sup>4</sup>Department of Gynecology and Obstetrics, Næstved Hospital, Region Zealand, Næstved, Denmark, <sup>5</sup>University of Southern Denmark, Department of Internal Medicine, Næstved Hospital, Region Zealand, Næstved, Denmark

### P127 AN OPEN-LABEL, RANDOMIZED, CONTROLLED STUDY OF THE EFFECTIVENESS AND SAFETY OF A HIGH INTENSITY FOCUSED ULTRASOUND DEVICE COMPARED WITH OBSERVATION IN PATIENTS WITH NON-MALIGNANT COLD THYROID NODULES

*Leenhardt L<sup>1</sup>, Rouxel A<sup>1</sup>, Lacoste F<sup>2</sup>, Menegaux F<sup>3</sup>, Esnault O<sup>4</sup>*

<sup>1</sup>Pierre et Marie Curie University, Nuclear Medicine, Paris, France, <sup>2</sup>Theraclion, Paris, France, <sup>3</sup>Pierre et Marie Curie University, Endocrine Surgery, Paris, France, <sup>4</sup>ENT Department, Paris, France

### P128 ASSOCIATION BETWEEN REAL-TIME NODULE ELASTOGRAPHY AND CLASSICAL MALIGNANCY RISK MARKERS BY ULTRASONOGRAPHY IN A REAL LIFE CLINICAL SETTING – A PROSPECTIVE PATIENT STUDY BEFORE THYROID SURGERY

*Motavaf AK<sup>1</sup>, Brilli L<sup>2</sup>, Pikeli A<sup>3</sup>, Baymler Pedersen H<sup>3</sup>, Laurberg P<sup>1</sup>*

<sup>1</sup>Aalborg University Hospital, Department of Endocrinology, Aalborg, Denmark, <sup>2</sup>University of Siena, Siena, Italy, <sup>3</sup>Aalborg University Hospital, Department of ENT Head and Neck Surgery, Aalborg, Denmark

### P129 THE ROLE OF BETHESDA CYTOLOGICAL CLASSIFICATION SYSTEM AND SONOGRAPHIC PARAMETERS TO DISCRIMINATE BENIGN AND MALIGNANCY IN THYROID NODULES ≥3CM

*Maia FFR<sup>1</sup>, Matos PS<sup>2</sup>, Pavin EJ<sup>1</sup>, Vassallo J<sup>3</sup>, Zantut-Wittmann DE<sup>1</sup>*

<sup>1</sup>University of Campinas – UNICAMP, Internal Medicine, Endocrinology Division, Campinas, Brazil, <sup>2</sup>Medical Science School, University of Campinas, Department of Pathology, Campinas, Brazil, <sup>3</sup>Laboratory of Investigative and Molecular Pathology, CIPED, University of Campinas, Department of Pathology, Campinas, Brazil

### P130 EFFICACY, SAFETY AND COSTS OF THERMAL ABLATION WITH RADIOFREQUENCY COMPARED TO SURGERY FOR THE TREATMENT OF BENIGN THYROID NODULES

*Bernardi S<sup>1</sup>, Dobrinja C<sup>2</sup>, Bazzocchi G<sup>3</sup>, Sabato N<sup>4</sup>, Barro E<sup>4</sup>, Carretta R<sup>4</sup>, Stacul F<sup>3</sup>, Fabris B<sup>4</sup>*

<sup>1</sup>Ospedale di Cattinara, Medicina Clinica, Trieste, Italy, <sup>2</sup>Ospedale di Cattinara, Chirurgia Generale, Trieste, Italy, <sup>3</sup>Ospedale Maggiore, Radiologia, Trieste, Italy, <sup>4</sup>University of Trieste, Dipartimento di Scienze Mediche Chirurgiche e della Salute, Trieste, Italy

### P131 THIAMAZOL INCREASES IODINE UPTAKE AND ALLOWS A REDUCTION OF RADIOIODINE DOSE NEEDED TO TREAT SUBCLINICAL HYPERTHYROIDISM IN PATIENTS WITH MULTINODULAR GOITER

*Kyrilli A<sup>1</sup>, Blocklet D<sup>2</sup>, Corvilain B<sup>1</sup>, Goldman S<sup>2</sup>, Moreno-Reyes R<sup>2</sup>*

<sup>1</sup>Université Libre de Bruxelles, Department of Endocrinology, Brussels, Belgium, <sup>2</sup>Université Libre de Bruxelles, Department of Nuclear Medicine, Brussels, Belgium

### P132 TWO NOVEL FORMULATIONS OF L-T4 (ORAL SOLUTION AND SOFT GEL CAPSULE) ARE REFRACTORY TO THE COFFEE-INDUCED INTESTINAL MALABSORPTION OF TABLET L-T4

*Saraceno G<sup>1</sup>, Vita R<sup>1</sup>, Trimarchi F<sup>1</sup>, Benvenga S<sup>1</sup>*

<sup>1</sup>University of Messina, Department of Clinical & Experimental Medicine, Messina, Italy

## PO15 Thyroid Cancer Therapeutics 2

Chair: Alicja Hubalewska-Dydejczyk, Poland

### P133 BASELINE AGGRESSIVENESS AND LONG-TERM OUTCOME OF PAPILLARY THYROID CANCER IN PATIENTS WITH OR WITHOUT POSITIVE CIRCULATING ANTI-THYROGLOBULIN ANTIBODY TITRE: RESULTS FROM A MULTICENTER, RETROSPECTIVE ANALYSIS

*Tognini S<sup>1</sup>, Durante C<sup>2</sup>, Montesano T<sup>2</sup>, Orlandi F<sup>3</sup>, Torlontano M<sup>4</sup>, Puxeddu E<sup>5</sup>, Attard M<sup>6</sup>, Polini A<sup>1</sup>, Pasqualetti G<sup>1</sup>, Costante G<sup>7</sup>, Meringolo D<sup>8</sup>, Tumino S<sup>9</sup>, Bruno R<sup>10</sup>, Monzani F<sup>1</sup>, Filetti S<sup>2</sup>*

<sup>1</sup>Università di Pisa, Dipartimento di Medicina Clinica e Sperimentale, Pisa, Italy, <sup>2</sup>Università di Roma Sapienza, Dipartimento di Medicina Interna e Specialità Mediche, Roma, Italy, <sup>3</sup>Università degli Studi di Torino, Dipartimento di Scienze Cliniche e Biologiche S.C.D.U, Torino, Italy, <sup>4</sup>Istituto di Ricovero e Cura a Carattere Scientifico, Casa Sollievo della Sofferenza, San Giovanni Rotondo, Unità Operativa di Endocrinologia, San Giovanni Rotondo, Italy, <sup>5</sup>Università di Perugia, Dipartimento di Medicina Interna, Perugia, Italy, <sup>6</sup>Azienda Ospedaliera Ospedali Riuniti Villa Sofia-Cervello, Unità Operativa di Endocrinologia, Palermo, Italy, <sup>7</sup>Università di Catanzaro Magna Graecia, Dipartimento di Scienze della Salute, Catanzaro, Italy, <sup>8</sup>Ospedale di Bentivoglio, Unità Operativa Semplice Dipartimentale di Endocrinologia, Bologna, Italy, <sup>9</sup>Università di Catania, Dipartimento di Scienze Mediche e Pediatriche, Catania, Italy, <sup>10</sup>Ospedale di Tinchi-Pisticci, Unità di Endocrinologia, Matera, Italy

### P134 PREDICTION OF RISK FOR SYMPTOMATIC SIALADENITIS BY POST-THERAPEUTIC DUAL <sup>131</sup>I SCINTIGRAPHY IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

*Lee SM<sup>1</sup>, Lee JW<sup>2</sup>, Kim YS<sup>3</sup>, Han SW<sup>4</sup>, Bae WK<sup>3</sup>*

<sup>1</sup>Soonchunhyang University Hospital, Department of Nuclear Medicine, Cheonan, Republic of Korea, <sup>2</sup>Yonsei University College of Medicine, Department of Nuclear Medicine, Seoul, Republic of Korea, <sup>3</sup>Soonchunhyang University Hospital, Department of Radiology, Cheonan, Republic of Korea, <sup>4</sup>Soonchunhyang University Hospital, Department of General Surgery, Cheonan, Republic of Korea

### P135 TREATMENT OF PATIENTS WITH PATHOLOGY PROVEN HÜRTHLE CELL THYROID CARCINOMA WITH PEPTIDE RECEPTOR RADIONUCLIDE THERAPY USING THE RADIOACTIVE SOMATOSTATIN ANALOGUE [LU-177-DOTA0, TYR3]OCTREOTATE

*Kam BLR<sup>1</sup>, Teunissen JJM<sup>1</sup>, Peeters RP<sup>2</sup>, de Herder WW<sup>2</sup>, Krenning EP<sup>1</sup>, Kwekkeboom DJ<sup>1</sup>*

<sup>1</sup>Erasmus Medical Center, Nuclear Medicine, Rotterdam, Netherlands, <sup>2</sup>Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands

### P136 CLINICAL SIGNIFICANCE OF DELPHIAN LYMPH NODE METASTASIS IN PAPILLARY THYROID CARCINOMA

*Oh EM<sup>1</sup>, Cheung YS<sup>1</sup>, Song WJ<sup>1</sup>, Lee YD<sup>1</sup>*

<sup>1</sup>Gachon Gil University Hospital, Thyroid Clinic, General Surgery, Incheon, Republic of Korea

### P137 THE PREDICTION OF PATIENTS, UNNECESSARY OF STIMULATED THYROGLOBULIN TEST IN THE LONG TERM MANAGEMENT OF DIFFERENTIATED THYROID CARCINOMA

*Hyun K<sup>1</sup>, Byon W<sup>1</sup>, Yun J-S<sup>1</sup>, Park Y<sup>1</sup>, Park C<sup>1</sup>*

<sup>1</sup>Kangbuk Samsung Hospital, Department: General Surgery, Seoul, Republic of Korea

### P138 DIFFERENTIATED THYROID CANCER LOCALIZED IN THE THYROID ISTHMUS: IS THERE ANY SPECIFICITY?

*Vija LM<sup>1,2</sup>, Meas T<sup>3</sup>, Faugeron J<sup>3</sup>, Toubert M-E<sup>3</sup>*

<sup>1</sup>APHP Hôpital Bicêtre, Biophysics and Nuclear Medicine, Le Kremlin-Bicêtre, France, <sup>2</sup>Paris Sud University, Le Kremlin-Bicêtre, France, <sup>3</sup>APHP Hôpital St Louis, Biophysics and Nuclear Medicine, Paris, France

### P139 LEVEL OF THYROGLOBULIN (TG) IN PATIENT WITH PAPILLARY THYROID CARCINOMA (PTC) RECEIVED RADIO IODINE (RAI) ABLATION THERAPY

*Frangos S<sup>1</sup>, Patsali L<sup>1</sup>, Vanezi A<sup>1</sup>*

<sup>1</sup>Bank of Cyprus Oncology Center, Nuclear Medicine, Strovolos-Nicosia, Cyprus

### P140 PYRAMIDAL LOBE DIFFERENTIATED THYROID CARCINOMA: A RARE AND ATYPICAL LOCALIZATION

*Vija LM<sup>1,2</sup>, Meas T<sup>3</sup>, Faugeron J<sup>3</sup>, Toubert M-E<sup>4</sup>*

<sup>1</sup>APHP Hôpital Bicêtre, Biophysics and Nuclear Medicine, Le Kremlin-Bicêtre, France, <sup>2</sup>Paris Sud University, Le Kremlin-Bicêtre, France, <sup>3</sup>APHP Hôpital St Louis, Paris, France, <sup>4</sup>APHP Hôpital St Louis, Biophysics and Nuclear Medicine, Paris, France

### P141 FOLLOW-UP OF CHILDREN WITH DIFFERENTIATED THYROID CANCER: AN INSTITUTIONAL EXPERIENCE

*Franceschi M<sup>1</sup>, Jukić T<sup>1</sup>, Granić R<sup>1</sup>, Staničić J<sup>1</sup>, Šiško Markoš I<sup>1</sup>, Dabelić N<sup>1</sup>, Punda M<sup>1</sup>, Lukinac L<sup>1</sup>, Kusić Z<sup>1</sup>*

<sup>1</sup>UHC'Sestre Milosrdnice, Zagreb Medical School, Department of Oncology and Nuclear Medicine, Zagreb, Croatia

## PO16 Case Reports 2

Chair: Bojan Lozanov, Bulgaria

### P142 FIRST DESCRIPTION OF A PATIENT WITH CONGENITAL GOITROUS HYPOTHYROIDISM DUE TO SODIUM/IODIDE SYMPORTER (NIS) DEFECT AND THYROID CANCER

*Bagattini B<sup>1</sup>, Di Cosmo C<sup>1</sup>, Montanelli L<sup>1</sup>, Agretti P<sup>1</sup>, De Marco G<sup>1</sup>, Vitti P<sup>1</sup>, Tonacchera M<sup>1</sup>*

<sup>1</sup>University of Pisa, Section of Endocrinology, Department of Clinical and Experimental Medicine, Pisa, Italy



**P143 A NEW TSHR VARIANT (L665F) AS THE MOLECULAR CAUSE FOR NON-AUTOIMMUNE HYPERTHYROIDISM IN AN AUSTRIAN FAMILY**

*Jaeschke H<sup>1</sup>, Eszlinger M<sup>1</sup>, Schaarschmidt J<sup>1</sup>, Huth S<sup>1</sup>, Puttinger R<sup>2</sup>, Rittinger O<sup>2</sup>, Paschke R<sup>1</sup>*

<sup>1</sup>University of Leipzig, Division of Endocrinology and Nephrology, Leipzig, Germany, <sup>2</sup>University Hospital Salzburg, Department of Pediatrics, Salzburg, Austria

**P144 REVERSIBLE CEREBRAL AND CEREBELLAR ATROPHY IN A PATIENT WITH HYPOTHYROIDISM**

*Tachibana M<sup>1</sup>, Mukouhara N<sup>1</sup>, Hiram R<sup>1</sup>, Fujio H<sup>1</sup>, Yumoto A<sup>1</sup>*

<sup>1</sup>Himeji Red Cross Hospital, Cardiology, Himeji, Japan

**P145 GRAVES' DISEASE IN AN ADULT WITH CONGENITAL HYPOTHYROIDISM**

*Simpson A<sup>1</sup>, Wilson JD<sup>1</sup>*

<sup>1</sup>The Canberra Hospital, Endocrinology, Canberra, Australia

**P146 POST-PARTY PARALYSIS (PPP)?**

*Çagiltay E<sup>1</sup>, Deniz F<sup>1</sup>, Ozsari L<sup>1</sup>, Tekin O<sup>2</sup>, Ozdemir G<sup>2</sup>, Yonem A<sup>1</sup>, Urhan M<sup>3</sup>*

<sup>1</sup>GATA Haydarpasa Teaching Hospital, Endocrinology and Metabolism, Istanbul, Turkey, <sup>2</sup>GATA Haydarpasa Teaching Hospital, Internal Medicine, Istanbul, Turkey, <sup>3</sup>GATA Haydarpasa Teaching Hospital, Nuclear Medicine, Istanbul, Turkey

**P147 THYROTOXICOSIS DURING PREGNANCY, COMPLICATED BY ALLERGIES TO ANTI-THYROID DRUGS**

*Carlos ADC<sup>1</sup>, Rosales RD<sup>1</sup>*

<sup>1</sup>St.Luke's Medical Center, Section of Endocrinology, Diabetes and Metabolism, Quezon City, Philippines

**P148 PRIMARY THYROID LYMPHOMA: A CASE REPORT**

*Barbosa L<sup>1</sup>, Póvoa AA<sup>1</sup>, Wen X<sup>2</sup>, Soares C<sup>1</sup>, Furtado A<sup>2</sup>, Vieira H<sup>3</sup>, Oliveira MJ<sup>4</sup>, Tente D<sup>2</sup>, Amândio JV<sup>1</sup>, Maciel JP<sup>1,5</sup>, Madaleno P<sup>6</sup>*

<sup>1</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Department of General Surgery, Vila Nova de Gaia, Portugal, <sup>2</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Department of Pathology, Vila Nova de Gaia, Portugal, <sup>3</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Department of Hematology, Vila Nova de Gaia, Portugal, <sup>4</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Department of Endocrinology, Vila Nova de Gaia, Portugal, <sup>5</sup>Universidade Fernando Pessoa, Porto, Portugal, <sup>6</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Department of Radiology, Vila Nova de Gaia, Portugal

**P149 STRESS INDUCED GRAVES' DISEASE: A CASE REPORT HIGHLIGHTING THE PRE AND POSTOPERATIVE IMPLICATIONS OF SUBCLINICAL THYROTOXICOSIS**

*Wilkinson S<sup>1</sup>*

<sup>1</sup>Trafford General Hospital, Foundation Programme, Manchester, United Kingdom

**P150 TOXIC ADENOMA A RISK FACTOR FOR THYROTOXIC HEART FAILURE**

*Ahmeti I<sup>1</sup>, Ristevska N<sup>2</sup>, Strateska Shubevska S<sup>1</sup>, Pop Gjorceva D<sup>2</sup>, Stojanoski S<sup>2</sup>*

<sup>1</sup>Clinic of Endocrinology, Diabetes and Metabolism, Skopje, the Former Yugoslav Republic of Macedonia, <sup>2</sup>Institute of Pathophysiology and Nuclear Medicine, Skopje, the Former Yugoslav Republic of Macedonia

**PO17 Clinical Thyroidology 2**

Chair: Joao de Castro, Portugal

**P151 THYROID-STIMULATING HORMONE AND THYROID VOLUME IN OBESE SUBJECTS**

*Formichi C<sup>1</sup>, Brusco L<sup>1</sup>, Ciulli C<sup>1</sup>, Chiofalo F<sup>1</sup>, Selmi F<sup>1</sup>, Neri O<sup>1</sup>, Pasqui L<sup>1</sup>, Pacini F<sup>1</sup>*

<sup>1</sup>University of Siena, Siena, Italy

**P152 THE GASTROINTESTINAL ABSORPTION OF IODINE IS NOT REDUCED AFTER MALABSORPTIVE BARIATRIC PROCEDURES**

*Michalaki M<sup>1</sup>, Volonakis S<sup>1</sup>, Mamali I<sup>1</sup>, Kalfarentzos F<sup>2</sup>, Vagenakis AG<sup>1</sup>, Markou KB<sup>1</sup>*

<sup>1</sup>University of Patras Medical School, Division of Endocrinology, Department of Internal Medicine, Patras, Greece, <sup>2</sup>University of Patras Medical School, Department of Surgery, Patras, Greece

**P153 TREATMENT OF CENTRAL HYPOTHYROIDISM WITH RECOMBINANT HUMAN TSH – A PILOT STUDY**

*Dixit K<sup>1</sup>, Iwen A<sup>2</sup>, Lehmphul I<sup>3</sup>, Hoefig C<sup>3</sup>, Köhrle J<sup>3</sup>, Brabant G<sup>1,2</sup>*

<sup>1</sup>University of Manchester, Endocrinology – The Christie, Manchester, United Kingdom, <sup>2</sup>University of Lübeck, Endocrinology, Lübeck, Germany, <sup>3</sup>Charité, Institute of Experimental Endocrinology, Berlin, Germany

**P154 POLYMORPHISM SER49GLY  $\beta$ 1-ADRENORECEPTOR GENE AND FREQUENCY OF SUPRAVENTRICULAR ARRHYTHMIAS IN PATIENTS WITH THYREOTOXICOSIS**

*Grineva E<sup>1</sup>, Babenko A<sup>1</sup>, Hromova N<sup>2</sup>, Savitskaya D<sup>2</sup>, Kostareva A<sup>2</sup>*

<sup>1</sup>Almazov Federal Heart, Blood and Endocrinology Centre, Institute of Endocrinology, Saint-Petersburg, Russian Federation, <sup>2</sup>Almazov Federal Heart, Blood and Endocrinology Centre, Institute of Molecular Biology and Genetics, Saint-Petersburg, Russian Federation

**P155 SELENIUM SUPPLEMENTATION IN EUTHYROID PATIENTS WITH AUTOIMMUNE THYROIDITIS. A PILOT CONTROLLED STUDY**

*Guglielmi R<sup>1</sup>, Misisch I<sup>1</sup>, Graziano F<sup>1</sup>, Chianelli M<sup>1</sup>, Rinaldi R<sup>1</sup>, Petrucci L<sup>1</sup>, Papini E<sup>1</sup>*

<sup>1</sup>Regina Apostolorum Hospital, Endocrinology, Albano Laziale, Italy



**P156 INFLUENCES ON SKIN MICROCIRCULATION IN HYPERTHYROID PATIENTS WITH GRAVES' DISEASE**

*Bedernjak Bajuk N<sup>1</sup>, Zaletel K<sup>1</sup>, Gaberšček S<sup>1</sup>, Lenasi H<sup>2</sup>*

<sup>1</sup>University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, Slovenia, <sup>2</sup>University of Ljubljana, Institute of Physiology, Faculty of Medicine, Ljubljana, Slovenia

**P157 Poster has been withdrawn**

**P158 CONCOMITANT THYROID AND THYMIC EXERESIS IN SURGERY OF HYPERPARATHYROIDISM**

*Diaconescu MR<sup>1</sup>, Glod M<sup>1</sup>, Costea I<sup>1</sup>, Grigorovici M<sup>2</sup>, Diaconescu S<sup>3</sup>*

<sup>1</sup>'Gr T Popa' University of Medicine and Pharmacy, Surgery (IVth Surgical Clinic), Iasi, Romania, <sup>2</sup>University CF Hospital, Pathology, Iasi, Romania, <sup>3</sup>'Gr T Popa' University of Medicine and Pharmacy, Pediatrics (Vth Pediatric Clinic), Iasi, Romania

**PO18 Environmental Influences on Thyroid Function**

Chair: *Leonidas Duntas, Greece*

**P159 PREVIOUS PREGNANCY IS A MAJOR RISK FACTOR FOR AUTOIMMUNE HYPOTHYROIDISM IN YOUNG WOMEN – A POPULATION-BASED CASE-CONTROL STUDY**

*Carlé A<sup>1</sup>, Knudsen N<sup>2</sup>, Pedersen IB<sup>1</sup>, Ovesen L<sup>3</sup>, Rasmussen LB<sup>4</sup>, Jørgensen T<sup>5,6</sup>, Perrild H<sup>2</sup>, Laurberg P<sup>1,6</sup>, all from the DanThyr group (The Danish Investigation on Iodine Intake and Thyroid Diseases)*

<sup>1</sup>Aalborg University Hospital, Department of Endocrinology & Medicine, Aalborg, Denmark, <sup>2</sup>Bispebjerg Hospital, Endocrine Unit, Medical Clinic I, Bispebjerg, Copenhagen, Denmark, <sup>3</sup>Slagelse Hospital, Department of Internal Medicine, Slagelse, Denmark, <sup>4</sup>Technical University of Denmark, Ministry of Food, Agriculture and Fisheries, National Food Institute, Copenhagen, Denmark, <sup>5</sup>Copenhagen County, Research Centre for Disease Prevention and Health, Copenhagen, Denmark, <sup>6</sup>University of Aalborg, Faculty of Medicine, Aalborg, Denmark

**P160 INCREASED INCIDENCE OF THYROID DISORDERS IN ADULT POPULATION OF UKRAINE AFTER THE CHERNOBYL NPP ACCIDENT IS RELATED TO COMPLEX HORMONAL PATHWAYS**

*Kaminskyi OV<sup>1</sup>, Afanasyev DE<sup>1</sup>, Kiselova IO<sup>2</sup>, Tepla OV<sup>1</sup>*

<sup>1</sup>State Enterprise 'National Research Center for Radiation Medicine of AMS of Ukraine', Endocrinology, Kiev, Ukraine, <sup>2</sup>Kiev City Center of Clinical Endocrinology, Kiev, Ukraine

**P161 INFLUENCE OF EXCESSIVE IODINE INTAKE ON THYROID FUNCTION AND PREVALENCE OF THYROID ABNORMALITIES IN ADULT POPULATION IN SVERDLOVSK REGION OF RUSSIA**

*Kiyaev A<sup>1</sup>, Abdulhabirova F<sup>2</sup>, Platonova N<sup>2</sup>, Troshina E<sup>2</sup>, Gerasimov G<sup>3</sup>*

<sup>1</sup>Ural Medical Academy, Yekaterinburg, Russian Federation, <sup>2</sup>Federal Endocrinological Research Center, Moscow, Russian Federation, <sup>3</sup>ICCIDD, Moscow, Russian Federation

**P162 INTERACTION OF SERUM COPPER WITH THYROID HORMONES IN POSTMENOPAUSAL WOMEN**

*Rijntjes E<sup>1</sup>, Pietschmann N<sup>1</sup>, Gogakos A<sup>2</sup>, Hoeg A<sup>1</sup>, Reid D<sup>3</sup>, Gluer C<sup>4</sup>, Murphy E<sup>2</sup>, Felsenberg D<sup>5</sup>, Roux C<sup>6</sup>, Eastell R<sup>7</sup>, Williams G<sup>2</sup>, Schomburg L<sup>1</sup>*

<sup>1</sup>Charité-Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany, <sup>2</sup>Molecular Endocrinology Group, Imperial College London, Department of Medicine, London, United Kingdom, <sup>3</sup>School of Medicine and Dentistry, University of Aberdeen, Aberdeen, United Kingdom, <sup>4</sup>Klinik fuer Diagnostische Radiologie, Universitaetsklinikum SH, Kiel, Germany, <sup>5</sup>Center for Muscle and Bone Research, Charite-Universitaetsmedizin Berlin, Berlin, Germany, <sup>6</sup>Paris Descartes University, Department of Rheumatology, Paris, France, <sup>7</sup>Bone Biomedical Research Unit, University of Sheffield, Sheffield, United Kingdom

**P163 PITFALLS OF THYROID SCREENING IN CHILDREN AFTER NUCLEAR POWER PLANT ACCIDENT IN FUKUSHIMA, JAPAN**

*Kikuchi S<sup>1</sup>, Kikuchi T<sup>1</sup>, Kikuchi K<sup>1</sup>, Yokozawa T<sup>2</sup>*

<sup>1</sup>Kikuchi Pediatric Clinic, Koriyama, Japan, <sup>2</sup>Sakuragaoka General Hospital, Shimizu, Japan

**P164 THYROID FUNCTION IN HEALTHY SUBJECTS AND IN EUTHYROID PATIENTS WITH HASHIMOTO'S THYROIDITIS THREE YEARS BEFORE AND THREE YEARS AFTER INCREASE IN MANDATORY SALT IODIZATION**

*Gaberšček S<sup>1,2</sup>, Novak N<sup>2</sup>, Zaletel K<sup>1</sup>, Pirnat E<sup>1</sup>, Hojker S<sup>1,2</sup>*

<sup>1</sup>University Medical Centre Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

**P165 THYROID DISORDERS AND KIDNEY TRANSPLANTATION**

*Gouveia S<sup>1</sup>, Bastos M<sup>1</sup>, Baptista C<sup>1</sup>, Alves R<sup>2</sup>, Ribeiro C<sup>1</sup>, Vieira A<sup>1</sup>, Alves M<sup>1</sup>, Saraiva J<sup>1</sup>, Moreno C<sup>1</sup>, Mota A<sup>3</sup>, Carvalho M<sup>1</sup>, Carrilho F<sup>1</sup>*

<sup>1</sup>Coimbra's University Hospital, Endocrinology, Diabetes and Metabolism Department, Coimbra, Portugal, <sup>2</sup>Coimbra's University Hospital, Nephrology Department, Coimbra, Portugal, <sup>3</sup>Coimbra's University Hospital, Kidney Transplantation and Urology Department, Coimbra, Portugal

**P166 AUTOIMMUNE THYROIDITIS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON-BETA**  
*Nonchev B<sup>1</sup>, Trenova A<sup>2</sup>, Pavlov P<sup>3</sup>, Manova M<sup>2</sup>, Argatska A<sup>1</sup>, Ginova-Noncheva G<sup>4</sup>, Orbetzova M<sup>1</sup>*

<sup>1</sup>Medical University – Plovdiv, Endocrinology, Plovdiv, Bulgaria,

<sup>2</sup>Medical University – Plovdiv, Neurology, Plovdiv, Bulgaria,

<sup>3</sup>Medical University – Plovdiv, Central Clinical Laboratory, Plovdiv, Bulgaria, <sup>4</sup>Medical University – Plovdiv, Nephrology, Plovdiv, Bulgaria

## **PO19 Hyperthyroidism 2**

Chair: Chantal Daumerie, Belgium

**P167 YOUNGER AND LESS HYPERTHYROID PATIENTS WITH GRAVES' DISEASE ARE MORE SUCCESSFULLY TREATED WITH THE FIRST DOSE OF RADIOIODINE**

*Pirnat E<sup>1</sup>, Gabersček S<sup>1,2</sup>, Šfiligoj D<sup>1</sup>, Jaki Mekjavič P<sup>1,2</sup>, Zaletel K<sup>1</sup>, Hojker S<sup>1,2</sup>*

<sup>1</sup>University Medical Centre Ljubljana, Ljubljana, Slovenia,

<sup>2</sup>Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

**P168 INCREASING THE RADIOIODINE DOSE DOES NOT IMPROVE CURE RATES IN SEVERE GRAVES' HYPERTHYROIDISM: A CLINICAL TRIAL WITH HISTORICAL CONTROL**

*Dora JM<sup>1</sup>, Machado W<sup>1</sup>, Andrade VA<sup>1</sup>, Scheffel RS<sup>1</sup>, Maia AL<sup>1</sup>*

<sup>1</sup>Hospital de Clínicas de Porto Alegre, Thyroid Section, Porto Alegre, Brazil

**P169 EFFECTS OF THIAMAZOLE, METOPROLOL, AND VITAMIN E ON OXIDATIVE STRESS IN GRAVES' DISEASE PATIENTS**

*Petrulea MS<sup>1</sup>, Muresan A<sup>2</sup>, Duncea I<sup>1</sup>*

<sup>1</sup>Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Endocrinology, Cluj-Napoca, Romania, <sup>2</sup>Iuliu Hatieganu University of Medicine and Pharmacy Cluj-Napoca, Physiology, Cluj-Napoca, Romania

**P170 POTENTIAL CAPABILITIES OF MINIMALLY INVASIVE APPROACH IN THE SURGICAL TREATMENT OF GRAVES' DISEASE**

*Nenkov RN<sup>1</sup>, Radev RS<sup>1</sup>, Hristosov K<sup>2</sup>*

<sup>1</sup>Medical University of Varna, Thoracic Surgery, Varna, Bulgaria,

<sup>2</sup>Medical University of Varna, Clinic of Endocrinology, Varna, Bulgaria

**P171 SUSTAINED INCREASE OF SERUM ADIPONECTIN FOLLOWING ADMINISTRATION OF RADIOIODINE IN TREATMENT OF THYROTOXICOSIS**

*Lewandowski K<sup>1</sup>, Brona A<sup>2</sup>, Karbownik-Lewińska M<sup>3</sup>, Milewicz A<sup>2</sup>, Lewiński A<sup>1</sup>*

<sup>1</sup>The Medical University of Lodz, Department of Endocrinology and Metabolic Diseases, Lodz, Poland, <sup>2</sup>The Medical University of Wrocław, Department of Endocrinology, Diabetology and Isotope Therapy, Wrocław, Poland, <sup>3</sup>The Medical University of Lodz, Department of Oncological Endocrinology, Lodz, Poland

**P172 THE TIME-LAG BETWEEN THE ONSET OF SYMPTOMS AND THE APPEARANCE OF ABNORMAL LABORATORY FINDINGS IN THE PATIENTS WITH SUBACUTE THYROIDITIS**

*Tachibana T<sup>1</sup>, Orita Y<sup>2</sup>, Ogawara Y<sup>1</sup>, Matsuyama Y<sup>1</sup>, Abe I<sup>1</sup>, Nishizaki K<sup>2</sup>*

<sup>1</sup>Himeji Red Cross Hospital, Otolaryngology, Himeji City, Japan,

<sup>2</sup>Okayama University, Otolaryngology-Head & Neck Surgery, Okayama City, Japan

**P173 GRAVES' DISEASE TREATMENT WITH FIXED ACTIVITY OF RADIOIODINE**

*Sleptsov I<sup>1</sup>, Isheiskaya M<sup>1</sup>, Chinchuk I<sup>1</sup>, Chernikov R<sup>1</sup>, Makarin V<sup>1</sup>, Uspenskaya A<sup>1</sup>, Semenov A<sup>1</sup>, Novokshonov K<sup>1</sup>, Bubnov A<sup>1</sup>, Fedotov Y<sup>1</sup>*

<sup>1</sup>National Medical&Surgical Center, Endocrine Surgery, St. Petersburg, Russian Federation

**P174 A WEB-BASED CLINICAL TRIAL MANAGEMENT SYSTEM FOR A PRAGMATIC MULTI-CENTER TRIAL OF SELENIUM SUPPLEMENTATION VERSUS PLACEBO IN PATIENTS WITH GRAVES' DISEASE**

*Cramon P<sup>1</sup>, Bue Bjorner J<sup>2</sup>, Joop Bonnema S<sup>3</sup>, Feldt-Rasmussen U<sup>1</sup>, Groenvold M<sup>4</sup>, Hegedüs L<sup>3</sup>, Holbech Nielsen S<sup>5</sup>, Nauta Pedersen A<sup>6</sup>, Krogh Rasmussen Å<sup>1</sup>, Watt T<sup>1</sup>*

<sup>1</sup>Copenhagen University Hospital – Rigshospitalet, Department of Medical Endocrinology, Copenhagen, Denmark, <sup>2</sup>National Research Centre for the Working Environment, Copenhagen, Denmark, <sup>3</sup>Odense University Hospital, Department of Endocrinology and Metabolism, Odense, Denmark, <sup>4</sup>University of Copenhagen, Institute of Public Health Science, Copenhagen, Denmark, <sup>5</sup>Admazely, Copenhagen, Denmark, <sup>6</sup>Bitkompagniet, Copenhagen, Denmark

**P175 THYROTROPIN-PRODUCING PITUITARY TUMOURS – A CHALLENGE FOR ENDOCRINOLOGIST AND NEUROSURGEON**

*Kostecka-Matyja M<sup>1</sup>, Fedorowicz A<sup>1</sup>, Hubalewska-Dydejczyk A<sup>1</sup>*

<sup>1</sup>Chair and Department of Endocrinology, Jagiellonian University College of Medicine, Krakow, Poland

## PO20 Hypothyroidism

Chair: Marek Niedziela, Poland

### P176 CHANGES IN T3 THERAPY RELATED QOL IN HYPOTHYROID PATIENTS IS NO SIGNIFICANTLY ASSOCIATED TO POLYMORPHISM IN DIO2, DIO1, MCT10, PDE8B OR SLC 16A10 GENES

*Nygaard B<sup>1</sup>, Steffensen R<sup>2</sup>, Faber J<sup>1</sup>, Kvetney J<sup>3</sup>, Jarloev A<sup>4</sup>, Jensen EW<sup>1</sup>, Laurberg P<sup>5</sup>*

<sup>1</sup>Herlev Hospital, University of Copenhagen, Dept of Endocrinology O 106, Herlev, Denmark, <sup>2</sup>Aalborg University Hospital, Dept Clinical Immunology Aalborg, Aalborg, Denmark, <sup>3</sup>Naestved Hospital, University of Southern Denmark, Dept Endocrinology, Naestved, Denmark, <sup>4</sup>Frederiksberg Hospital, University of Copenhagen, Dept of Endocrinology, Frederiksberg, Denmark, <sup>5</sup>Aalborg University Hospital, Dept of Endocrinology, Aalborg, Denmark

### P177 PREVALENCE OF HYPOTHYROIDISM AMONG CHILDREN AND ADOLESCENTS WITH DIABETES MELLITUS

*Kiyaev A<sup>1</sup>, Alexandrov K<sup>1</sup>, Kovtun O<sup>1</sup>*

<sup>1</sup>Ural Medical Academy, Yekaterinburg, Russian Federation

### P178 THE INCIDENCE OF THYROID DYSFUNCTION IN EUROPE: A META-ANALYSIS

*Garmendia Madariaga A<sup>1</sup>, Guillén-Grima F<sup>2</sup>, Galofré JC<sup>1</sup>*

<sup>1</sup>Clínica Universidad de Navarra, Department of Endocrinology and Nutrition, Pamplona, Spain, <sup>2</sup>Clínica Universidad de Navarra, Department of Preventive Medicine, Pamplona, Spain

### P179 QUALITY OF LIFE AND EMOTIONAL STATUS OF PATIENTS WITH HYPOTHYROIDISM DUE TO RADIOIODINE TREATMENT OR SURGERY

*Dreval A<sup>1</sup>, Nechaeva O<sup>1</sup>, Mamedova T<sup>1</sup>, Shestakova T<sup>1</sup>, Chikh I<sup>1</sup>, Komerdous I<sup>1</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute, Moscow, Russian Federation

### P180 COMPARATIVE EFFECTIVENESS OF REPLACEMENT THERAPY WITH L-THYROXINE IN WOMEN WITH POSTOPERATIVE AND AUTOIMMUNE HYPOTHYROIDISM

*Fadeyev V<sup>1,2</sup>, Madiyarova M<sup>1</sup>, Morgunova T<sup>1</sup>*

<sup>1</sup>I.M. Sechenov First Moscow State Medical University, Endocrinology, Moscow, Russian Federation, <sup>2</sup>Federal Endocrinological Research Centre, Moscow, Russian Federation

### P181 QUALITY OF LIFE AND THE PSYCHOEMOTIONAL STATUS OF THE PATIENTS WHO HAVE RECEIVED RADICAL TREATMENT OF GRAVES' DISEASE

*Mamedova T<sup>1</sup>, Dreval A<sup>1</sup>, Nechaeva O<sup>1</sup>, Shestakova T<sup>1</sup>, Chikh I<sup>1</sup>, Komerdous I<sup>1</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute, Moscow, Russian Federation

### P182 THE QUALITY OF LIFE AND PSYCHO-EMOTIONAL STATUS OF PATIENTS WITH LOW AND UPPER-NORMAL LEVELS OF TSH

*Dreval A<sup>1</sup>, Nechaeva O<sup>1</sup>, Mamedova T<sup>1</sup>, Chikh I<sup>1</sup>, Shestakova T<sup>1</sup>, Komerdous I<sup>1</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute, Moscow, Russian Federation

### P183 SLEEP APNEA, MYOPATHY, HYPOTHYROIDISM: CASE REPORT

*Parhimovich RM<sup>1</sup>, Chikh ID<sup>1</sup>, Zgulov DA<sup>2</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute, Endocrinology, Moscow, Russian Federation, <sup>2</sup>Moscow Regional Research Clinical Institute, Reanimatology, Moscow, Russian Federation



Poster Exhibition Area

12.00–13.00

Poster Session 3

**PO21 Thyroid Cancer Diagnostics 3**

Chair: Kalliopi Pazaitou-Panayiotou, Greece

**P184 EARLY POSTOPERATIVE VOCAL FUNCTION EVALUATION AFTER THYROIDECTOMY USING THYROIDECTOMY RELATED VOICE QUESTIONNAIRE**

*Chun B-J<sup>1</sup>, Bae J-S<sup>2</sup>, Chae B-J<sup>2</sup>, Hwang Y-S<sup>1</sup>, Shim M-R<sup>1</sup>, Sun D-I<sup>1</sup>*

<sup>1</sup>College of Medicine, The Catholic University of Korea, Department of Otolaryngology-Head and Neck Surgery, Seoul, Republic of Korea, <sup>2</sup>College of Medicine, The Catholic University of Korea, Department of Surgery, Seoul, Republic of Korea

**P185 HIGH THYROGLOBULIN LEVELS AT REMNANT ABLATION MAY PREDICT RECURRENT/PERSISTENT DISEASE IN DIFFERENTIATED THYROID CANCER(DTC)**

*Aydoğan B<sup>1</sup>, Güllü S<sup>1</sup>, Can F<sup>1</sup>, Yüksel B<sup>1</sup>, Özkan E<sup>2</sup>, Emral R<sup>1</sup>, Küçük Ö<sup>2</sup>, Çorapçioğlu D<sup>1</sup>, Başkal N<sup>1</sup>, Uysal AR<sup>1</sup>, Erdogan MF<sup>1</sup>*

<sup>1</sup>Ankara University School of Medicine, Endocrinology and Metabolism Diseases, Ankara, Turkey, <sup>2</sup>Ankara University School of Medicine, Nuclear Medicine, Ankara, Turkey

**P186 REVIEW OF CLINICAL AND PATHOLOGICAL FEATURES OF THYROID CARCINOMA FROM FOLLICULAR ORIGIN IN CHILDREN FROM SOUTH PORTUGAL REGIONAL CANCER REGISTRY BETWEEN 1964 AND 2006**

*Silva-Vieira M<sup>1</sup>, Macedo D<sup>1</sup>, Simões-Pereira J<sup>1</sup>, Marques P<sup>1</sup>, Santos R<sup>1</sup>, Leite V<sup>1</sup>, Limbert E<sup>1</sup>*

<sup>1</sup>Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisboa, Portugal

**P187 OUR EXPERIENCES OF TRI-ANNUAL THYROID FINE-NEEDLE ASPIRATION BIOPSIES AT THE DOUBLE-HEAD CENTER IN AN ENDEMIC AREA: THE RETROSPECTIVE DESCRIPTIVE CYTOPATHOLOGICAL ANALYSIS OF 1196 CASES**

*Findik Guvendi G<sup>1</sup>, Sengul D<sup>2</sup>, Sengul I<sup>3</sup>, Oksuz H<sup>1</sup>, Guvendi B<sup>4</sup>, Akgedik S<sup>1</sup>, Maras Ozdemir Z<sup>5</sup>, Erverdi B<sup>5</sup>, Ozhan C<sup>5</sup>, Gorgen F<sup>5</sup>, Duzcu S<sup>5</sup>, Yilmaz ZC<sup>5</sup>*

<sup>1</sup>The Ministry of Health, Prof. Dr. A. Ilhan Ozdemir State Hospital, Pathology, Giresun, Turkey, <sup>2</sup>The Health Application and Research Center, Giresun University Faculty of Medicine, Pathology, Giresun, Turkey, <sup>3</sup>The Health Application and Research Center, Giresun University Faculty of Medicine, General Surgery, Giresun, Turkey, <sup>4</sup>The Ministry of Health, Prof. Dr. A. Ilhan Ozdemir State Hospital, General Surgery, Giresun, Turkey, <sup>5</sup>The Ministry of Health, Prof. Dr. A. Ilhan Ozdemir State Hospital, Radiology, Giresun, Turkey

**P188 PREDICTION OF MALIGNANCY IN PATIENTS WITH SUSPICIOUS THYROID NODULE IN THE BACKGROUND OF HETEROGENEOUS PARENCHYMA**

*Nam SY<sup>1,2</sup>, Shin JH<sup>1</sup>, Han B-K<sup>1</sup>, Ko EY<sup>1</sup>, Ko ES<sup>1</sup>, Hahn SY<sup>1</sup>*

<sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Radiology, Seoul, Korea, Republic of, <sup>2</sup>Gil Hospital, Gachon University of Medicine and Science, Radiology, Incheon, Republic of Korea

**P189 ECHOGRAPHIC, CYTOLOGICAL AND HISTOLOGICAL CHARACTERISTICS OF THYROID FOLLICULAR TUMOR**

*Gasparyan E<sup>1</sup>, Goroshko O<sup>2</sup>, Vorobyov S<sup>1</sup>, Zaitseva I<sup>1</sup>*

<sup>1</sup>Medical Centre 'Professor', Endocrinology, Saint Petersburg, Russian Federation, <sup>2</sup>Medical Centre 'Professor', Ultrasound Diagnostic, Saint Petersburg, Russian Federation

**P190 RETROSPECTIVE VALUE OF THE ECHOGRAPHIC PICTURE OF THYROID PAPILLARY CARCINOMA**

*Zaitseva I<sup>1</sup>, Gasparyan E<sup>1</sup>, Goroshko O<sup>2</sup>, Vorobyov S<sup>1</sup>*

<sup>1</sup>Medical Centre 'Professor', Endocrinology, Saint Petersburg, Russian Federation, <sup>2</sup>Medical Centre 'Professor', Ultrasound Diagnostic, Saint Petersburg, Russian Federation

**P191 PAPILLARY THYROID CARCINOMA PRESENTING SPONGIFORM OR PREDOMINANTLY CYSTIC NODULE**

*Kim SJ<sup>1</sup>, Park SH<sup>1</sup>, Lee SJ<sup>1</sup>, Chung B<sup>1</sup>*

<sup>1</sup>Chung-Ang University Hospital, Seoul, Republic of Korea

**P192 THYROID PAPILLARY CARCINOMA: ECHOGRAPHIC PICTURE**

*Goroshko O<sup>1</sup>, Gasparyan E<sup>2</sup>, Vorobyov S<sup>2</sup>*

<sup>1</sup>Medical Centre 'Professor', Ultrasound Diagnostics, Saint Petersburg, Russian Federation, <sup>2</sup>Medical Academy of Postgraduate Studies, Endocrinology, Saint Petersburg, Russian Federation

**PO22 Thyroid Cancer Diagnostics 4**

Chair: *Valeriano Leite*, Portugal

**P193 THE IMPORTANT ROLE OF PREOPERATIVE ULTRASOUND AND CT FINDINGS OF THE PRIMARY TUMOR IN PREDICTING THE CERVICAL LYMPH NODE METASTASES OF PAPILLARY THYROID CARCINOMAS**

*Cho J-G<sup>1</sup>, Park M-W<sup>1</sup>, Baek S-K<sup>1</sup>, Kwon S-Y<sup>1</sup>, Jung K-Y<sup>1</sup>, Woo J-S<sup>1</sup>*

<sup>1</sup>Korea University Medical College, Otorhinolaryngology-Head and Neck Surgery, Seoul, Republic of Korea

**P194 PREOPERATIVE ULTRASOUND, FINE NEEDLE ASPIRATION CYTOLOGY AND TG IN ASPIRATES IN THE ASSESSMENT OF LATERAL LYMPH NODES IN PATIENTS WITH PAPILLARY THYROID CARCINOMA**

*Sisko Markos I<sup>1</sup>, Franceschi M<sup>1</sup>, Jukic T<sup>1</sup>, Stanicic J<sup>1</sup>, Petranovic Ovcariček P<sup>1</sup>, Granic R<sup>1</sup>, Punda M<sup>1</sup>, Lukinac L<sup>1</sup>, Kusic Z<sup>1</sup>*

<sup>1</sup>University Hospital Center Sestre Milosrdnice, Department of Nuclear Medicine and Oncology, Zagreb, Croatia

**P195 DIAGNOSIS OF THYROID NODULES BY MEANS OF FINE-NEEDLE ASPIRATION CYTOLOGY, RESEARCH RESULTS**

*Dundua T<sup>1</sup>, Javashvili L<sup>1</sup>, Kaloiani T<sup>2</sup>, Kherkheulidze V<sup>1</sup>*

<sup>1</sup>Clinic Cortex, Tbilisi, Georgia, <sup>2</sup>National Centre of Oncology, Tbilisi, Georgia

**P196 PREDICTORS OF MALIGNANCY IN THYROID NODULES WITH CYTOLOGICAL DIAGNOSIS OF FOLLICULAR NEOPLASM**

*Lim JA<sup>1</sup>, Lee SH<sup>2</sup>, Cho SY<sup>3</sup>, Lee TH<sup>4</sup>, Ku YH<sup>2</sup>, Kim HI<sup>2</sup>, Kim MJ<sup>2</sup>*

<sup>1</sup>Eulji University School of Medicine, Department of Internal Medicine, Seoul, Republic of Korea, <sup>2</sup>Korea Cancer Center Hospital, Department of Internal Medicine, Seoul, Republic of Korea, <sup>3</sup>Korea Cancer Center Hospital, Department of Pathology, Seoul, Republic of Korea, <sup>4</sup>Korea Cancer Center Hospital, Department of Radiology, Seoul, Republic of Korea

**P197 THYROID CANCER IN GRAVES' DISEASE PATIENTS**

*Chinchuk I<sup>1</sup>, Sleptsov I<sup>2</sup>, Isheiskaya M<sup>1</sup>, Chernikov R<sup>1</sup>, Semenov A<sup>1</sup>, Makarin V<sup>1</sup>, Novokshonov K<sup>1</sup>, Uspenskaya A<sup>1</sup>, Bubnov A<sup>1</sup>, Fedotov Y<sup>1</sup>, Karelina Y<sup>1</sup>*

<sup>1</sup>National Medical & Surgical Center, Endocrine Surgery, St. Petersburg, Russian Federation, <sup>2</sup>North-Western Regional Medical Center of Roszdrav, Endocrine Surgery, St. Petersburg, Russian Federation

**P198 FALSE POSITIVE IODINE-131 SCAN IN A PATIENT WITH DIFFERENTIATED THYROID CARCINOMA AND CHRONIC INFLAMMATORY LUNGS DISEASE**

*Oliveira MJ<sup>1</sup>, Babosa L<sup>2</sup>, Povoa A<sup>2</sup>, Soares C<sup>2</sup>, Oliveira JM<sup>3</sup>*

<sup>1</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, EPE, Endocrinology, Porto, Portugal, <sup>2</sup>Centro Hospitalar de Vila Nova de Gaia / Espinho, Surgery, Vila Nova Gaia, Portugal, <sup>3</sup>HPP-MN, Nuclear Medicine, Porto, Portugal

**P199 DIAGNOSIS OF PAPILLARY CANCER BY MEASUREMENT OF THYROGLOBULIN IN FINE NEEDLE ASPIRATES: CLINICAL CASES**

*Ribeiro C<sup>1</sup>, Paiva S<sup>1</sup>, Gouveia S<sup>1</sup>, Melo M<sup>1</sup>, Martins MJ<sup>2</sup>, Fernandes G<sup>2</sup>, Leitão F<sup>3</sup>, Carrilho F<sup>1</sup>*

<sup>1</sup>University Hospital of Coimbra, Endocrinology, Coimbra, Portugal, <sup>2</sup>University Hospital of Coimbra, Pathology, Coimbra, Portugal, <sup>3</sup>University Hospital of Coimbra, Clinical Pathology, Coimbra, Portugal

**P200 ANAPLASTIC CARCINOMA AND TOXIC MULTINODULAR GOITER, AN UNUSUAL PRESENTATION**

*Marcelino M<sup>1</sup>, Marques P<sup>2</sup>, Lopes L<sup>1</sup>, Leite V<sup>2</sup>, de Castro JJ<sup>1</sup>*

<sup>1</sup>Armed Forces University Hospital, Endocrinology, Lisbon, Portugal, <sup>2</sup>Portuguese Cancer Institute, Endocrinology, Lisbon, Portugal

**P201 REVIEW OF PAPILLARY THYROID CARCINOMA VARIANTS: IMAGING, PATHOLOGICAL AND CLINICAL CORRELATION**

*Nam SY<sup>1,2</sup>, Shin JH<sup>1</sup>, Lee JH<sup>1</sup>*

<sup>1</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Radiology, Seoul, Korea, Republic of, <sup>2</sup>Gil Hospital, Gachon University of Medicine and Science, Radiology, Incheon, Republic of Korea

**PO23 Thyroid Cancer Therapeutics 3**

Chair: *Françoise Borson-Chazot*, France

**P202 BRAF<sup>V600E</sup> MUTATION IN PATIENTS WITH PAPILLARY THYROID CARCINOMA CONCURRENT WITH HASHIMOTO THYROIDITIS**

*Kwak HY<sup>1</sup>, Choi H<sup>1</sup>, Chae BJ<sup>1</sup>, Song BJ<sup>1</sup>, Jung SS<sup>1</sup>, Bae JS<sup>1</sup>*

<sup>1</sup>Catholic University of Korea, College of Medicine, Department of Surgery, Seoul, Republic of Korea

**P203 LONG TERM UTILITY OF INJECTION LARYNGOPLASTY IN THE MANAGEMENT OF PERMANENT POST-THYROIDECTOMY VOCAL FOLD PARALYSIS – PROSPECTIVE STUDY**

*Park KN<sup>1</sup>, Park JH<sup>2</sup>, Kim JW<sup>3</sup>, Lee SW<sup>1</sup>*

<sup>1</sup>Soonchunhyang University Hospital, Otorhinolaryngology and Head and Neck Surgery, Bucheon, Republic of Korea, <sup>2</sup>Soonchunhyang University Hospital, Otorhinolaryngology and Head and Neck Surgery, Cheon An, Republic of Korea, <sup>3</sup>Soonchunhyang University Hospital, Otorhinolaryngology and Head and Neck Surgery, Seoul, Republic of Korea

**P204 SIALENDOSCOPY FOR DYSFUNCTIONS OF SALIVARY GLANDS AFTER RADIOACTIVE IODINE THERAPY**

*Choi J-S<sup>1</sup>, Lim J-Y<sup>1</sup>, Kim Y-M<sup>1</sup>*

<sup>1</sup>Inha University School of Medicine, Otorhinolaryngology-Head and Neck Surgery, Incheon, Republic of Korea

**P205 LEARNING CURVE FOR GASLESS ENDOSCOPIC THYROIDECTOMY USING THE TRANS-AXILLARY APPROACH: CUSUM ANALYSIS OF A SINGLE SURGEON'S EXPERIENCE**

*Kwak HY<sup>1</sup>, Choi H<sup>1</sup>, Chae BJ<sup>1</sup>, Song BJ<sup>1</sup>, Jung SS<sup>1</sup>, Bae JS<sup>1</sup>*

<sup>1</sup>Catholic University of Korea, College of Medicine, Department of Surgery, Seoul, Republic of Korea

**P206 COMPARATIVE ANALYSIS OF THE CENTRAL NODE METASTASIS BETWEEN WITH OR WITHOUT CHRONIC LYMPHOCYTIC THYROIDITIS IN PAPILLARY THYROID CANCER**

*Son G-T<sup>1</sup>, Lee J-H<sup>1</sup>, Choi J-E<sup>1</sup>, Kang S-H<sup>1</sup>, Lee S-J<sup>1</sup>*

<sup>1</sup>Yeungnam University College of Medicine, General Surgery, Daegu, Republic of Korea

**P207 PROSPECTIVE STUDY ON SUTURELESS AND DRAINLESS OPEN THYROIDECTOMY USING ULTRASONIC COAGULATOR: PRELIMINARY STUDY**

*Jeon YS<sup>1</sup>*

<sup>1</sup>Goo Hospital, Endocrine Surgery, Dae-Gu, Republic of Korea

**P208 ROBOTIC THYROID SURGERY USING BILATERAL AXILLO-BREAST APPROACH: A SINGLE SURGEON'S EXPERIENCE AND OUTCOME WITH THE FIRST 200 CASES**

*Kim WW<sup>1</sup>, Kang JG<sup>1</sup>, Choi HH<sup>1</sup>, Hwang SO<sup>1</sup>, Jung JH<sup>1</sup>, Park HY<sup>1</sup>*

<sup>1</sup>Kyungpook National University, Daegu, Republic of Korea

**P209 COMPARISON STUDY BETWEEN HARMONIC FOCUS® AND LIGASURE® IN OPEN THYROIDECTOMY: A PROSPECTIVE, RANDOMIZED STUDY**

*Kim WW<sup>1</sup>, Kang JG<sup>1</sup>, Choi HH<sup>1</sup>, Hwang SO<sup>1</sup>, Jung JH<sup>1</sup>, Park HY<sup>1</sup>*

<sup>1</sup>Kyungpook National University, Daegu, Republic of Korea

**P210 SURGICAL SURVIVAL FIGURES FOR THYROID CANCER IN THE NORTHERN AND WEST YORKSHIRE REGIONS OF THE UNITED KINGDOM: IMPROVEMENTS AFTER TEN YEARS?**

*Flatley MJ<sup>1</sup>, Gerrard G<sup>1</sup>, Lawton S<sup>2</sup>, Aravani A<sup>2</sup>*

<sup>1</sup>St James's University Hospital, Institute of Oncology, Leeds, United Kingdom, <sup>2</sup>Public Health England (NYCRIS), St James's Institute of Oncology, Leeds, United Kingdom

**PO24 Thyroid Cancer Therapeutics 4**

Chair: *Lionel Groussin, France*

**P211 TRANSORAL ENDOSCOPIC THYROIDECTOMY VIA THE TRI-VESTIBULAR ROUTE: RESULTS OF A PRECLINICAL CADAVER FEASIBILITY STUDY**

*Park J-O<sup>1</sup>, Cho J-H<sup>1</sup>, Chun B-J<sup>1</sup>, Sun D-I<sup>1</sup>*

<sup>1</sup>The Catholic University of Korea, Seoul, Republic of Korea

**P212 SHORTTERM CHANGES OF ELECTROLYTES AND PARATHYROID HORMONE IN PERMANENT HYPOCALCEMIA AFTER TOTAL THYROIDECTOMY IN PAPILLARY THYROID CANCER**

*Lee K-H<sup>1</sup>, Cho J-H<sup>1</sup>*

<sup>1</sup>St. Vincent's Hospital, The Catholic University of Korea, Otolaryngology Head & Neck Surgery, Suwon, Republic of Korea

**P213 EXPERIENCE WITH THE USE OF RECOMBINANT HUMAN THYROTROPIN (RHTSH) IN FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA AND THERAPY OF METASTATIC DISEASE**

*Mackova M<sup>1</sup>, Vlcek P<sup>1</sup>*

<sup>1</sup>Motol University Hospital, Department of Nuclear Medicine and Endocrinology, Praha, Czech Republic

**P214 HEMITHYROIDECTOMY IN PAPILLARY THYROID MICROCARCINOMA WITH THYROIDITIS INCREASES THE RISK OF POSTOPERATIVE HYPOTHYROIDISM**

*Kim YS<sup>1</sup>*

<sup>1</sup>Ulsan University Hospital, Surgery, Ulsan, Republic of Korea

**P215 UTILITY OF RECOMBINANT HUMAN TSH TO FACILITATE RADIO-IODINE UPTAKE BY LUNG METASTASES WHEN PITUITARY FAILS TO PRODUCE ENDOGENOUS TSH**

*Dillikar G<sup>1</sup>, Kumaresan K<sup>1</sup>, Kavitha N<sup>2</sup>*

<sup>1</sup>KK Nuclear Scans, Hyderabad, India, <sup>2</sup>Nizam's Institute of Medical Sciences, Nuclear Medicine, Hyderabad, India



**P216 VISUAL AND QUANTITATIVE EVALUATION OF POSTOPERATIVE RADIOIODINE ABLATION WITH I-131 WITH 1850MBQ IN PATIENTS WITH DIFFERENTIATED THYROID CANCER**

*Kawabe J<sup>1</sup>, Higashiyama S<sup>1</sup>, Kotani K<sup>1</sup>, Yoshida A<sup>1</sup>, Onoda N<sup>2</sup>, Shiomi S<sup>1</sup>*

<sup>1</sup>Graduate School of Medicine, Osaka City University, Department of Nuclear Medicine, Osaka City, Japan,

<sup>2</sup>Graduate School of Medicine, Osaka City University, Department of Surgical Oncology, Osaka City, Japan

**P217 THE CLINICAL FEATURES IN PATIENTS WITH POORLY DIFFERENTIATED THYROID CARCINOMA**

*Kim YS<sup>1</sup>*

<sup>1</sup>Ulsan University Hospital, Surgery, Ulsan, Republic of Korea

**P218 THYROID CANCER RATE IN PATIENTS WHO UNDERWENT TOTAL THYROIDECTOMY WITH THE DIAGNOSIS OF TNG**

*Tam AA<sup>1</sup>, Kaya C<sup>1</sup>, Kiyak G<sup>2</sup>, Ersoy PE<sup>2</sup>, Yalçın S<sup>3</sup>, Yıldırım Poyraz N<sup>4</sup>, Kılıçyazgan A<sup>5</sup>, Guler G<sup>5</sup>, Ersoy R<sup>6</sup>, Cakır B<sup>6</sup>*

<sup>1</sup>Ataturk Education and Research Hospital, Department of Endocrinology and Metabolism, Ankara, Turkey, <sup>2</sup>Ataturk Education and Research Hospital, Department of General Surgery, Ankara, Turkey, <sup>3</sup>Yıldırım Beyazıt University Faculty of Medicine, Department of General Surgery, Ankara, Turkey, <sup>4</sup>Ataturk Education and Research Hospital, Department of Nuclear Medicine, Ankara, Turkey, <sup>5</sup>Yıldırım Beyazıt University Faculty of Medicine, Department of Pathology, Ankara, Turkey, <sup>6</sup>Yıldırım Beyazıt University Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey

**PO25 Case Reports 3**

Chair: *Valentin Fadayevev*, Russia

**P219 COMBINED THYROID DYSFUNCTION IN PATIENTS WITH ACROMEGALY**

*Ilovaiskaja I<sup>1</sup>, Dreval A<sup>1</sup>, Shestakova T<sup>1</sup>*

<sup>1</sup>Moscow Regional Research Clinical Institute n.M.F Vladimirskii, Endocrinology, Moscow, Russian Federation

**P220 Poster has been withdrawn**

**P221 MASSIVE PERICARDIAL EFFUSION: MYXEDEMA OR SOMETHING MORE?**

*Trifanescu RA<sup>1,2</sup>, Zaharia D<sup>3,4</sup>, Dobrescu M<sup>2</sup>, Coman I<sup>5,6</sup>, Bogdan MA<sup>3,4</sup>, Poiana C<sup>1,2</sup>*

<sup>1</sup>Carol Davila University of Medicine and Pharmacy, Endocrinology Dept., Bucharest, Romania, <sup>2</sup>C.I. Parhon National Institute of Endocrinology, Bucharest, Romania, <sup>3</sup>Carol Davila University of Medicine and Pharmacy, Pneumology Dept., Bucharest, Romania, <sup>4</sup>Marius Nasta Institute of Pneumology, Bucharest, Romania, <sup>5</sup>Carol Davila University of Medicine and Pharmacy, Cardiology Dept., Bucharest, Romania, <sup>6</sup>C.C. Iliescu Institute of Cardiology, Bucharest, Romania

**P222 ALOPECIA AREATA AFTER RADIOIODINE TREATMENT OF BONE METASTASES FROM THYROID FOLLICULAR CARCINOMAS**

*Begolli AG<sup>1</sup>, Gerqari I<sup>2</sup>, Rizvanolli N<sup>3</sup>, Miftari R<sup>4</sup>, Ferizi M<sup>1</sup>, Halimi S<sup>5</sup>, Daka A<sup>1</sup>*

<sup>1</sup>University Clinical Center of Kosovo, Dermatovenerologic Clinic, Pristina, Albania, <sup>2</sup>University Clinical Center of Kosovo, Nuclear Medicine Service & Diagnostika plus, Pristina, Albania, <sup>3</sup>Diagnostika plus, Nuclear Medicine Service & Diagnostika plus, Pristina, Albania, <sup>4</sup>University Clinical Center of Kosovo, Nuclear Medicine Service, Pristina, Albania, <sup>5</sup>University Clinical Center of Kosovo, Dermatovenerologic Clinic, Pristina, Albania

**P223 THYROTROPIN SECRETING ADENOMA AND THYROID HORMONE RESISTANCE: TWO CASES**

*Algün E<sup>1</sup>, Anaforoglu I<sup>1</sup>, Kose M<sup>1</sup>, Incecayır O<sup>1</sup>*

<sup>1</sup>Trabzon Kanuni Education and Research Hospital, Endocrinology and Metabolism, Trabzon, Turkey

**P224 FAMILIAL PAPILLARY THYROID CARCINOMA: AGGRESSIVE TREATMENT OR CAREFUL SURVEILLANCE?**

*Siddiqi AI<sup>1</sup>, Chung TT<sup>1</sup>*

<sup>1</sup>University College London Hospitals, Diabetes and Endocrinology, London, United Kingdom

**P225 VANISHING BRAIN METASTASES FOLLOWING RADIO-IODINE THERAPY IN I-131 SCAN AS WELL AS IN MAGNETIC RESONANCE IMAGING – A RARE OCCURRENCE**

*Zakir Ali A<sup>1</sup>, Kumaresan K<sup>2</sup>*

<sup>1</sup>Basavatarakam Indo-American Cancer Institute, Nuclear Medicine, Hyderabad, India, <sup>2</sup>KK Nuclear Scans, Hyderabad, India

**P226 AUTOIMMUNE HYPO TO HYPERTHYROIDISM, A RARE EVOLUTION**

*Marcelino M<sup>1</sup>, Silva J<sup>1</sup>, Passos D<sup>1</sup>, de Castro JJ<sup>1</sup>*

<sup>1</sup>Armed Forces University Hospital, Endocrinology, Lisbon, Portugal

**P227 CLINICAL CASE – RADIOTHERAPY IN ENDOCRINE OPHTHALMOPATHY**

*Luchina E<sup>1</sup>, Lukashova M<sup>1</sup>, Meleshkevich T<sup>1</sup>*

<sup>1</sup>Central Clinical Hospital #2 n.a. N.A. Semashko Public Corporation 'Russian Railways', Endocrinology, Moscow, Russian Federation

## PO26 Imaging

Chair: Markus Luster, Germany

### P228 IDO1 (INDOLEAMINE-2,3-DIOXYGENASE 1) INHIBITION DECREASES PROLIFERATION OF FOLLICULAR THYROID CARCINOMA-DERIVED FTC133 CELLS: IN VITRO AND IN VIVO DATA

Moretti S<sup>1</sup>, Menicali E<sup>1</sup>, Voce P<sup>1</sup>, Puxeddu E<sup>1</sup>

<sup>1</sup>University of Perugia, Internal Medicine, Perugia, Italy

### P229 FDG POSITIVE, IODINE NEGATIVE PATIENTS ARE STRONGLY ASSOCIATED WITH A POSITIVE TG DOUBLING TIME, HOWEVER, THE 'FLIP-FLOP' PHENOMENON IN DIFFERENTIATED THYROID CARCINOMA IS OFTEN INCOMPLETE

Kelders A<sup>1</sup>, Kennes L<sup>2</sup>, Krohn T<sup>1</sup>, Behrendt F<sup>1</sup>, Mottaghy F<sup>1</sup>, Verburg FA<sup>1</sup>

<sup>1</sup>University Hospital Aachen, Nuclear Medicine, Aachen, Germany, <sup>2</sup>University Hospital Aachen, Medical Statistic, Aachen, Germany

### P230 ACCURACY AND OBSERVER VARIATION OF THE ASSESSMENT OF THYROID RADIOIODINE UPTAKE AND GOITER SIZE BY VISUAL INTERPRETATION OF THYROID SCINTIGRAMS

Soelberg KK<sup>1</sup>, Grupe P<sup>2</sup>, Jørgensen HB<sup>3</sup>, Jørgensen PH<sup>4</sup>, Fast S<sup>1</sup>, Nielsen VE<sup>1</sup>, Hegedüs L<sup>1</sup>, Bonnema SJ<sup>1</sup>

<sup>1</sup>Odense University Hospital, Endocrinology, Odense, Denmark, <sup>2</sup>Odense University Hospital, Nuclear Medicine, Odense, Denmark, <sup>3</sup>Sygehus Lillebælt, Nuclear Medicine, Vejle, Denmark, <sup>4</sup>Odense University Hospital, Cardiology, Odense, Denmark

### P231 METASTASES TO THE THYROID GLAND; US CLASSIFICATION ACCORDING TO ORIGINAL MALIGNANCIES

Lee KH<sup>1</sup>, Shin JH<sup>2</sup>, Han B-K<sup>2</sup>, Ko EY<sup>2</sup>

<sup>1</sup>Inje University Haeundae Paik Hospital, Radiology, Busan, Republic of Korea, <sup>2</sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Radiology, Seoul, Republic of Korea

### P232 Poster has been withdrawn

### P233 PRINCIPLES OF PROPER APPLICATION OF ULTRASOUND (US) AND A FINE-NEEDLE ASPIRATION BIOPSY (FNAB) IN PATIENTS WITH NODULES/US FOCAL LESIONS OF THE THYROID GLAND

Lewiński A<sup>1,2</sup>, Adamczewski Z<sup>1,2</sup>

<sup>1</sup>The Medical University of Lodz, Department of Endocrinology and Metabolic Diseases, Lodz, Poland, <sup>2</sup>Polish Mother's Memorial Hospital – Research Institute, Lodz, Poland

### P234 GRAY SCALE ULTRASONOGRAPHY IN DETECTING NEOPLASTIC THYROID NODULES. IS IT USEFUL?

Aslan A<sup>1,2</sup>, Sancak S<sup>3,4</sup>, Aslan M<sup>2,5</sup>, Buğdaycı O<sup>6</sup>, Güllüoğlu B<sup>7</sup>, Ahiskalı RA<sup>8</sup>, Akalin NS<sup>4</sup>, Arıbal ME<sup>2</sup>

<sup>1</sup>Şevket Yılmaz Educational Hospital, Department of Radiology, Bursa, Turkey, <sup>2</sup>Marmara Medical School, Department of Radiology, Istanbul, Turkey, <sup>3</sup>Fatih Sultan Mehmet Educational Hospital, Section of Endocrinology and Metabolism, Istanbul, Turkey, <sup>4</sup>Marmara Medical School, Department of Endocrinology and Metabolism, Istanbul, Turkey, <sup>5</sup>Zübeyde Hanım Doğumevi, Department of Radiology, Bursa, Turkey, <sup>6</sup>İnebolu State Hospital, Department of Radiology, Kastamonu, Turkey, <sup>7</sup>Marmara Medical School, General Surgery Department, Istanbul, Turkey, <sup>8</sup>Marmara Medical School, Department of Pathology, Istanbul, Turkey

### P235 <sup>131</sup>I SPECT/CT FALSE POSITIVE IMAGES IN DIFFERENTIATED THYROID CANCER, OR HOW TO DISTINGUISH BETWEEN PHYSIOLOGICAL AND PATHOLOGICAL UPTAKE? ON BEHALF OF THE FRENCH TUTHYREF (TUMEURS DE LA THYROÏDE REFRACTAIRES) NETWORK

Méas T<sup>1</sup>, Godbert Y<sup>2</sup>, Kelly A<sup>3</sup>, Schvartz C<sup>4</sup>, Ciappuccini R<sup>5</sup>, Faugeron I<sup>1</sup>, Toubert M-E<sup>1</sup>

<sup>1</sup>Saint-Louis Hospital, APHP, Nuclear Medicine, Paris, France, <sup>2</sup>Institut Bergonie, Nuclear Medicine, Bordeaux, France, <sup>3</sup>Centre Jean Perrin, Nuclear Medicine, Clermont-Ferrand, France, <sup>4</sup>Centre Jean Godinot, Nuclear Medicine, Reims, France, <sup>5</sup>Centre François Baclesse, Nuclear Medicine, Caen, France

### P236 ULTRASOUND RISK STRATIFICATION OF THYROID FOLLICULAR NEOPLASMS

Russ G<sup>1,2</sup>, Royer B<sup>2,3</sup>, Bigorgne C<sup>2</sup>, Rouxel A<sup>1,2</sup>, Bienvenu-Perrard M<sup>2,4</sup>, Leenhardt L<sup>1,5</sup>

<sup>1</sup>Pitié-Salpêtrière Hospital, Nuclear Medicine, Paris, France, <sup>2</sup>Centre de Pathologie et d'Imagerie, Paris, France, <sup>3</sup>Cochin Hospital, Pathology, Paris, France, <sup>4</sup>Cochin Hospital, Nuclear Medicine, Paris, France, <sup>5</sup>Pierre et Marie Curie University, Paris, France

### P237 NON-DIAGNOSTIC RESULTS OF FINE NEEDLE ASPIRATION CYTOLOGY OF THYROID NODULES

Jacobs S<sup>1</sup>, van Nederveen F<sup>2</sup>, Burger P<sup>2</sup>, Peeters R<sup>2</sup>, Vernooij M<sup>2</sup>, van der Lugt A<sup>2</sup>

<sup>1</sup>Erasmus Medical Center, Radiology, Rotterdam, Netherlands, <sup>2</sup>Erasmus Medical Center, Rotterdam, Netherlands

## P027 Thyroid Hormone Metabolism and Action

Chair: Maria Jesus Obregon, Spain

### P238 HISTOPATHOLOGICAL ANALYSIS OF MCT8-DEFICIENT HUMAN BRAINS

*Lopez-Espindola D<sup>1,2</sup>, Morales-Bastos C<sup>3</sup>, Refetoff S<sup>4</sup>, Lev D<sup>5</sup>, Sugo E<sup>6</sup>, Bernal J<sup>1,7</sup>, Guadaño-Ferraz A<sup>1</sup>*

<sup>1</sup>Instituto de Investigaciones Biomédicas (CSIC-UAM), Madrid, Spain, <sup>2</sup>Universidad de Valparaíso, Valparaíso, Chile, <sup>3</sup>La Paz University Hospital, Madrid, Spain, <sup>4</sup>University of Chicago, Chicago, United States, <sup>5</sup>Wolfson Medical Center, Holon, Israel, <sup>6</sup>Prince of Wales Hospital, Randwick, Australia, <sup>7</sup>CIBERER, Madrid, Spain

### P239 ALTERED THYROID HORMONE METABOLISM IN THE PREMATURELY AGING KLOTHO MUTANT MICE

*Doycheva D<sup>1</sup>, Laubscher U<sup>1</sup>, Darras VM<sup>2</sup>, Boelen A<sup>3</sup>, Zevenbergen C<sup>4</sup>, Visser WE<sup>4</sup>, Visser TJ<sup>4</sup>, Kuro-o M<sup>5</sup>, Kaether C<sup>1</sup>, Heuer H<sup>1</sup>*

<sup>1</sup>Leibniz Institute for Age Research/Fritz Lipmann Institute, Jena, Germany, <sup>2</sup>KU Leuven, Leuven, Belgium, <sup>3</sup>Academical Medical Centre, Amsterdam, Netherlands, <sup>4</sup>Erasmus Medical Center, Rotterdam, Netherlands, <sup>5</sup>The University of Texas Southwestern Medical Center, Dallas, United States

### P240 TSH EFFECTS ON THERMOGENESIS IN RAT BROWN ADIPOCYTES

*Martinez-de-Mena R<sup>1</sup>, Anedda A<sup>2</sup>, Cadenas S<sup>2</sup>, Obregon M-J<sup>1</sup>*

<sup>1</sup>CSIC, Fisiopatología Endocrina, Madrid, Spain, <sup>2</sup>Hospital de la Princesa, Madrid, Spain

### P241 SIMULTANEOUS ANALYSIS OF ALL NINE POSSIBLE IODOTHYRONINES BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY

*Köhrle J<sup>1</sup>, Martin C<sup>2</sup>, Renko K<sup>1</sup>, Hoefig CS<sup>1,3</sup>*

<sup>1</sup>Charité-Universitätsmedizin Berlin, Institut für experimentelle Endokrinologie, Berlin, Germany, <sup>2</sup>Waters GmbH, Eschborn, Germany, <sup>3</sup>Karolinska Institute, Department of Cell & Molecular Biology, Stockholm, Sweden

### P242 DIVERSE ASPECTS OF 3-T1AM INDUCED SIGNALING AT HUMAN AND MOUSE TRACE AMINE-ASSOCIATED RECEPTOR 5 (TAAR5)

*Mühlhaus J<sup>1</sup>, Pratzka J<sup>1</sup>, Piechowski CL<sup>1</sup>, Krude H<sup>1</sup>, Grüters-Kieslich A<sup>1</sup>, Köhrle J<sup>2</sup>, Kleinau G<sup>1</sup>, Biebermann H<sup>1</sup>*

<sup>1</sup>Charité Universitätsmedizin Campus Virchow-Klinikum, Institute for Experimental Pediatric Endocrinology, Berlin, Germany, <sup>2</sup>Charité Universitätsmedizin Campus Virchow-Klinikum, Institute for Experimental Endocrinology, Berlin, Germany

### P243 TISSUE-SPECIFIC FUNCTION OF THE MURINE THYROID HORMONE TRANSPORTER MCT8

*Horn S<sup>1</sup>, Müller J<sup>1</sup>, Liebsch C<sup>1</sup>, Visser TJ<sup>2</sup>, Heuer H<sup>1</sup>*

<sup>1</sup>Leibniz Institute for Age Research / Fritz Lipmann Institute (FLI), Jena, Germany, <sup>2</sup>Erasmus Medical Center, Erasmus University, Internal Medicine, Rotterdam, Netherlands

### P244 TRANSCRIPTIONAL ACTIVITY OF A TRE IN THE HUMAN KLF9 PROMOTER

*Moeller LC<sup>1</sup>, Saygün G<sup>1</sup>, Jaeger A<sup>1</sup>, Führer D<sup>1</sup>*

<sup>1</sup>University Duisburg-Essen, Endocrinology and Metabolism, Essen, Germany

### P245 A NOVEL HPLC-MS-MS METHOD TO ASSAY TISSUE THYROID HORMONES

*Saba A<sup>1</sup>, Colligiani D<sup>1</sup>, Donzelli R<sup>1</sup>, Chiellini G<sup>1</sup>, Nannipieri M<sup>1</sup>, Kusmic C<sup>2</sup>, Dos Remedios C<sup>3</sup>, Simonides W<sup>4</sup>, Iervasi G<sup>2</sup>, Zucchi R<sup>1</sup>*

<sup>1</sup>University of Pisa, Pisa, Italy, <sup>2</sup>CNR Institute of Clinical Physiology, Pisa, Italy, <sup>3</sup>University of Sydney, Sydney, Australia, <sup>4</sup>VU University Medical Center, Amsterdam, Netherlands

### P246 ESTABLISHMENT OF A COMPETITIVE CHEMILUMINESCENCE IMMUNOASSAY TO DETECT 3,5-DIODO-L-THYRONINE IN HUMAN SERUM

*Lehmphul I<sup>1</sup>, Wu Z<sup>2</sup>, Strasburger CJ<sup>2</sup>, Köhrle J<sup>1</sup>*

<sup>1</sup>Charité – Universitätsmedizin Berlin, Institut für Experimentelle Endokrinologie, Berlin, Germany, <sup>2</sup>Charité – Universitätsmedizin Berlin, Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine, Berlin, Germany

### P247 EXPRESSION AND LOCALIZATION OF TRACE AMINE-ASSOCIATED RECEPTORS IN RODENT THYROID EPITHELIAL CELLS WITH ALTERED ACTIVITIES OF THE THYROGLOBULIN-PROCESSING CYSTEINE CATHEPSINS B, K, AND L

*Qatato M<sup>1</sup>, Szumska J<sup>1</sup>, Venugopalan V<sup>1</sup>, Rehders M<sup>1</sup>, Mc Innes J<sup>1</sup>, Oellrich N<sup>1</sup>, Pratzka J<sup>2</sup>, Saftig P<sup>3</sup>, Peters C<sup>4</sup>, Reinheckel T<sup>4</sup>, Führer D<sup>5</sup>, Biebermann H<sup>2</sup>, Brix K<sup>1</sup>*

<sup>1</sup>Jacobs University Bremen, School of Engineering and Science, Bremen, Germany, <sup>2</sup>Charité – Universitätsmedizin Berlin, Institut für Experimentelle Pädiatrische Endokrinologie, Berlin, Germany, <sup>3</sup>Christian-Albrechts Universität zu Kiel, Institute of Biochemistry, Kiel, Germany, <sup>4</sup>Albert-Ludwigs-Universität Freiburg, Institut für Molekulare Medizin und Zellforschung, Freiburg, Germany, <sup>5</sup>Universitätsklinikum Essen, Klinik für Endokrinologie und Stoffwechselerkrankungen, Essen, Germany

### P248 HOMOLOGY MODEL OF THE L-TYPE AMINO ACID TRANSPORTER LAT2 FOR ELUCIDATING THE STRUCTURE-FUNCTION RELATIONSHIPS OF SUBSTRATE TRANSPORT

*Hinz K<sup>1</sup>, Kinne A<sup>1</sup>, Krause G<sup>1</sup>*

<sup>1</sup>Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany



**P249 COLLECTING MULTIPLE URINARY IODINE CONCENTRATION SAMPLES FROM EACH PARTICIPANT IN POPULATION SURVEYS – IS IT WORTH IT?**

*Samidurai AJ<sup>1</sup>, Davies PSW<sup>1</sup>, Ware RS<sup>2,3</sup>*

<sup>1</sup>Childrens Nutrition Research Centre, Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Australia, <sup>2</sup>Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Australia, <sup>3</sup>School of Population Health, The University of Queensland, Brisbane, Australia

**PO28 Medullary Thyroid Cancer**

Chair: *Laura Fugazzola*, Italy

**P250 WHOLE EXOME SEQUENCING OF MEDULLARY THYROID CARCINOMA CASES IDENTIFIES 86 VARIATIONS IN GENES POSSIBLY INVOLVED IN TUMORAL TRANSFORMATION**

*Ciampi R<sup>1</sup>, Lami P<sup>1</sup>, Romei C<sup>1</sup>, Tacito A<sup>1</sup>, Vivaldi A<sup>1</sup>, Vitti P<sup>1</sup>, Elisei R<sup>1</sup>*

<sup>1</sup>Pisa, Department of Clinical and Experimental Medicine, Pisa, Italy

**P251 LESS CANCER REOPERATIONS AFTER INITIAL SURGERY ACCORDING TO ATA GUIDELINES IN MEDULLARY THYROID CANCER**

*Verbeek HHG<sup>1</sup>, Meijer JAA<sup>2,3</sup>, Zandee WT<sup>3</sup>, Kramp KH<sup>1</sup>, Sluiter WJ<sup>1</sup>, Smit JW<sup>3,4</sup>, Kievit J<sup>5</sup>, Links TP<sup>1</sup>, Plukker JTM<sup>6</sup>*

<sup>1</sup>University of Groningen, University Medical Center Groningen, Department of Endocrinology, Groningen, Netherlands, <sup>2</sup>Albert Schweitzer Hospital, Internal Medicine, Dordrecht, Netherlands, <sup>3</sup>Leiden University Medical Center, Department of Endocrinology, Leiden, Netherlands, <sup>4</sup>Radboud University Nijmegen Medical Center, Department of Internal Medicine, Nijmegen, Netherlands, <sup>5</sup>Leiden University Medical Center, Department of Surgery, Leiden, Netherlands, <sup>6</sup>University of Groningen, University Medical Center Groningen, Department of Surgical Oncology, Groningen, Netherlands

**P252 ANTI-NEOPLASTIC ACTIVITY OF CLM3 AND CLM94, MULTI-TARGET PYRAZOLOPYRIMIDINE DERIVATES, IN MEDULLARY THYROID CANCER IN VITRO**

*Fallahi P<sup>1</sup>, Ferrari SM<sup>1</sup>, La Motta C<sup>1</sup>, Di Domenicantonio A<sup>1</sup>, Mancusi C<sup>1</sup>, Materazzi G<sup>1</sup>, Galleri D<sup>1</sup>, Da Settimo F<sup>1</sup>, Miccoli P<sup>1</sup>, Antonelli A<sup>1</sup>*

<sup>1</sup>University of Pisa, Pisa, Italy

**P253 COMBINED TREATMENT WITH EVEROLIMUS AND 5-AZA-2'-DEOXYCYTIDINE: A NEW THERAPEUTIC STRATEGY IN MEDULLARY THYROID CANCER**

*Dicitore A<sup>1</sup>, Gaudenzi G<sup>2</sup>, Caraglia M<sup>3</sup>, Misso G<sup>3</sup>, Borghi MO<sup>2,4</sup>, Hofland L<sup>5</sup>, Persani L<sup>1,2</sup>, Vitale G<sup>1,2</sup>*

<sup>1</sup>Istituto Auxologico Italiano, Laboratory of Endocrine and Metabolic Research, Cusano Milanino, Italy, <sup>2</sup>University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy, <sup>3</sup>Second University of Naples, Department of Biochemistry, Biophysics and General Pathology, Naples, Italy, <sup>4</sup>Istituto Auxologico Italiano, Laboratory of Immunology, Cusano Milanino, Italy, <sup>5</sup>Erasmus MC, Department of Internal Medicine, Division of Endocrinology, Rotterdam, Netherlands

**P254 TIMING OF TOTAL THYROIDECTOMY IN RET GENE CARRIERS <18 YEARS OF AGE**

*Romei C<sup>1</sup>, Bottici V<sup>1</sup>, Opocher G<sup>2</sup>, Mian C<sup>2</sup>, Brandi ML<sup>3</sup>, Giusti F<sup>3</sup>, Loli P<sup>4</sup>, Castellano M<sup>5</sup>, Cappelli C<sup>5</sup>, Persani L<sup>6</sup>, Filetti S<sup>7</sup>, Fugazzola L<sup>6</sup>, Verga U<sup>6</sup>, degli Uberti E<sup>8</sup>, Zatelli MC<sup>8</sup>, Colao A<sup>9</sup>, Faggiano A<sup>9</sup>, Creminini N<sup>10</sup>, Taccaliti A<sup>11</sup>, Boscaro M<sup>11</sup>, Giorgino F<sup>12</sup>, Orlandi F<sup>13</sup>, Elisei R<sup>1</sup>, ItaMEN network*

<sup>1</sup>University of Pisa, Section of Endocrinology, Department of Clinical and Experimental Medicine, Pisa, Italy, <sup>2</sup>Dept. of Medicine-DIMED, University of Padua, Padua, Italy, <sup>3</sup>Unit of Metabolic Bone Diseases, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy, <sup>4</sup>Dept of Medical Specialties, Endocrinology Unit, Ospedale Niguarda Cà Granda, Milano, Italy, <sup>5</sup>Dept of Clinical and Experimental Sciences, Internal Medicine and Endocrinology Unit, University of Brescia, Brescia, Italy, <sup>6</sup>Dept. of Clinical Sciences and Community Health, University of Milan, Milan, Italy, <sup>7</sup>Department of Internal Medicine and Medical Specialties, University of Rome 'Sapienza', Rome, Italy, <sup>8</sup>Dept of Medical Sciences, University of Ferrara, Ferrara, Italy, <sup>9</sup>Dept of Clinical Medicine and Surgery, 'Federico II' University of Naples, Naples, Italy, <sup>10</sup>Endocrinology Unit – Maggiore Hospital – Bologna, Bologna, Italy, <sup>11</sup>Dept. of Clinical and Molecular Science, Polytechnic University of Marche, Ancona, Italy, <sup>12</sup>Dept of Emergenza e Trapianto di Organi, University of Bari, Bari, Italy, <sup>13</sup>Dept of Oncology, University of Turin, Turin, Italy

**P255 CLINICAL CHARACTERISTICS IN SPORADIC AND FAMILIAL MEDULLARY THYROID CARCINOMAS (MTCs) AT PRESENTATION ARE CURRENTLY SIMILAR**

*Alevizaki M<sup>1</sup>, Saltiki K<sup>1</sup>, Rentziou G<sup>1</sup>, Athanasiadou A<sup>1</sup>, Kyrtzoglou E<sup>1</sup>, Sarika L<sup>1</sup>, Anastasiou E<sup>1</sup>*

<sup>1</sup>Athens University School of Medicine, Endocrine Unit, Dept Medical Therapeutics, Athens, Greece

**P256 RETROSPECTIVE ANALYSIS OF 140 CASES OF MEDULLARY THYROID CARCINOMA IN A SINGLE INSTITUTION**

*Simões-Pereira J<sup>1</sup>, Silva Vieira M<sup>2</sup>, Macedo D<sup>2</sup>, Marques P<sup>2</sup>, Moura M<sup>2</sup>, Limbert E<sup>2</sup>, Bugalho MJ<sup>2</sup>, Leite V<sup>2</sup>*

<sup>1</sup>Instituto Português de Oncologia de Lisboa Francisco Gentil, Endocrinology, Lisbon, Portugal, <sup>2</sup>Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal

**P257 TWO GENETIC VARIANT IN THE 3'UTR OF THE RET PROTO-ONCOGENE ARE IN LINKAGE DISEQUILIBRIUM WITH S836S POLYMORPHISM IN PATIENTS WITH MEDULLARY THYROID CARCINOMA**

*Ceolin L<sup>1</sup>, Siqueira DR<sup>1</sup>, Romitti M<sup>1</sup>, Ferreira CV<sup>1</sup>, Maia AL<sup>1</sup>*

<sup>1</sup>Universidade Federal do Rio Grande do Sul, Endocrinology, Porto Alegre, Brazil

P258 **Poster has been withdrawn**

**PO29 Thyroid Nodules and Goitre 2**

Chair: *Ralf Paschke*, Germany

**P259 SOMATIC MUTATIONS IN 33 HOT THYROID NODULES IN CHILDREN**

*Eszlinger M<sup>1</sup>, Niedziela M<sup>2</sup>, Typlt E<sup>1</sup>, Huth S<sup>1</sup>, Jäschke H<sup>1</sup>, Schaarschmidt J<sup>1</sup>, Krohn K<sup>3</sup>, Paschke R<sup>1</sup>*

<sup>1</sup>Universität Leipzig, Klinik & Poliklinik für Endokrinologie und Nephrologie, Leipzig, Germany, <sup>2</sup>Poznan University of Medical Sciences, Department of Pediatric Endocrinology and Rheumatology, Poznan, Poland, <sup>3</sup>Universität Leipzig, IZKF Leipzig, Leipzig, Germany

**P260 RARE ALLELE OF RS944289 AT CHROMOSOME 14Q13.3 ASSOCIATES WITH RISK OF BOTH MALIGNANT AND BENIGN THYROID TUMORS IN JAPANESE POPULATION**

*Rogounovitch TI<sup>1</sup>, Saenko VA<sup>2</sup>, Bychkov A<sup>1</sup>, Nikitski AV<sup>1</sup>, Takahashi M<sup>3</sup>, Nakashima M<sup>4</sup>, Hayashi T<sup>5</sup>, Hirokawa M<sup>6</sup>, Miyauchi A<sup>6</sup>, Shigematsu K<sup>7</sup>, Mitsutake N<sup>1</sup>, Matsuda F<sup>3</sup>, Yamashita S<sup>1,2</sup>*

<sup>1</sup>Nagasaki University, Department of Radiation Medical Sciences, Nagasaki, Japan, <sup>2</sup>Nagasaki University, Department of Health Risk Control, Nagasaki, Japan, <sup>3</sup>Kyoto University Graduate School of Medicine, Center for Genomic Medicine, Kyoto, Japan, <sup>4</sup>Nagasaki University, Department of Tumour and Diagnostic Pathology, Nagasaki, Japan, <sup>5</sup>Nagasaki University Hospital, Department of Pathology, Nagasaki, Japan, <sup>6</sup>Kuma Hospital, Kobe, Japan, <sup>7</sup>Japanese Red Cross Nagasaki Genbaku Hospital, Department of Pathology, Nagasaki, Japan

**P261 SYSTEMIC OXIDATIVE STRESS TO NUCLEIC ACIDS IS UNALTERED FOLLOWING RADIOIODINE THERAPY OF PATIENTS WITH BENIGN NODULAR GOITER**

*Bonnema SJ<sup>1</sup>, Stovgaard ES<sup>2</sup>, Fast S<sup>1</sup>, Broedbaek K<sup>2</sup>, Andersen JT<sup>2</sup>, Grupe P<sup>3</sup>, Hegedüs L<sup>1</sup>, Weimann A<sup>2</sup>, Poulsen HE<sup>2,4,5</sup>*

<sup>1</sup>Odense University Hospital, Endocrinology, Odense, Denmark, <sup>2</sup>Rigshospitalet, Laboratory of Clinical Pharmacology, Copenhagen, Denmark, <sup>3</sup>Odense University Hospital, Nuclear Medicine, Odense, Denmark, <sup>4</sup>Bispebjerg Hospital, Department of Clinical Pharmacology, Copenhagen, Denmark, <sup>5</sup>University of Copenhagen, Faculty of Health Sciences, Copenhagen, Denmark

**P262 MANAGEMENT OF MULTINODULAR GOITERS OF ENDEMIC ZONES BY SPECIALLY TRAINED SURGEONS**

*Maudar KK<sup>1,2</sup>*

<sup>1</sup>Bhopal Memorial Hospital and Research Centre, Surgery, Bhopal, India, <sup>2</sup>Manipal College of Medical Sciences, Surgery, Pokhara, Nepal

**P263 CALCITONIN LEVELS IN PREGNANT WOMEN**

*Sanchez E<sup>1</sup>, Grunenwald S<sup>1</sup>, d'Herbomez M<sup>2</sup>, Caron P<sup>1</sup>*

<sup>1</sup>CHU Larrey, Endocrinology and Metabolic Diseases, Toulouse, France, <sup>2</sup>CHRU Lille, Department of Nuclear Medicine, Lille, France

**P264 LATE FOLLOW-UP RESULTS AFTER I-131 THERAPY OF TOXIC MULTINODULAR GOITER**

*Petrovski Z<sup>1</sup>*

<sup>1</sup>Clinical Hospital, Department of Nuclear Medicine, Bitola, the Former Yugoslav Republic of Macedonia

**P265 HIGH INTENSITY FOCUSED ULTRASOUND [HIFU] – A FEASIBLE OPTION FOR THE TREATMENT OF BENIGN THYROID NODULES**

*Kovatcheva RD<sup>1</sup>, Vlahov JD<sup>1</sup>, Stoinov JP<sup>2</sup>, Ivanova RS<sup>3</sup>, Shinkov AD<sup>1</sup>*

<sup>1</sup>University Hospital of Endocrinology, Thyroid and Metabolic Bone Diseases, Sofia, Bulgaria, <sup>2</sup>University Hospital of Endocrinology, Endocrine Surgery, Sofia, Bulgaria, <sup>3</sup>University Hospital of Endocrinology, Pathology, Sofia, Bulgaria

**P266 PREGNANCY AND EUTHYROID GOITER: CHOICE OF THERAPY**

*Badalyan M<sup>1</sup>, Harutyunyan A<sup>1</sup>, Azatyan K<sup>2</sup>, Florov V<sup>1</sup>*

<sup>1</sup>Yerevan State Medical University, Yerevan, Armenia, <sup>2</sup>Polyclinic medical center N8, Yerevan, Armenia



## PO30 Thyroid in Reproduction and Development

Chair: Peter Bisschop, The Netherlands

### P267 PREDICTIVE VALUE OF MATERNAL SECOND GENERATION TBII ASSAY FOR NEONATAL AUTOIMMUNE HYPERTHYROIDISM

*Abeillon – du Payrat J<sup>1</sup>, Chikh K<sup>2,3</sup>, Bossard N<sup>4</sup>, Bretones P<sup>5</sup>, Gaucherand P<sup>6,7</sup>, Claris O<sup>7,8</sup>, Charrié A<sup>2,9</sup>, Raverot V<sup>10</sup>, Orgiazzi J<sup>7,11</sup>, Borson – Chazot F<sup>7,12,13</sup>, Bournaud C<sup>7,13,14</sup>*

<sup>1</sup>Hospices Civils de Lyon, GH Est, Fédération d'endocrinologie, Bron Cedex, France, <sup>2</sup>Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service de biochimie, Lyon, France, <sup>3</sup>Faculté de pharmacie, Lyon, France, <sup>4</sup>Hospices Civils de Lyon, Service de biostatistiques, Lyon, France, <sup>5</sup>Hospices Civils de Lyon, GH Est, Service d'endocrinologie pédiatrique, Lyon, France, <sup>6</sup>Hospices Civils de Lyon, GH Est, Service de gynécologie obstétrique, Lyon, France, <sup>7</sup>Université Lyon 1, Faculté de médecine Lyon Est, Lyon, France, <sup>8</sup>Hospices Civils de Lyon, GH Est, Service de néonatalogie, Lyon, France, <sup>9</sup>Faculté de médecine et de maïeutique Lyon Sud, CARMEN INSERM U1060, Lyon, France, <sup>10</sup>Hospices Civils de Lyon, GH Est, Service de biochimie, Lyon, France, <sup>11</sup>Hospices Civils de Lyon, Centre hospitalier Lyon Sud, Service d'endocrinologie, Lyon, France, <sup>12</sup>Hospices Civils de Lyon, GH Est, Fédération d'endocrinologie, Lyon, France, <sup>13</sup>INSERM, U1052, Lyon, France, <sup>14</sup>Hospices Civils de Lyon, GH Est, Service de Médecine nucléaire, Lyon, France

### P268 EFFECTS OF IODINE SUPPLEMENTATION ON THYROID FUNCTION IN INFANTS

*Belykh NA<sup>1</sup>, Mamenko MY<sup>1</sup>, Dontsova EM<sup>1</sup>*

<sup>1</sup>Luhansk State Medical University, Department of Postgraduate Education of Pediatrics, Lugansk, Ukraine

### P269 SUBCLINICAL HYPOTHYROIDISM IN PREGNANCY: 5 YEAR FOLLOW-UP INDICATES THE MAJORITY OF CASES ARE TRANSIENT

*Shields BM<sup>1</sup>, Knight BA<sup>1</sup>, Hill AV<sup>1</sup>, Hattersley AT<sup>1</sup>, Vaidya B<sup>1,2</sup>*

<sup>1</sup>University of Exeter Medical School, Exeter, United Kingdom, <sup>2</sup>Royal Devon & Exeter Hospital, Endocrinology, Exeter, United Kingdom

### P270 EFFECTS OF IODINE SUPPLEMENTATION ON PREGNANCY AND ON THE OFFSPRING

*Mamenko M<sup>1</sup>, Belykh N<sup>1</sup>, Valiyev O<sup>2</sup>, Mimyaylo N<sup>3</sup>, Kovalenko N<sup>4</sup>*

<sup>1</sup>Luhansk State Medical University, Department of Postgraduate Education of Pediatrics, Lugansk, Ukraine, <sup>2</sup>Luhansk State Medical University, Obstetrics and Gynecology, Luhansk, Ukraine, <sup>3</sup>Krasnodon Obstetrics Hospital, Krasnodon, Ukraine, <sup>4</sup>Pervomaysk Obstetrics Hospital, Pervomaysk, Ukraine

### P271 IODINE PROPHYLAXIS RATHER THAN L-THYROXINE TREATMENT IS EFFECTIVE IN IMPROVING NEUROINTELLECTUAL PERFORMANCES IN CHILDREN BORN TO MOTHERS FROM A MODERATELY IODINE DEFICIENT (ID) AREA: RESULTS OF A LONGITUDINAL PILOT STUDY

*Moleti M<sup>1</sup>, Ilardo G<sup>2</sup>, Boncoddo M<sup>2</sup>, Candia Longo A<sup>2</sup>, Di Bella B<sup>1</sup>, Presti S<sup>1</sup>, Sturniolo G<sup>1</sup>, Tortorella G<sup>2</sup>, Trimarchi F<sup>1</sup>, Vermiglio F<sup>1</sup>*

<sup>1</sup>University of Messina, Endocrinology, Messina, Italy,

<sup>2</sup>University of Messina, Neuroscience, Messina, Italy

### P272 CROSS-CULTURAL VALIDITY OF THE THYROID-RELATED QUALITY OF LIFE INSTRUMENT THYPRO

*Watt T<sup>1</sup>, Barbesino G<sup>2</sup>, Bjorner JB<sup>3</sup>, Bonnema SJ<sup>4</sup>, Bukvic B<sup>5</sup>, Drummond R<sup>6</sup>, Groenvold M<sup>3</sup>, Hegedüs L<sup>4</sup>, Kantzer V<sup>7</sup>, Lasch KE<sup>8</sup>, Marcocci C<sup>9</sup>, Mishra A<sup>10</sup>, Netea-Maier R<sup>11</sup>, Paunovic I<sup>12</sup>, Quinn T<sup>6</sup>, Åse RK<sup>13</sup>, Russell A<sup>14</sup>, Sabaretnam M<sup>15</sup>, Smit JWA<sup>16</sup>, Törring O<sup>17</sup>, Zivaljevic V<sup>12</sup>, Feldt-Rasmussen U<sup>13</sup>*

<sup>1</sup>Copenhagen University Hospital Rigshospitalet, Department of Medical Endocrinology, Copenhagen, Denmark, <sup>2</sup>Massachusetts General Hospital, Boston, United States, <sup>3</sup>University of Copenhagen, Copenhagen, Denmark, <sup>4</sup>Odense University Hospital, Odense, Denmark, <sup>5</sup>University of Belgrade, Belgrade, Serbia, <sup>6</sup>University of Glasgow, Glasgow, United Kingdom, <sup>7</sup>Health Research Associates, Seattle, United States, <sup>8</sup>Pharmerit, Boston, United States, <sup>9</sup>University of Pisa, Pisa, Italy, <sup>10</sup>Sanjay Gandhi Postgraduate Medical Institute, Lucknow, India, <sup>11</sup>University Nijmegen Medical Center, Nijmegen, Netherlands, <sup>12</sup>Clinical Centre of Serbia, Belgrade, Serbia, <sup>13</sup>Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark, <sup>14</sup>University of Cork, Cork, Ireland, <sup>15</sup>Christian Medical College, Vellore, India, <sup>16</sup>Nijmegen University Medical Center, Nijmegen, Netherlands, <sup>17</sup>Karolinska Institutet, Stockholm, Sweden

### P273 IODINE SUPPLEMENTATION DURING PREGNANCY AND OFFSPRING NEUROCOGNITIVE DEVELOPMENT AT 2 YEARS OF AGE IN AN AREA OF MILD IODINE DEFICIENCY

*Brucker-Davis F<sup>1</sup>, Chauliac F<sup>2</sup>, Panaia-Ferrari P<sup>3</sup>, Fenichel P<sup>1</sup>, Hieronimus S<sup>1</sup>*

<sup>1</sup>CHU Nice, Endocrinology, Nice, France, <sup>2</sup>CHU Nice, Neurology, Nice, France, <sup>3</sup>CHU Nice, Biochemistry, Nice, France

### P274 IODINE STATUS AMONG PREGNANT PATIENTS IN NORTH-EAST OF TURKEY, TRABZON, AFTER MANDATORY SALT IODINATION

*Anaforoglu I<sup>1</sup>, Algun E<sup>1</sup>, Incecayir O<sup>1</sup>, Topbas M<sup>2</sup>, Erdogan MF<sup>3</sup>*

<sup>1</sup>Trabzon Kanuni Education and Research Hospital, Endocrinology and Metabolism, Trabzon, Turkey, <sup>2</sup>Karadeniz Technical University, Faculty of Medicine, Department of Public Health, Trabzon, Turkey, <sup>3</sup>Ankara University, Faculty of Medicine, Endocrinology and Metabolism, Ankara, Turkey

### P275 THE RELATION OF THYROID STIMULATING HORMONE AND METABOLIC PARAMETERS IN THE SUBJECTS FOR HEALTH CHECK-UP

*Yu HM<sup>1</sup>, Park KS<sup>1</sup>, Lee JM<sup>1</sup>, Hong JH<sup>1</sup>, Ryu AJ<sup>1</sup>*

<sup>1</sup>Research Institute of Clinical Medicine, Eulji University Hospital, Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon, Republic of Korea



### Venue

City Music Hall (Stadsgehoorzaal)  
Breestraat 60  
2311 CS Leiden, The Netherlands  
Tel. +31 900 9001705

All conference rooms are fully equipped with up-to-date presentation systems. Powerpoint is the preferred format for presentations. In the Media Check Room speakers can also check their presentation at several working stations.

### Opening Times of Media Check

Saturday:	07.30–18.30
Sunday:	07.30–19.00
Monday:	07.30–17.30
Tuesday:	07.30–18.00
Wednesday:	07.30–12.30

All presenters are requested to hand in their lecture at least 1 hour before the scheduled talk, or the day before if your talk is early the next morning.

### Poster Displays

Maximum Poster sizes are 125 cm high and 90 cm wide. The poster should be easily readable from a distance of about 1m. All posters have to be in English. Mounting material will be available on site. All poster boards will be numbered. Staff will assist you in locating your poster wall and setting up your poster.

**Poster discussion sessions are from 12.00-13.00 from Sunday to Tuesday.**

**Your poster should be in place well before discussion time.**

**See below for a time guide:**

P1–P94:	Sunday 8th from 07.30 to be removed by 18.00
P95–P183:	Monday 9th from 07.30 to be removed by 17.00
P184–P275:	Tuesday 10th from 07.30 to be removed by 18.00

**Authors must be present at their poster session.**

Thank you for your understanding that posters not removed by the above mentioned times cannot be stored.

### Programme Changes

The organisers do not assume liability for any changes in the programme due to external or unforeseen circumstances.



### Language

The official congress language is English.

### Name Badges

Entrance to the Congress area will be limited to badge holders only. If the badge is lost, please contact the Congress registration desk.

### Congress Lunches

Lunch boxes will be provided in the exhibition areas as well as two other catering stations within the venue (see floor plans).

### Coffee Breaks

Coffee breaks will be served in the exhibition areas as well as at various stations within the venue. The coffee bar in the Catherina Foyer is a self-paying bar which only offers free coffee during the official coffee breaks.

### Congress Material

The Congress participants who have pre-registered will receive the congress material, together with their name badge from the Pre-Registered desk of the Congress Secretariat.

### Banks and Exchange

Banks are open from Monday to Friday, from 9.00–17.00 and are closed on public holidays. Most hotels, restaurants and shops accept credit cards. ATMs are located throughout the city.

### Climate

The Netherlands is located in a temperate weather region with moderate temperatures. Early September should still be relatively warm.

### Currency

The official currency in the Netherlands is the Euro.

### Dutch Time

Leiden is located in the Central European Time Zone (GMT +1). During the congress the official time will be summer time, i.e. GMT +2.

### Electricity

The electricity supply is 220 volts. Foreign appliances may require a power converter and/or an adapter.

### Emergency phone numbers

For emergencies dial 112.



## Health

Free first aid and hospital services are available to all citizens of the Europe who have a special card (EHIC, European Health Insurance Card, formerly E111) issued by the health authority of the relative country. Visitors from other countries are advised to take out special insurance for the duration of the trip, to avoid the cost of possible medical treatment. American visitors may find that reimbursement of medical expenses incurred abroad is covered by their private insurance. Prescription medication can only be obtained in the pharmacies (Apotheek).

## Insurance

The registration fee does not include the insurance of participants against personal accidents, illness, cancellations by any party, loss or damage to personal possessions, theft. All participants are strongly advised to make adequate personal insurance arrangements to cover travel, accommodation, cancellation and personal effects prior to travel.

## Italian Secretariat

Alijet & Fargo International S.r.l. has been appointed to be the referent between the Italian Pharmaceutical Companies and the Italian Health Ministry as to the collection and submission of the legal documentation required by the Italian Legislative Order n. 219 of 24th April 2006 – art. 124 from Italian delegates visiting the congress. Contact: Alijet & Fargo International S.r.l. , Via Pietro Maroncelli 44/46, 50137 Firenze, Italy, Tel. 011 39 055 600555 – Fax 011 39 055 609078.

## Smoking Policy

For the general comfort and health of all participants, smoking is not permitted at any of the official functions during the Congress. This includes all scientific sessions, business and other meetings, evening functions and registration area & foyers.

## Telephone

The international code for The Netherlands is ++31. The prefix for Leiden is (0)71.

## Tipping

Value-added tax (VAT) and service charges are included in hotel, restaurant, shopping bills and taxi fares. Tips for extra services are always appreciated but not absolutely necessary. It is customary to give taxi drivers and waiters a tip of about 10 per cent.


## Visa Requirements

Citizens of countries in the European Union and the European Economic Area do not need a visa for The Netherlands.

We advise you to consult the following website:

<http://www.justlanded.com/english/Netherlands/Netherlands-Guide/Visas-Permits/Visa-requirements> for updated and detailed information for foreigners regarding entrance visas for The Netherlands and permits of stay. Foreign participants should contact the Dutch Embassy or Consulate in their home country as soon as possible to determine their particular visa requirements. Participants requiring visas must initiate the application process at least 3 months prior to their departure date. Visa





application procedures are easier when the confirmation of registration is included. Refunds cannot be made if a visa application is not granted. The conference organizers are not obliged to assist participants with their visa application process.

### Leiden Information

Leiden can be reached easily by international visitors, with Schiphol just 20 minutes away and Rotterdam's smaller airport at 25 minutes distance. Leiden is within 10 kilometres of Holland's North Sea coast, and the Green Heart of the Netherlands is also close at hand.

Leiden is ideally located within a short travelling distance of major centres such as The Hague and Amsterdam.

#### By car

Leiden is located between the A4 and A44 motorways, which makes it easy to reach by car. The city centre is a pedestrian-only area, but visitors will find space for more than 3,000 cars in the many small and large car parks and garages spread around the periphery of the centre.

#### Haagweg car park (recommended for visitors)

Leiden's biggest car park is on the Haagweg, and provides full park-and-ride services to the city centre. During the daytime and in the evenings, shuttle buses will take you from the car park to all the main spots in the city – and bring you back, of course. Special arrangements can be made for groups, so that you can always be sure of transport to the city centre. For more information: [www.stadsparkeerplan.com](http://www.stadsparkeerplan.com).

#### Cycling in and around Leiden

As well as the city centre, the area around Leiden also has a lot to offer. Cycling is the ideal mode of transport for discovering the region, and there are many different cycle routes starting in Leiden see [http://portal.leiden.nl/en/tourism\\_leisure/discover/walking\\_and\\_cycling](http://portal.leiden.nl/en/tourism_leisure/discover/walking_and_cycling)

#### Bicycle Rental Leiden

De Rijwielshop, at the rear of the main station.

See further information under **Transportation**.

#### Airports

##### Amsterdam Airport/AMS (<http://www.amsterdamairport.info/>)

Officially known by the name Amsterdam Airport Schiphol, this airport is of great importance in Europe. It is an international airport and is located 20 minutes from Amsterdam city and approximately 9 miles south-west of the center of Amsterdam in Haarlemmermeer municipality. This is an international airport connecting to many notable European airports.

##### Rotterdam Airport/RTM (<http://rotterdam-rtm.airports-guides.com/>)

Rotterdam Airport is a small airport that handles flights from a small number of local carriers to destinations throughout Europe. The airport is situated around 8 km / 5 miles to the north-west of central Rotterdam and close to Kethel, Schiebroek, Schiedam and Zestienhoven.



### **Transportation**

Leiden can be reached in a variety of ways: by car, boat, train, bus and by air. At Amsterdam (Schiphol) and Rotterdam Airport, flights are continually landing from the major cities of neighbouring countries. The number of international flights is increasing.

Inside the city, a network of busses, maintains excellent connections. Parking places for coaches can be found, for example, near Municipal Windmill Museum 'De Valk'. Trains from all directions stop at Leiden Central Station, and the city centre is just a short walk from the station. Or, if you prefer, there is a frequent bus service from the station to almost anywhere in the city.

See also [http://portal.leiden.nl/en/tourism\\_leisure/practical/accessibility](http://portal.leiden.nl/en/tourism_leisure/practical/accessibility)

### **Bus**

Connexxion Stationsplein 3F (at AKO at Leiden Central Station), 2312 AJ Leiden, customer service tel. 0900-2666399 Veolia Transport Haaglanden/Service point Zoetermeer, Kelvinstraat 5 2723 RJ Zoetermeer

### **Train**

Dutch Railways [www.ns.nl](http://www.ns.nl)

Information OV Chipkaart: [www.ov-chipkaart.nl](http://www.ov-chipkaart.nl)

### **Taxi Information**

Taxi stands

Stations: Leiden Central, Leiden Lammenschans

### **Information about the Netherlands**

For further information about the Netherlands please visit [www.holland.com](http://www.holland.com)



### Welcome Reception

**Saturday, 7th September, 19.30–21.00**

**Hooglandse Kerk (Highlands Church)**  
**Middelweg 2**  
**2312 KH Leiden**

The Hooglandse Kerk is a cross-shaped church dating from the 14th century. Although emptied of its art by Calvinist iconoclasm, its elegant architecture has been beautifully restored. The first place of worship on this elevated site was a simple wooden chapel consecrated to St. Pancras around the beginning of the 14th century. In 1315, it was replaced by a sturdier stone church, and in 1377 construction of the present Late Gothic church got underway, beginning with the choir. The Collegiate Church of St. Pancras was consecrated in phases in 1381 and 1436. Other buildings sprung up around the church in this period, including homes for the canons, a beguinage, and an inn. The Hooglandse Kerk is located where the Old Rhine and New Rhine rivers meet. A beautiful landmark of Leiden. For further information go to [www.hooglandsekerk.com](http://www.hooglandsekerk.com). After the welcome address from Jan Smit and Theo Visser, you will be able to enjoy a short organ concert before the buffet opens. The Hooglandse Kerk is within walking distance of the congress venue.

**Price per person:** included in the fee for registered participants and registered accompanying persons.



Photo: Courtesy of Scheltema Leiden

### ETA Excursion: Canal Trip and Scheltema Complex, Marktsteeg 1

**Monday, 9th September, 18.00**

The excursion will be an impressive encounter with past and present of Leiden. A canal tour through the beautiful Leiden canals will be held with small motorboats [http://www.schuitjevaart.nl/e\\_index.html](http://www.schuitjevaart.nl/e_index.html). For those of you who prefer a more stable ride, a guided city walking tour will be provided. After the canal tour, all will meet at the Scheltema complex (Marktsteeg 1) <http://www.scheltemaleiden.nl/Historie> (Dutch language only) which originally housed a factory of sheets and plaids. After the factory was closed, the building was renovated into a cultural center, where modern art and science meet in exhibitions, performances and symposia. No better place for thyroid scientists to meet! We will have an informal party at Scheltema with typical Dutch food, drinks and dance. The boats for the canal tour will leave from the canal directly behind the congress venue, within walking distance.

**NB:** Drinks are complimentary from 19.00–22.00 only. Any drinks consumed after 22.00 must be paid for by the participant.

**Price per person: 50 €**



**Gala Dinner: National Museum of Antiquities, Rapenburg 28, Leiden**  
**Tuesday, 10th September, 20.00**

The formal congress dinner will be in the National Museum of Antiquities, <http://www.rmo.nl/english>, Rapenburg 28, Leiden. The Museum hosts an internationally renowned collection of fine Egyptian, Greek and Roman art and archeology as well as remains from ancient Dutch history. The dinner will be at the main hall in the museum where the Temple of Taffeh, transported piece by piece from Nubia will ensure a stylish atmosphere. During the evening, the collection can be visited. This venue is in the old city centre.

**Price per person: 75 € (formal dress)**



Photo: Courtesy of the Rijksmuseum van Oudheden





The Executive Committee and the Standing Office of the ETA are most grateful to the following ETA Corporate members and all other sponsors for their generous logistical support of the ETA 2013 Annual Meeting

AstraZeneca	30,000 € for a satellite symposium 6,000 € for an exhibition booth 1,500 € for a one page advert
Bayer Healthcare Pharmaceuticals	30,000 € for a satellite symposium 7,500 € for an exhibition booth 1,500 € for a one page advert
Eisai Europe Limited	30,000 € for a satellite symposium 1,500 € for a one page advert
Esaote SpA	1,200 lanyards 3,000 € for an exhibition booth
Esaote Benelux	2 Ultrasonic scanners
Exelixis, Inc.	3,000 € for an exhibition booth
Genzyme Europe bv	30,000 € for a satellite symposium 1,500 € for a one page advert 9,000 € for an exhibition booth
inomed Medizintechnik GmbH	Exhibition booth
Merck Serono	10,000 € for congress bags 30,000 € for a satellite symposium 15,000 € for an exhibition booth Internet Café 1,000 writing pads and 100 pens
Oxigene, Inc.	3,000 € for an exhibition booth
Pfizer bv	1,000 congress pens 2,000 € for an exhibition booth
Philips, The Netherlands	2 Ultrasonic scanners 1,000 € for an exhibition booth
Roche Diagnostics International Ltd.	6,000 € for an exhibition booth
Theraclion SA	3,000 € for an exhibition booth
Thermo Fisher Scientific	7,500 € for an exhibition booth
WON TECH Co., Ltd.	3,000 € for an exhibition booth